{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0c9eee24",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/yashrepal/My_Workspace/RAG/.venv/lib/python3.12/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import(\n",
    "    PyPDFLoader, PyMuPDFLoader, UnstructuredPDFLoader\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "eb9a43dc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 0, 'page_label': '1'}, page_content='1.  Is  ‘reversal’  possible  in  NASH?  \\n Recent  clinical  evidence  confirms  that  Non-Alcoholic  Steatohepatitis  (NASH)  reversal  is  \\nachievable\\n,\\n \\nparticularly\\n \\nwhen\\n \\nintervention\\n \\noccurs\\n \\nin\\n \\nearlier\\n \\nstages\\n \\nof\\n \\nthe\\n \\ndisease.\\n \\nAlongside\\n \\nstructured\\n \\nlifestyle\\n \\nchanges,\\n \\nSaroglitazar\\n,\\n \\na\\n \\nnovel\\n \\ndual\\n \\nPPAR-\\nα/γ\\n \\nagonist,\\n \\nhas\\n \\nemerged\\n \\nas\\n \\na\\n \\npromising\\n \\npharmacological\\n \\noption.\\n \\nIt\\n \\noffers\\n \\na\\n \\nunique\\n \\ndual\\n \\nbenefit—targeting\\n \\nboth\\n \\nhepatic\\n \\npathology\\n \\nand\\n \\nunderlying\\n \\nmetabolic\\n \\ndysfunction—making\\n \\nit\\n \\na\\n \\nvaluable\\n \\naddition\\n \\nto\\n \\nthe\\n \\nevolving\\n \\nNASH\\n \\ntreatment\\n \\nlandscape.\\n \\nKey  Reversible  Components  \\n●  Steatohepatitis :  Weight  loss  of  ≥7–10%  has  been  consistently  associated  with  \\nhistological\\n \\nresolution,\\n \\nreduced\\n \\nhepatocellular\\n \\ninflammation,\\n \\nimproved\\n \\nliver\\n \\nenzymes,\\n \\nand\\n \\ndecreased\\n \\nhepatic\\n \\nfat\\n \\non\\n \\nimaging.\\n1\\n \\n●  Fibrosis :  Contrary  to  earlier  beliefs,  fibrosis  regression  is  possible—even  in  \\nadvanced\\n \\nstages\\n \\n(F3)—with\\n \\nsustained\\n \\nmetabolic\\n \\nimprovement\\n \\nand\\n \\ntherapeutic\\n \\nsupport.\\n2\\n \\nEvidence-Based  Interventions  \\n●  Weight  Management :  Achieving  ≥7–10%  weight  loss  through  lifestyle  intervention,  \\nGLP-1\\n \\nreceptor\\n \\nagonists,\\n \\nor\\n \\nbariatric\\n \\nsurgery\\n \\ncan\\n \\nsignificantly\\n \\nimpact\\n \\ndisease\\n \\nprogression.\\n ●  Metabolic  Optimization :  Tight  glycemic  control,  lipid  management,  and  blood  \\npressure\\n \\nregulation\\n \\nare\\n \\nessential.\\n \\nInsulin\\n \\nsensitizers\\n \\nmay\\n \\nfurther\\n \\nsupport\\n \\nhepatic\\n \\nrecovery.\\n ●  Dietary  Strategies :  A  Mediterranean-style  diet,  reduction  in  refined  carbohydrates  \\nand\\n \\nsaturated\\n \\nfats,\\n \\nand\\n \\navoidance\\n \\nof\\n \\nfructose-sweetened\\n \\nbeverages\\n \\nhave\\n \\nshown\\n \\nhepatoprotective\\n \\neffects.\\n3\\n \\n●  Physical  Activity :  At  least  150  minutes  of  moderate  aerobic  exercise  weekly,  \\ncombined\\n \\nwith\\n \\nresistance\\n \\ntraining,\\n \\nsupports\\n \\nmetabolic\\n \\nhealth\\n \\nand\\n \\nprevents\\n \\nsarcopenia.\\n \\nSaroglitazar:  A  Dual-Action  Therapeutic  Option  \\nSaroglitazar  addresses  multiple  NASH  mechanisms:\\n 6  \\n●  Enhances  insulin  sensitivity  (PPAR- γ)  ●  Improves  lipid  metabolism  and  reduces  hepatic  lipotoxicity  (PPAR- α)  ●  Exerts  anti-inflammatory  effects  on  hepatic  stellate  cells  ●  Modulates  adipokine  secretion  and  systemic  metabolic  balance  \\nClinical  Evidence :'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 1, 'page_label': '2'}, page_content='●  EVIDENCE  IV :  Demonstrated  dose-dependent  liver  fat  reduction  (up  to  5.5%),  \\nimproved\\n \\nALT/AST,\\n \\nand\\n \\nfavorable\\n \\nsafety.\\n4\\n \\n●  EVIDENCE  VI :  In  diabetic  NAFLD  patients,  showed  improvements  in  liver  enzymes,  \\nglycemic\\n \\ncontrol,\\n \\nlipid\\n \\nprofile,\\n \\nand\\n \\nliver\\n \\nstiffness.\\n4\\n \\n●  Indian  Real-World  Data :  Consistent  improvements  in  hepatic  steatosis,  fibrosis  \\nscores,\\n \\nand\\n \\nmetabolic\\n \\nparameters\\n \\nin\\n \\nMASLD\\n \\npatients.\\n5\\n \\n  \\nSaroglitazar  is  particularly  suited  for:  \\n●  NASH  patients  with  diabetic  dyslipidemia  ●  Individuals  with  suboptimal  response  to  lifestyle  alone  ●  Asian  populations  with  MASLD  and  metabolic  comorbidities  \\n  \\nReferences:  \\n1.Promrat  K,  et  al.  (2010),  Hepatology.  2010;51(1):121-129.  3.  Chalasani  N,  et  al.  (2018),  \\nHepatology.\\n \\n2018;67(1):328-357.\\n \\n2.  Sanyal  AJ,  et  al.  (2021),  N  Engl  J  Med.  2021;384(12):1113-1124.  \\n3.  Romero-Gómez  M,  et  al.  (2017),  J  Hepatol.  2017;67(4):829-846.  \\n4.  Gawrieh,  S.,  Noureddin,  M.,  et  al.  (2021)  Saroglitazar,  a  PPAR- α/γ  agonist,  for  treatment  \\nof\\n \\nNAFLD:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n \\nphase\\n \\n2\\n \\ntrial.\\n \\nHepatology,\\n \\n74\\n(4),\\n \\n1809–1824.\\n \\nBajaj  S,  et  al.  2022;  Diabetes  Metab  Syndr.  \\n5.  Dang,  N.,  &  Wairokpam,  T.  (2024).  Clinical  case  series  on  assessment  of  therapeutic  \\nefficacy\\n \\nof\\n \\nSaroglitazar\\n \\nin\\n \\nMASLD\\n \\npatients.\\n \\nAsian\\n \\nJournal\\n \\nof\\n \\nMedicine\\n \\nand\\n \\nHealth,\\n \\n22(9),\\n \\n11–18.\\n \\n6.Staels,  B.,  &  Fruchart,  J.  C.  (2005).  Therapeutic  roles  of  peroxisome  proliferator–activated  \\nreceptor\\n \\nagonists.\\n \\nDiabetes,\\n \\n54(8),\\n \\n2460–2470.\\n  \\n  \\n2.  What  %  of  patients  have  benefited  from  saroglitazar? \\nApproximately  7  out  of  10  NAFLD/NASH  patients  (70-75%)  derive  clinically  meaningful  \\nbenefit\\n \\nfrom\\n \\nsaroglitazar\\n,\\n \\nwith\\n \\n4-5\\n \\nout\\n \\nof\\n \\n10\\n \\npatients\\n \\nachieving\\n \\nrobust\\n \\nresponses\\n \\nincluding\\n \\nenzyme\\n \\nnormalization\\n \\nand\\n \\nsignificant\\n \\nhepatic\\n \\nfat\\n \\nreduction.\\n \\nThe\\n \\ndrug\\n \\ndemonstrates'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 2, 'page_label': '3'}, page_content='consistent  efficacy  across  biochemical,  imaging,  and  metabolic  endpoints,  with  the  highest  \\nresponse\\n \\nrates\\n \\nobserved\\n \\nin\\n \\npatients\\n \\nwith\\n \\nmoderate\\n \\ndisease\\n \\nseverity,\\n \\nbaseline\\n \\nhepatic\\n \\ninflammation,\\n \\nand\\n \\nconcomitant\\n \\nmetabolic\\n \\ndysfunction.\\n \\nBreakdown  by  Clinical  Endpoints  \\n1.  Hepatic  Fat  Reduction  (Gold  Standard  MRI-PDFF  Measurement)  \\nEVIDENCE  IV  Trial  (Gawrieh  S,  et  al.  J  Hepatol.  2021;74(4):862-871) :  \\n●  45-50%  of  patients  achieved  ≥30%  relative  reduction  in  liver  fat  with  saroglitazar  4  \\nmg\\n ●  Mean  absolute  liver  fat  reduction:  5.5%  (vs.  0.3%  with  placebo;  p<0.001)  ●  Dose-dependent  response  demonstrated  across  1  mg,  2  mg,  and  4  mg  doses  \\n  \\n2.  Liver  Enzyme  Normalization  \\nEVIDENCE  VI  Study  (Bajaj  S,  et  al.  Diabetes  Metab  Syndr.  2022;16(5):102479) :  \\n●  ALT  normalization:  62.5%  of  patients  (n=325,  24  weeks)  ●  AST  normalization:  68.3%  of  patients  ●  Mean  ALT  reduction:  42.8  IU/L  (48.5%  reduction  from  baseline)  ●  Mean  AST  reduction:  38.6  IU/L  (45.2%  reduction  from  baseline)  \\nMeta-Analysis  (Siddiqui  MS,  et  al.  Aliment  Pharmacol  Ther.  2021;53(9):998-1007):  \\n●  65-72%  showed  significant  ALT  reduction  across  pooled  studies  ●  60-68%  showed  significant  AST  reduction  ●  NNT:  4-5  for  ALT  normalization  \\n  \\n3.  Composite  Metabolic-Hepatic  Benefit  \\nReal-World  Indian  Data  (Goyal  O,  et  al.  J  Clin  Exp  Hepatol.  2020;10(5):433-440) :  \\n●  Complete  response  (enzyme  normalization  +  steatosis  improvement):  40-45%  ●  Partial  response  (≥50%  improvement):  30-35%  ●  Overall  clinical  benefit  rate:  70-80%  ●  Non-responders:  20-30%  \\nKaul  U,  et  al.  (Sci  Rep.  2021;11(1):9414) :  \\n●  71%  of  diabetic  NAFLD  patients  showed  improvement  in  hepatic  parameters  ●  Subgroup  analysis  from  larger  diabetes  cohort  (n=186  NAFLD  patients)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 3, 'page_label': '4'}, page_content='4.  Non-Invasive  Fibrosis  Markers  \\nEVIDENCE  VI  Study:  \\n●  FIB-4  score  improvement:  55-60%  of  patients  ●  CAP  reduction:  Mean  decrease  of  25-30  dB/m  \\nImprovement  in  hepatic  steatosis  by  imaging:  55-65%  (Meta-analysis  data)  \\n  \\n5.  Metabolic  Parameters  \\nAcross  Multiple  Studies:  \\n●  Triglyceride  reduction:  70-75%  of  patients  (30-40%  reduction  from  baseline)  ●  HbA1c  reduction:  Mean  decrease  of  0.8-1.2%  ●  Lipid  profile  improvement:  70-80%  of  patients  \\n  \\n  \\n  \\n  \\n  \\n \\n  \\n3.  In  which  concomitant  conditions,  patients  get  maximum  \\nbenefit\\n \\nfrom\\n \\nsaroglitazar?\\n \\nSaroglitazar  demonstrates  maximum  therapeutic  efficacy  in  NAFLD/NASH  patients  with  \\nspecific\\n \\nmetabolic\\n \\ncomorbidities,\\n \\nreflecting\\n \\nits\\n \\ndual\\n \\nPPAR-\\nα/γ\\n \\nagonist\\n \\nmechanism\\n \\nthat\\n \\naddresses\\n \\nmultiple\\n \\npathophysiological\\n \\npathways.\\n \\nThe  Ideal  Candidate  for  Saroglitazar  (Maximum  Benefit):  \\n✓  Type  2  diabetes  mellitus  (HbA1c  7.0-9.0%)  \\n \\n✓\\n \\nHypertriglyceridemia\\n \\n(>200\\n \\nmg/dL)\\n \\n \\n✓\\n \\nMetabolic\\n \\nsyndrome\\n \\n(≥3\\n \\ncomponents)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 4, 'page_label': '5'}, page_content='✓  Baseline  ALT  1.5-4×  ULN  \\n \\n✓\\n \\nEarly-stage\\n \\nfibrosis\\n \\n(F0-F2)\\n \\n \\n✓\\n \\nBMI\\n \\n25-35\\n \\nkg/m²\\n \\n \\n✓\\n \\nAsian\\n \\nethnicity\\n \\n \\n✓\\n \\nWillingness\\n \\nto\\n \\ncombine\\n \\nwith\\n \\nlifestyle\\n \\nmodification\\n \\nExpected  Outcome:  75-85%  probability  of  clinically  meaningful  improvement  \\n  \\nClinical  Evidence  in  Coexisting  Conditions  \\n1.  Type  2  Diabetes  Mellitus  with  NAFLD/NASH  \\nResponse  Rates:  70-80%  Clinical  Benefit  \\nMechanistic  Rationale:  \\n●  Enhanced  insulin  sensitivity  via  PPAR- γ  activation  ●  Improved  glycemic  control  reducing  hepatic  gluconeogenesis  ●  Reduction  in  hepatic  lipotoxicity  from  improved  glucose  metabolism  ●  Favorable  adipokine  profile  modulation  \\nClinical  Evidence:  \\nEVIDENCE  VI  Study  (Bajaj  S,  et  al.  Diabetes  Metab  Syndr.  2022;16(5):102479):  \\n●  Exclusively  enrolled  diabetic  NAFLD  patients  (n=325)  ●  ALT  normalization:  62.5%  ●  AST  normalization:  68.3%  ●  HbA1c  reduction:  0.8-1.2%  (mean  baseline  HbA1c:  8.2%)  ●  Dual  benefit:  Hepatic  and  glycemic  improvement  in  65-70%  of  patients  \\nKaul  U,  et  al.  ( Sci  Rep.  2021;11(1):9414):  \\n●  Diabetic  NAFLD  subgroup  analysis  (n=186)  ●  71%  showed  hepatic  parameter  improvement  ●  Greater  benefit  in  patients  with  HbA1c  7.5-9.0%  vs.  HbA1c  >9%  ●  Synergistic  effects  on  liver  fat  and  glycemic  control  \\nOptimal  Candidate  Profile:  \\n●  Type  2  diabetes  with  HbA1c  7.0-9.0%  ●  Baseline  hepatic  transaminitis  (ALT  >1.5×  ULN)  ●  Duration  of  diabetes  <10  years  ●  Preserved  beta-cell  function'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 5, 'page_label': '6'}, page_content='2.  Diabetic  Dyslipidemia  (Hypertriglyceridemia)  \\nResponse  Rates:  75-85%  Lipid  Improvement  +  65-70%  Hepatic  Benefit  \\nMechanistic  Rationale:  \\n●  Potent  PPAR- α  activation  reducing  hepatic  VLDL  synthesis  ●  Enhanced  lipoprotein  lipase  activity  ●  Improved  fatty  acid  oxidation  ●  Reduced  hepatic  lipid  accumulation  \\nClinical  Evidence:  \\nPRESS  V  Study  (Pai  V,  et  al.  Indian  Heart  J.  2014;66(4):428-436):  \\n●  Primary  diabetic  dyslipidemia  with  NAFLD  subgroup  ●  Triglyceride  reduction:  45-50%  from  baseline  ●  Non-HDL  cholesterol  reduction:  22-25%  ●  Hepatic  steatosis  improvement:  68%  (ultrasound-based)  \\nMeta-Analysis  (Siddiqui  MS,  et  al.  Aliment  Pharmacol  Ther.  2021;53(9):998-1007):  \\n●  Triglyceride  improvement:  70-80%  of  patients  ●  Hepatic  fat  reduction  correlated  with  triglyceride  reduction  (r=0.65,  p<0.01)  ●  Greater  hepatic  benefit  in  patients  with  baseline  triglycerides  >200  mg/dL  \\nOptimal  Candidate  Profile:  \\n●  Fasting  triglycerides  >200  mg/dL  but  <500  mg/dL  ●  Low  HDL-cholesterol  (<40  mg/dL  in  men,  <50  mg/dL  in  women)  ●  Elevated  small  dense  LDL  particles  ●  Metabolic  syndrome  phenotype  \\n \\n3.  Metabolic  Syndrome  \\nResponse  Rates:  70-75%  Overall  Clinical  Benefit  \\nMechanistic  Rationale:  \\n●  Addresses  multiple  components  simultaneously  ●  Improves  insulin  resistance  (central  pathophysiology)  ●  Reduces  visceral  adiposity  and  hepatic  fat  ●  Anti-inflammatory  effects  on  adipose  tissue'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 6, 'page_label': '7'}, page_content='Clinical  Evidence:  \\nReal-World  Indian  Studies  (Goyal  O,  et  al.  J  Clin  Exp  Hepatol.  2020;10(5):433-440):  \\n●  Metabolic  syndrome  patients  (defined  by  ATP  III  criteria)  with  NAFLD  ●  Complete  response:  48%  (vs.  35%  in  non-metabolic  syndrome  NAFLD)  ●  Number  of  metabolic  syndrome  components  correlates  with  response:  ○  3  components:  65%  response  rate  ○  4-5  components:  75%  response  rate  ●  Greatest  benefit  in  patients  with:  Central  obesity  +  hypertriglyceridemia  +  impaired  \\nfasting\\n \\nglucose\\n \\nComponent-Specific  Improvements:  \\n●  Waist  circumference  reduction:  3-5  cm  (in  60%  of  patients)  ●  Blood  pressure  reduction:  Systolic  BP  decreased  5-8  mmHg  (in  55%)  ●  Fasting  glucose  improvement:  65-70%  of  patients  ●  HDL-cholesterol  increase:  15-20%  from  baseline  \\nOptimal  Candidate  Profile:  \\n●  Meeting  ≥3  ATP  III  metabolic  syndrome  criteria  ●  Central  obesity  (waist  circumference:  >90  cm  men,  >80  cm  women  for  Asians)  ●  Pre-diabetes  or  early  diabetes  (HbA1c  5.7-8.0%)  ●  Mixed  dyslipidemia  pattern  \\n \\n4.  NAFLD  with  Insulin  Resistance  (Non-Diabetic)  \\nResponse  Rates:  60-65%  Clinical  Benefit  \\nMechanistic  Rationale:  \\n●  Primary  insulin  sensitization  prevents  progression  to  diabetes  ●  Interrupts  lipotoxicity  cascade  early  ●  Preserves  hepatocyte  function  before  extensive  injury  \\nClinical  Evidence:  \\nEVIDENCE  IV  Subgroup  Analysis  (Gawrieh  S,  et  al.  J  Hepatol.  2021;74(4):862-871):  \\n●  Pre-diabetic/insulin-resistant  subgroup  without  established  diabetes  ●  Hepatic  fat  reduction:  50-55%  achieved  ≥30%  reduction  ●  HOMA-IR  improvement:  Mean  reduction  of  2.5-3.0  points  ●  Better  response  in  early-stage  disease  (F0-F1  fibrosis)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 7, 'page_label': '8'}, page_content='Optimal  Candidate  Profile:  \\n●  HOMA-IR  >2.5  ●  Fasting  insulin  >15  μ U/mL  ●  Pre-diabetes  (HbA1c  5.7-6.4%)  ●  BMI  25-35  kg/m²  (overweight  to  moderate  obesity)  \\n \\n5.  NAFLD/NASH  with  Moderate  Baseline  ALT  Elevation  \\nResponse  Rates:  70-75%  ALT  Normalization  \\nMechanistic  Rationale:  \\n●  Elevated  ALT  indicates  active  hepatocellular  injury  amenable  to  intervention  ●  Greater  potential  for  measurable  improvement  ●  Reflects  inflammatory  component  responsive  to  PPAR  modulation  \\nClinical  Evidence:  \\nStratified  Analysis  Across  Multiple  Studies:  \\nBaseline  ALT  >2×  ULN  (>80  IU/L):  \\n●  ALT  normalization:  70-75%  ●  Mean  ALT  reduction:  50-60  IU/L  ●  NNT:  3  for  achieving  normal  ALT  \\nBaseline  ALT  1.5-2×  ULN  (60-80  IU/L):  \\n●  ALT  normalization:  60-65%  ●  Mean  ALT  reduction:  35-45  IU/L  \\nBaseline  ALT  <1.5×  ULN  (<60  IU/L):  \\n●  ALT  normalization:  45-50%  ●  Limited  room  for  measurable  improvement  \\nOptimal  Candidate  Profile:  \\n●  ALT  60-150  IU/L  (1.5-4×  ULN)  ●  AST/ALT  ratio  <1.0  (suggesting  NAFLD  rather  than  cirrhosis)  ●  Absence  of  alternative  liver  disease'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 8, 'page_label': '9'}, page_content='6.  Early-Stage  Fibrosis  (F0-F2)  \\nResponse  Rates:  75-80%  Overall  Improvement  \\nMechanistic  Rationale:  \\n●  Hepatic  architecture  relatively  preserved  ●  Greater  hepatocyte  regenerative  capacity  ●  Reduced  fibrotic  burden  allows  better  drug  distribution  ●  Earlier  intervention  prevents  progression  \\nClinical  Evidence:  \\nFibrosis  Stage-Stratified  Outcomes:  \\nF0-F1  (No  or  Minimal  Fibrosis):  \\n●  Overall  response:  78-82%  ●  Hepatic  fat  reduction:  55-60%  (≥30%  reduction)  ●  Prevention  of  fibrosis  progression:  85-90%  \\nF2  (Moderate  Fibrosis):  \\n●  Overall  response:  70-75%  ●  Fibrosis  improvement  (to  F0-F1):  20-25%  ●  Stabilization  (no  progression):  65-70%  \\nF3-F4  (Advanced  Fibrosis/Cirrhosis):  \\n●  Overall  response:  40-50%  ●  Biochemical  improvement  only:  Limited  structural  benefit  ●  Fibrosis  regression:  10-15%  (compensated  cirrhosis)  \\nOptimal  Candidate  Profile:  \\n●  FIB-4  score  <2.67  ●  Liver  stiffness  <10  kPa  (transient  elastography)  ●  No  clinical  or  radiological  cirrhosis  ●  NAFLD  Activity  Score  (NAS)  ≥4  \\n \\n7.  Asian  Ethnicity  (Metabolic  NAFLD  Phenotype)  \\nResponse  Rates:  70-80%  in  Asian  Populations  \\nMechanistic  Rationale:'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 9, 'page_label': '10'}, page_content='●  Genetic  predisposition  to  metabolic  NAFLD  (PNPLA3,  TM6SF2  polymorphisms)  ●  Lower  BMI  threshold  for  metabolic  dysfunction  in  Asians  ●  Greater  visceral  adiposity  at  lower  body  weight  ●  Enhanced  PPAR-mediated  metabolic  effects  in  this  population  \\nClinical  Evidence:  \\nIndian  Population  Studies:  \\n●  Consistently  higher  response  rates  (70-80%)  compared  to  Western  populations  ●  Rathi  P,  et  al.  ( Indian  J  Gastroenterol.  2023;42(1):7-15):  Expert  consensus  on  Indian  \\ndata\\n ●  Better  outcomes  even  at  BMI  23-27  kg/m²  (vs.  BMI  >30  in  Western  studies)  \\nOptimal  Candidate  Profile:  \\n●  Asian  ethnicity  with  \"metabolically  obese,  normal  weight\"  phenotype  ●  BMI  >23  kg/m²  with  central  obesity  ●  Strong  family  history  of  diabetes  or  metabolic  syndrome  \\n  \\n  \\n  \\n \\n  \\n4.  How  does  Vitamin  E  help  treat  NAFLD  /  NASH?  \\nVitamin  E  (α- tocopherol)  functions  as  a  potent  lipophilic  antioxidant  that  targets  oxidative  \\nstress—a\\n \\ncentral\\n \\npathophysiological\\n \\nmechanism\\n \\nin\\n \\nNASH\\n \\nprogression.\\n \\nIts\\n \\ntherapeutic\\n \\neffects\\n \\nare\\n \\nmediated\\n \\nthrough\\n \\nseveral\\n \\nkey\\n \\npathways:\\n \\nPrimary  Mechanisms:  \\n●  Antioxidant  Activity:  Scavenges  reactive  oxygen  species  (ROS)  and  lipid  peroxyl  \\nradicals,\\n \\ninterrupting\\n \\nthe\\n \\noxidative\\n \\ncascade\\n \\nresponsible\\n \\nfor\\n \\nhepatocellular\\n \\nlipotoxicity\\n \\nand\\n \\nmitochondrial\\n \\ndysfunction\\n ●  Anti-inflammatory  Effects:  Inhibits  NF- κ B  signaling,  thereby  reducing  \\npro-inflammatory\\n \\ncytokine\\n \\nproduction\\n \\n(TNF-\\nα,\\n \\nIL-6,\\n \\nIL-1\\nβ)\\n ●  Hepatic  Stellate  Cell  Modulation:  Suppresses  stellate  cell  activation  and  collagen  \\nsynthesis,\\n \\npotentially\\n \\nattenuating\\n \\nfibrogenesis'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 10, 'page_label': '11'}, page_content='●  Membrane  Protection:  Preserves  hepatocyte  membrane  integrity  against  lipid  \\nperoxidation-induced\\n \\ndamage\\n ●  Mitochondrial  Preservation:  Maintains  mitochondrial  function  and  prevents  \\napoptosis\\n \\nsignaling\\n \\npathways\\n \\n  \\nResults  of  PIVENS  Trial  \\n(Sanyal  AJ,  et  al.  N  Engl  J  Med.  2010;362(18):1675-1685)  \\nThis  landmark  randomized,  double-blind,  placebo-controlled  trial  evaluated  vitamin  E  in  non-diabetic  \\nNASH\\n \\npatients,\\n \\n  NASH  Resolution:  36%  with  vitamin  E  vs.  21%  with  placebo  (p=0.001)  \\n  Hepatocellular  Ballooning  Improvement:  58%  (p<0.001  vs.  placebo)  \\n  Lobular  Inflammation  Reduction:  47%  (statistically  significant)  \\n  ALT  Normalization:  54%  vs.  31%  with  placebo  \\n  Steatosis  Improvement:  Significant  dose-dependent  reduction  \\n  Fibrosis:  No  significant  difference  compared  to  placebo—a  critical  limitation  \\n  \\nResults  of  TONIC  Trial  \\n(Lavine  JE,  et  al.  JAMA.  2011;305(17):1659-1668)  \\n●\\n \\nSustained  ALT  Reduction:  58%  with  vitamin  E  \\n●\\n \\nNASH  Resolution:  28%  vs.  16%  with  placebo  (p=0.006)  \\n●\\n \\nSuperior  histological  response  in  pediatric  population  compared  to  adult  \\ndata\\n \\n●\\n \\nMetformin  showed  no  significant  benefit  over  placebo  \\n  \\nCritical  Limitations  of  Vitamin  E  in  NAFLD/NASH  \\n●\\n \\nAbsence  of  significant  fibrosis  regression—the  primary  determinant  of  \\nlong-term\\n \\nclinical\\n \\noutcomes'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 11, 'page_label': '12'}, page_content='●\\n \\nReduced  or  absent  efficacy  in  diabetic  patients  (post-hoc  subgroup  analyses)  \\n●\\n \\nNo  long-term  data  on  clinical  endpoints  (mortality,  hepatic  decompensation,  \\nhepatocellular\\n \\ncarcinoma)\\n \\n●\\n \\nUncertain  durability:  Benefits  may  not  persist  after  treatment  \\ndiscontinuation\\n \\n  \\nVitamin  E  represents  a  modestly  effective  therapeutic  option  for  carefully  selected  NASH  \\npatients,\\n \\ndemonstrating\\n \\nhistological\\n \\nimprovement\\n \\nand\\n \\nNASH\\n \\nresolution\\n \\nin\\n \\napproximately\\n \\none-third\\n \\nof\\n \\nnon-diabetic,\\n \\nnon-cirrhotic\\n \\nindividuals.\\n \\nHowever,\\n \\nits\\n \\ninability\\n \\nto\\n \\nsignificantly\\n \\nimprove\\n \\nfibrosis—coupled\\n \\nwith\\n \\npotential\\n \\nlong-term\\n \\nsafety\\n \\nconcerns—necessitates\\n \\njudicious\\n \\npatient\\n \\nselection\\n \\nand\\n \\nthorough\\n \\ninformed\\n \\nconsent\\n \\ndiscussions.\\n \\nThe  cornerstone  of  NASH  management  remains  intensive  lifestyle  modification  targeting  \\n≥7-10%\\n \\nweight\\n \\nloss.\\n \\nVitamin\\n \\nE\\n \\nshould\\n \\nbe\\n \\npositioned\\n \\nas\\n \\nadjunctive\\n \\ntherapy\\n \\nin\\n \\npatients\\n \\nwho\\n \\nmeet\\n \\nstrict\\n \\neligibility\\n \\ncriteria\\n \\nand\\n \\nunderstand\\n \\nthe\\n \\ncurrent\\n \\nevidence\\n \\nlimitations\\n.\\n \\nAs\\n \\nthe\\n \\ntherapeutic\\n \\nlandscape\\n \\nevolves\\n \\nwith\\n \\nemerging\\n \\npharmacological\\n \\nagents\\n \\ndemonstrating\\n \\nfibrosis\\n \\nregression,\\n \\nthe\\n \\nrole\\n \\nof\\n \\nvitamin\\n \\nE\\n \\nmay\\n \\nrequire\\n \\nreevaluation.\\n \\n  \\n  \\n \\n  \\n  \\n5.  Is  UDCA  proven  to  reverse  fibrosis?  Are  there  any  clinical  \\nstudy\\n \\nresults\\n \\navailable?\\n \\nUrsodeoxycholic  acid  (UDCA)  has  not  demonstrated  consistent  efficacy  in  reversing  \\nhepatic\\n \\nfibrosis\\n \\nin\\n \\nNAFLD/NASH\\n \\npatients,\\n \\ndespite\\n \\ntheoretical\\n \\nmechanistic\\n \\nrationale\\n \\nand\\n \\nearly\\n \\ninvestigational\\n \\ninterest.\\n \\nClinical  Trial  Evidence  \\nNegative/Neutral  Trials  \\n1.  Lindor  KD,  et  al.  (Hepatology.  2004;39(3):770-778)  \\n●  Randomized,  placebo-controlled  trial;  UDCA  13-15  mg/kg/day  for  2  years  in  NASH  \\npatients\\n \\n(n=166)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 12, 'page_label': '13'}, page_content='●  Results:  ○  No  improvement  in  liver  histology  (steatosis,  inflammation,  fibrosis)  ○  No  significant  ALT  reduction  ○  No  benefit  over  placebo  on  any  histological  endpoint  ●  Conclusion:  UDCA  ineffective  for  NASH  treatment  \\n2.  Ratziu  V,  et  al.  (Gastroenterology.  2011;140(3):711-717)  \\n●  High-dose  UDCA  (28-35  mg/kg/day)  vs.  placebo;  12-month  trial  in  NASH  patients  \\n(n=126)\\n ●  Results:  ○  No  histological  improvement  in  NAS  score  ○  No  fibrosis  regression  ○  No  benefit  on  metabolic  or  biochemical  parameters  ●  Conclusion:  Even  high-dose  UDCA  ineffective  in  NASH  \\n3.  Leuschner  UF,  et  al.  (Hepatology.  2010;52(2):472-479)  \\n●  UDCA  combined  with  vitamin  E  vs.  placebo;  NASH  patients  followed  for  18  months  \\n(n=147)\\n ●  Results:  ○  Combination  therapy  no  better  than  placebo  ○  No  significant  histological  changes  ○  Minimal  biochemical  improvements  only  \\n  \\nPrimary  Biliary  Cholangitis  (Different  Disease  Entity)  \\nNote:  UDCA  shows  proven  benefit  in  Primary  Biliary  Cholangitis  (PBC) ,  but  this  does  not  \\ntranslate\\n \\nto\\n \\nNAFLD/NASH\\n:\\n \\n●  PBC:  UDCA  13-15  mg/kg/day  improves  biochemical  markers,  delays  histological  \\nprogression,\\n \\nreduces\\n \\nneed\\n \\nfor\\n \\ntransplantation\\n ●  NAFLD/NASH:  No  such  benefits  demonstrated;  different  pathophysiology  \\nCurrent  Guideline  Position  \\nAASLD  Guidelines  (Rinella  ME,  et  al.  Hepatology.  2023;78(6):1797-1835):  \\n●  UDCA  is  NOT  recommended  for  treatment  of  NAFLD  or  NASH  ●  Insufficient  evidence  of  benefit  on  histological  or  clinical  outcomes  \\nEASL  Guidelines:  \\n●  Similar  stance:  No  recommendation  for  UDCA  in  NAFLD/NASH'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 13, 'page_label': '14'}, page_content='●  Reserved  exclusively  for  cholestatic  liver  diseases  (PBC,  PSC)  ○  However,  worsened  lipid  profile  and  pruritus  ○  FDA  approval  pathway  complicated  by  safety  concerns  \\nUDCA  does  NOT  reverse  fibrosis  in  NAFLD/NASH  and  is  not  recommended  by  any  major  \\nhepatology\\n \\nsociety\\n \\nfor\\n \\nthis\\n \\nindication.\\n \\nMultiple\\n \\nwell-designed\\n \\nRCTs\\n \\nhave\\n \\nconsistently\\n \\nshown\\n \\nlack\\n \\nof\\n \\nhistological\\n \\nbenefit.\\n \\nEvidence  Level:  High-quality  negative  evidence  (multiple  RCTs)  \\nRecommendation:  Do  not  prescribe  UDCA  for  NAFLD/NASH  treatment;  reserve  for  \\nappropriate\\n \\ncholestatic\\n \\nindications\\n \\n(PBC,\\n \\ngallstone\\n \\ndissolution).\\n \\n  \\n  \\n6.  How  does  Saroglitazar  impact  ALT/AST  values?  \\nSaroglitazar  demonstrates  robust  and  dose-dependent  reduction  in  ALT  and  AST  levels  \\nacross\\n \\nmultiple\\n \\nclinical\\n \\ntrials\\n \\nand\\n \\nreal-world\\n \\nstudies\\n \\nin\\n \\nNAFLD/NASH\\n \\npatients.\\n \\nSummarised  findings:  \\n●  Mean  reduction:  35-45  IU/L  (40-50%  from  baseline)  ●  Normalization  rate:  60-70%  in  diabetic  NAFLD  patients  ●  Dose-dependent  effect  with  4  mg  optimal  ●  Response  evident  by  12  weeks,  maximal  at  24  weeks  ●  Correlates  with  hepatic  fat  reduction  but  imperfect  predictor  of  fibrosis  changes  \\n  \\nThe  Quantitative  Impact  of  key  Clinical  Trials  is  listed  below:  \\n1.\\n      \\nEVIDENCE  IV  Trial  (Gawrieh  S,  et  al.  J  Hepatol.  2021;74(4):862-871)  \\nStudy  Design:  RCT,  non-cirrhotic  NASH  patients  (n=106),  16  weeks  \\nALT  Reduction  (Mean  Decrease  from  Baseline):  \\n●  Saroglitazar  4  mg:  -26  to  -30  IU/L  (approximately  30-35%  reduction)  ●  Saroglitazar  2  mg:  -18  to  -22  IU/L  (approximately  22-28%  reduction)  ●  Placebo:  -3  to  -5  IU/L  \\nALT  Normalization  Rate:'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 14, 'page_label': '15'}, page_content='●  Saroglitazar  4  mg:  35-40%  of  patients  achieved  normal  ALT  (<40  IU/L  for  men,  <32  \\nIU/L\\n \\nfor\\n \\nwomen)\\n ●  Statistically  significant  vs.  placebo  (p<0.01)  \\nAST  Reduction:  \\n●  Similar  pattern  with  25-30%  mean  reduction  from  baseline  ●  Parallel  improvement  with  ALT  \\n  \\n2.\\n      \\nEVIDENCE  VI  Study  (Bajaj  S,  et  al.  Diabetes  Metab  Syndr.  2022;16(5):102479)  \\nStudy  Design:  Prospective  observational  study,  diabetic  NAFLD  patients  (n=325),  24  weeks  \\nResults:  \\nALT:  \\n●  Mean  baseline:  88.3  IU/L  ●  Mean  reduction:  -42.8  IU/L  (48.5%  reduction)  ●  Normalization  rate:  62.5%  of  patients  \\nAST:  \\n●  Mean  baseline:  85.4  IU/L  ●  Mean  reduction:  -38.6  IU/L  (45.2%  reduction)  ●  Normalization  rate:  68.3%  of  patients  \\nTime  Course:  \\n●  Significant  reduction  observed  by  Week  12  ●  Maximal  effect  at  Week  24  ●  Sustained  response  through  follow-up  period  \\n  \\n3.\\n      \\nMeta-Analysis  (Siddiqui  MS,  et  al.  Aliment  Pharmacol  Ther.  2021;53(9):998-1007)  \\nPooled  Data  Across  Multiple  Studies:  \\n●  ALT  reduction:  65-72%  of  patients  showed  significant  improvement  (≥30%  \\nreduction\\n \\nor\\n \\nnormalization)\\n ●  AST  reduction:  60-68%  of  patients  ●  Mean  ALT  decrease:  35-45  IU/L  across  studies  ●  Mean  AST  decrease:  30-40  IU/L  ●  Number  Needed  to  Treat  (NNT)  for  ALT  normalization:  4-5'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 15, 'page_label': '16'}, page_content='Dose-Response  Relationship  \\nEstablished  Dose-Dependent  Effect:  \\n●  1  mg:  Modest  reduction  (15-20%  from  baseline)  ●  2  mg:  Moderate  reduction  (22-28%  from  baseline)  ●  4  mg:  Maximum  reduction  (30-50%  from  baseline)  -  Standard  clinical  dose  \\n  \\n \\n  \\n  \\n7.  Has  exposure  to  Covid  infection  affected  fibrosis  patients?  \\nThe  intersection  of  COVID-19  infection  and  Non-Alcoholic  Fatty  Liver  Disease  (NAFLD)  or  \\nNon-Alcoholic\\n \\nSteatohepatitis\\n \\n(NASH)\\n \\nhas\\n \\nemerged\\n \\nas\\n \\na\\n \\nsignificant\\n \\nclinical\\n \\nconcern.\\n \\nThe  impact  of  Covid  infection  varies  based  on  phase  of  Covid  infection,  severity  of  fibrosis,  \\nstatus\\n \\nof\\n \\npatient\\n \\nand\\n \\nco-existing\\n \\nconditions.\\n  \\n \\nDISEASE  TRAJECTORY:  Three-Phase  Impact  \\nAcute  Phase  (0-4  Weeks)  \\n●  65-78%  of  NAFLD/NASH  patients  show  hepatic  enzyme  elevations  with  ALT  rising  \\n2.5-4.2\\n \\ntimes\\n \\nbaseline\\n \\nvalues.\\n1,2\\n \\n●  12-18%  of  hospitalized  patients  develop  clinically  significant  hepatic  dysfunction  \\nrequiring\\n \\nintensive\\n \\nmonitoring.\\n3\\n \\n●  Advanced  fibrosis  patients  experience  more  pronounced  enzyme  elevations  and  \\nhigher\\n \\nacute-on-chronic\\n \\nliver\\n \\nfailure\\n \\nincidence.\\n4\\n \\nPost-Acute  Phase  (1-6  Months)  \\n●  28%  demonstrate  persistently  elevated  aminotransferases  beyond  viral  clearance.\\n 5  \\n●  Liver  stiffness  increases  by  2.8-4.1  kPa  compared  to  pre-infection  values,  indicating  \\nmeasurable\\n \\nfibrosis\\n \\nprogression.\\n6,7\\n \\n●  Persistent  metabolic  derangements  (insulin  resistance,  dyslipidemia)  create  a  \\npro-fibrotic\\n \\nhepatic\\n \\nmicroenvironment.\\n8\\n \\nExtended  Recovery  Phase  (6-24  Months)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 16, 'page_label': '17'}, page_content='●  Fibrosis  progression  accelerates  from  0.2-0.3  to  0.6-0.9  stages/year  (two  to  \\nthree-fold\\n \\nacceleration).\\n9,10\\n \\n●  Only  34%  achieve  complete  biochemical  and  histological  normalization  by  24  \\nmonths.\\n11\\n \\n●  66%  demonstrate  persistent  hepatic  dysfunction,  ongoing  inflammation,  or  \\nprogressive\\n \\nfibrosis.\\n11\\n \\n  \\n  \\nSEVERITY  CORRELATIONS:  Dose-Response  Relationship  \\nMild  COVID-19  (Outpatient  Management)  \\n●  15-22%  show  liver  enzyme  elevations.\\n 12  \\n●  78%  achieve  complete  biochemical  recovery  by  6  months.\\n 12  \\n●  22%  with  incomplete  recovery  require  systematic  follow-up  with  non-invasive  fibrosis  \\nassessment.\\n13\\n \\nModerate  COVID-19  (Hospitalization,  Supplemental  Oxygen)  \\n●  45-58%  demonstrate  significant  liver  enzyme  elevations  during  acute  illness.\\n 14  \\n●  35%  maintain  persistent  hepatic  dysfunction  at  6  months;  25%  at  12  months.\\n 14,15  \\n●  Critical  population  for  timely  therapeutic  intervention  to  prevent  progression.\\n 15  \\nSevere  COVID-19  (ICU,  Mechanical  Ventilation)  \\n●  72-85%  develop  acute  liver  injury  during  hospitalization.\\n 16,17  \\n●  58%  demonstrate  persistent  hepatic  dysfunction  at  12  months.\\n 17  \\n●  Highest  risk  for  progression  to  cirrhosis,  hepatocellular  carcinoma,  and  liver-related  \\nmortality.\\n18\\n \\n \\nRISK  STRATIFICATION:  Identifying  Highest-Risk  Patients  \\nBy  Baseline  Fibrosis  Stage  \\nEarly  Fibrosis  (F0-F1):  \\n●  1.2-fold  hospitalization  risk;  0.8%  mortality.\\n 19  \\n●  15-18%  show  measurable  fibrosis  progression  post-COVID.  \\n 19  \\nIntermediate  Fibrosis  (F2-F3):  \\n●  2.8-fold  ICU  admission  risk;  4.2%  mortality.  \\n 20'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 17, 'page_label': '18'}, page_content='●  32-38%  progress  to  advanced  fibrosis/cirrhosis  within  24  months  (3x  expected  \\nrate).\\n20\\n \\nAdvanced  Fibrosis/Cirrhosis  (F4):  \\n●  4.1-fold  mortality  risk;  12.3%  develop  acute-on-chronic  liver  failure.\\n 21  \\n●  31.4%  experience  first  decompensation  within  24  months  vs.  18.7%  pre-pandemic  \\n(68%\\n \\nrelative\\n \\nincrease).\\n22\\n \\nBy  Body  Mass  Index  \\n●  BMI  25-29.9:  1.6-fold  severe  COVID  risk.\\n 23  \\n●  BMI  30-34.9:  2.3-fold  risk;  28-35%  show  accelerated  fibrosis  progression  at  12-24  \\nmonths.\\n \\n23,24\\n \\n●  BMI  ≥35:  3.8-fold  risk;  45%  rapid  fibrosis  advancement  post-infection.\\n 24  \\nBy  Diabetes  Status  \\nNon-Diabetic:  \\n●  12.4%  hospitalization  rate.\\n 25  \\n●  0.3  additional  fibrosis  stages/year  post-COVID.\\n 25  \\nDiabetic:  \\n●  28.9%  hospitalization  rate  (2.4-fold  higher).  \\n 25  \\n●  0.7  additional  fibrosis  stages/year  (more  than  double  non-diabetics)\\n 25  \\n●  Synergistic  cycle:  infection  worsens  glycemic  control,  amplifying  hepatic  \\ninflammation\\n \\nand\\n \\nfibrogenesis.\\n \\n26\\n \\n \\nCOMORBIDITY  INTERACTIONS:  Synergistic  Risk  Amplification  \\nHypertension  +  NAFLD/NASH  \\n●  4.2-fold  increased  severe  COVID  risk.\\n 27  \\n●  19.3%  major  adverse  cardiac  events  during  hospitalization/post-discharge.  \\n 27  \\n●  Complete  Metabolic  Syndrome  ●  24.7%  ICU  admission  vs.  8.2%  isolated  NAFLD  (3-fold  elevation).\\n 28  \\n●  42-48%  show  significant  fibrosis  progression  within  18  months.\\n 28  \\nCoronary  Artery  Disease  +  NAFLD/NASH  \\n●  11.2%  experience  acute  coronary  syndrome  during  COVID  hospitalization  (10-fold  \\nincrease).\\n29'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 18, 'page_label': '19'}, page_content='●  Mechanism:  COVID-induced  hypercoagulability,  endothelial  dysfunction,  increased  \\nmyocardial\\n \\noxygen\\n \\ndemand.\\n29\\n \\nChronic  Kidney  Disease  +  NAFLD/NASH  \\n●  Frequently  precipitates  acute  kidney  injury  on  chronic  kidney  disease.\\n 30  \\n●  Complex  hepatorenal  interactions  complicate  management  and  increase  mortality.\\n 30  \\nLONG-TERM  CONSEQUENCES:  Lasting  Disease  Impact  \\nAccelerated  Cirrhosis  Progression  \\n●  22%  of  F3  patients  progress  to  F4  within  24  months  vs.  8%  pre-pandemic  (3-fold  \\nacceleration).\\n31\\n \\n●  Compresses  typical  5-10  year  progression  into  less  than  2  years.\\n 31  \\nHepatocellular  Carcinoma  Risk  \\n●  2.8  per  1000  patient-years  (1.9-fold  increase  vs.  pre-pandemic  rates).\\n 32  \\n●  Mediated  through  accelerated  fibrosis,  persistent  inflammation,  and  prolonged  \\nimmune\\n \\ndysregulation.\\n32\\n \\nHepatic  Decompensation  \\n●  31.4%  first  decompensation  at  24  months  vs.  18.7%  historical  controls.\\n 22  \\n●  Events  include  ascites,  hepatic  encephalopathy,  variceal  hemorrhage,  hepatorenal  \\nsyndrome.\\n \\n22\\n \\nIncomplete  Recovery  \\n●  Only  34%  achieve  complete  normalization  by  24  months.\\n 11  \\n●  66%  show  persistent  abnormalities:  elevated  aminotransferases,  increased  liver  \\nstiffness,\\n \\nongoing\\n \\ninflammation,\\n \\nprogressive\\n \\nmetabolic\\n \\ndysfunction.\\n11\\n \\n \\nCLINICAL  RECOMMENDATIONS  \\nEnhanced  Surveillance  Protocols  \\n●  Baseline  assessment  within  3  months  of  infection  recovery.\\n 33  \\n●  6-month  interval  surveillance  for  first  2  years.  \\n 33  \\n●  Include:  metabolic  panels,  liver  function  tests,  non-invasive  fibrosis  assessment  \\n(FibroScan/serum\\n \\nbiomarkers),\\n \\ndecompensation\\n \\nevaluation.\\n33\\n \\nRisk-Based  Management'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 19, 'page_label': '20'}, page_content='●  Prioritize  patients  with:  advanced  fibrosis,  severe  obesity,  diabetes,  multiple  \\nmetabolic\\n \\ncomorbidities.\\n34\\n \\n●  Consider  earlier  pharmacological  interventions  and  aggressive  metabolic  \\noptimization\\n34\\n \\n●  Earlier  liver  transplant  evaluation  for  rapid  disease  progression.\\n 35  \\nMultidisciplinary  Collaboration  \\n●  Establish  care  pathways  involving  hepatology,  endocrinology,  cardiology,  primary  \\ncare.\\n36\\n \\n●  Comprehensive  management  of  all  contributing  factors  improves  outcomes.\\n 36  \\nPrevention  and  Patient  Education  \\n●  Emphasize  vaccination  importance  and  preventive  measures.\\n 37  \\n●  Educate  patients  that  COVID-19  may  accelerate  liver  disease  progression.\\n 37  \\n \\nKEY  TAKEAWAYS  \\n1.  COVID-19  creates  a  three-phase  hepatic  impact  with  66%  showing  persistent  \\ndysfunction\\n \\nat\\n \\n24\\n \\nmonths.\\n 2.  Dose-response  relationship  exists:  severe  COVID  causes  profound,  lasting  hepatic  \\nconsequences.\\n 3.  Advanced  fibrosis  (F3-F4)  patients  face  4.1-fold  mortality  risk  and  68%  increased  \\ndecompensation\\n \\nrates.\\n 4.  Severe  obesity  (BMI  ≥35)  and  diabetes  create  multiplicative  risk  amplification.  5.  Metabolic  syndrome  patients  show  3-fold  ICU  admission  rates  and  42-48%  fibrosis  \\nprogression.\\n 6.  Fibrosis  progression  accelerates  2-3  fold ,  compressing  years  of  natural  history  \\ninto\\n \\nmonths.\\n 7.  Enhanced  surveillance  and  risk-stratified  management  are  essential  for  optimal  \\noutcomes.\\n \\n  \\nREFERENCES  \\n1.  Bloom,  P.  P.,  Meyerowitz,  E.  A.,  Reinus,  Z.,  et  al.  (2021).  Liver  biochemistries  in  \\nhospitalized\\n \\npatients\\n \\nwith\\n \\nCOVID-19.\\n \\nHepatology,\\n \\n73\\n(3),\\n \\n890-900.\\n 2.  Phipps,  M.  M.,  Barraza,  L.  H.,  LaSota,  E.  D.,  et  al.  (2020).  Acute  liver  injury  in  \\nCOVID-19:\\n \\nPrevalence\\n \\nand\\n \\nassociation\\n \\nwith\\n \\nclinical\\n \\noutcomes\\n \\nin\\n \\na\\n \\nlarge\\n \\nU.S.\\n \\ncohort.\\n \\nHepatology,\\n \\n72\\n(3),\\n \\n807-817.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 20, 'page_label': '21'}, page_content=\"3.  Marjot,  T.,  Moon,  A.  M.,  Cook,  J.  A.,  et  al.  (2021).  Outcomes  following  SARS-CoV-2  \\ninfection\\n \\nin\\n \\npatients\\n \\nwith\\n \\nchronic\\n \\nliver\\n \\ndisease:\\n \\nAn\\n \\ninternational\\n \\nregistry\\n \\nstudy.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n74\\n(3),\\n \\n567-577.\\n 4.  Sarin,  S.  K.,  Choudhury,  A.,  Lau,  G.  K.,  et  al.  (2020).  Pre-existing  liver  disease  is  \\nassociated\\n \\nwith\\n \\npoor\\n \\noutcome\\n \\nin\\n \\npatients\\n \\nwith\\n \\nSARS\\n \\nCoV2\\n \\ninfection.\\n \\nHepatology\\n \\nInternational,\\n \\n14\\n(5),\\n \\n802-807.\\n 5.  Roth,  N.  C.,  Kim,  A.,  Vitkovski,  T.,  et  al.  (2021).  Post-acute  COVID-19  syndrome  \\nnegatively\\n \\nimpacts\\n \\nphysical\\n \\nfunction,\\n \\ncognitive\\n \\nfunction,\\n \\nhealth-related\\n \\nquality\\n \\nof\\n \\nlife,\\n \\nand\\n \\nparticipation.\\n \\nAmerican\\n \\nJournal\\n \\nof\\n \\nPhysical\\n \\nMedicine\\n \\n&\\n \\nRehabilitation,\\n \\n100\\n(1),\\n \\n48-49.\\n 6.  Méndez-Sánchez,  N.,  Valencia-Rodríguez,  A.,  Coronel-Castillo,  C.,  et  al.  (2022).  The  \\nimpact\\n \\nof\\n \\nCOVID-19\\n \\non\\n \\nthe\\n \\nprogression\\n \\nof\\n \\nliver\\n \\nfibrosis\\n \\nin\\n \\npatients\\n \\nwith\\n \\nNAFLD.\\n \\nAnnals\\n \\nof\\n \\nHepatology,\\n \\n27\\n(1),\\n \\n100556.\\n 7.  Iavarone,  M.,  D'Ambrosio,  R.,  Soria,  A.,  et  al.  (2021).  High  rates  of  30-day  mortality  \\nin\\n \\npatients\\n \\nwith\\n \\ncirrhosis\\n \\nand\\n \\nCOVID-19.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n73\\n(5),\\n \\n1063-1071.\\n 8.  Targher,  G.,  Mantovani,  A.,  Byrne,  C.  D.,  et  al.  (2020).  Risk  of  severe  illness  from  \\nCOVID-19\\n \\nin\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction-associated\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\nincreased\\n \\nfibrosis\\n \\nscores.\\n \\nGut,\\n \\n69\\n(8),\\n \\n1545-1547.\\n 9.  Eslam,  M.,  Newsome,  P.  N.,  Sarin,  S.  K.,  et  al.  (2020).  A  new  definition  for  metabolic  \\ndysfunction-associated\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nAn\\n \\ninternational\\n \\nexpert\\n \\nconsensus\\n \\nstatement.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n73\\n(1),\\n \\n202-209.\\n 10.  Huang,  C.,  Huang,  L.,  Wang,  Y.,  et  al.  (2021).  6-month  consequences  of  COVID-19  \\nin\\n \\npatients\\n \\ndischarged\\n \\nfrom\\n \\nhospital:\\n \\nA\\n \\ncohort\\n \\nstudy.\\n \\nThe\\n \\nLancet,\\n \\n397\\n(10270),\\n \\n220-232.\\n 11.  Roca-Fernández,  A.,  Wamil,  M.,  Telford,  A.,  et  al.  (2023).  One-year  persistent  \\nsymptoms\\n \\nand\\n \\nfunctional\\n \\nimpairment\\n \\nin\\n \\nSARS-CoV-2\\n \\npositive\\n \\nand\\n \\nnegative\\n \\nindividuals.\\n \\nJournal\\n \\nof\\n \\nInternal\\n \\nMedicine,\\n \\n293\\n(1),\\n \\n103-116.\\n 12.  Zhou,  Y.  J.,  Zheng,  K.  I.,  Wang,  X.  B.,  et  al.  (2020).  Younger  patients  with  MAFLD  are  \\nat\\n \\nincreased\\n \\nrisk\\n \\nof\\n \\nsevere\\n \\nCOVID-19\\n \\nillness:\\n \\nA\\n \\nmulticenter\\n \\npreliminary\\n \\nanalysis.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n73\\n(3),\\n \\n719-721.\\n 13.  Portincasa,  P.,  Krawczyk,  M.,  Smyk,  W.,  et  al.  (2020).  COVID-19  and  non-alcoholic  \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nTwo\\n \\nintersecting\\n \\npandemics.\\n \\nEuropean\\n \\nJournal\\n \\nof\\n \\nClinical\\n \\nInvestigation,\\n \\n50\\n(10),\\n \\ne13338.\\n 14.  Bramante,  C.  T.,  Buse,  J.  B.,  Liebovitz,  D.  M.,  et  al.  (2021).  Outpatient  treatment  of  \\nCOVID-19\\n \\nand\\n \\nincidence\\n \\nof\\n \\npost-COVID-19\\n \\ncondition\\n \\nover\\n \\n10\\n \\nmonths\\n \\n(COVID-OUT):\\n \\nA\\n \\nmulticentre,\\n \\nrandomised,\\n \\nquadruple-blind,\\n \\nparallel-group,\\n \\nphase\\n \\n3\\n \\ntrial.\\n \\nThe\\n \\nLancet\\n \\nInfectious\\n \\nDiseases,\\n \\n23\\n(10),\\n \\n1119-1129.\\n 15.  Nardo,  A.  D.,  Schneeweiss-Gleixner,  M.,  Bakail,  M.,  et  al.  (2021).  Pathophysiological  \\nmechanisms\\n \\nof\\n \\nliver\\n \\ninjury\\n \\nin\\n \\nCOVID-19.\\n \\nLiver\\n \\nInternational,\\n \\n41\\n(1),\\n \\n20-32.\\n 16.  Cai,  Q.,  Huang,  D.,  Yu,  H.,  et  al.  (2020).  COVID-19:  Abnormal  liver  function  tests.  \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n73\\n(3),\\n \\n566-574.\\n 17.  Hundt,  M.  A.,  Deng,  Y.,  Ciarleglio,  M.  M.,  et  al.  (2020).  Abnormal  liver  tests  in  \\nCOVID-19:\\n \\nA\\n \\nretrospective\\n \\nobservational\\n \\ncohort\\n \\nstudy\\n \\nof\\n \\n1,827\\n \\npatients\\n \\nin\\n \\na\\n \\nmajor\\n \\nU.S.\\n \\nhospital\\n \\nnetwork.\\n \\nHepatology,\\n \\n72\\n(4),\\n \\n1169-1176.\"), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 21, 'page_label': '22'}, page_content='18.  Sharma,  A.,  Jaiswal,  P.,  Kerakhan,  Y.,  et  al.  (2021).  Liver  disease  and  outcomes  \\namong\\n \\nCOVID-19\\n \\nhospitalized\\n \\npatients:\\n \\nA\\n \\nsystematic\\n \\nreview\\n \\nand\\n \\nmeta-analysis.\\n \\nAnnals\\n \\nof\\n \\nHepatology,\\n \\n21\\n,\\n \\n100273.\\n 19.  Hashemi,  N.,  Viveiros,  K.,  Redd,  W.  D.,  et  al.  (2020).  Impact  of  chronic  liver  disease  \\non\\n \\noutcomes\\n \\nof\\n \\nhospitalized\\n \\npatients\\n \\nwith\\n \\nCOVID-19:\\n \\nA\\n \\nmulticentre\\n \\nUnited\\n \\nStates\\n \\nexperience.\\n \\nLiver\\n \\nInternational,\\n \\n40\\n(10),\\n \\n2515-2521.\\n 20.  Singh,  S.,  Khan,  A.,  Chowdhry,  M.,  et  al.  (2020).  Risk  of  severe  coronavirus  disease  \\n2019\\n \\nin\\n \\npatients\\n \\nwith\\n \\nchronic\\n \\nliver\\n \\ndisease\\n \\nin\\n \\nthe\\n \\nUnited\\n \\nStates.\\n \\nClinical\\n \\nGastroenterology\\n \\nand\\n \\nHepatology,\\n \\n18\\n(11),\\n \\n2524-2526.\\n 21.  Bajaj,  J.  S.,  et  al.  (2020).  First  decompensation  events  in  cirrhosis:  trends  and  \\noutcomes.\\n \\nHepatology,\\n \\n72(4),\\n \\n1261–1270.\\n 22.  Lighter,  J.,  Phillips,  M.,  Hochman,  S.,  et  al.  (2020).  Obesity  in  patients  \\nyounger\\n \\nthan\\n \\n60\\n \\nyears\\n \\nis\\n \\na\\n \\nrisk\\n \\nfactor\\n \\nfor\\n \\nCOVID-19\\n \\nhospital\\n \\nadmission.\\n \\nClinical\\n \\nInfectious\\n \\nDiseases,\\n \\n71(15),\\n \\n896–897.\\n 23.  Simonnet,  A.,  Chetboun,  M.,  Poissy,  J.,  et  al.  (2020).  High  prevalence  of  \\nobesity\\n \\nin\\n \\nsevere\\n \\nacute\\n \\nrespiratory\\n \\nsyndrome\\n \\ncoronavirus-2.\\n \\nObesity,\\n \\n28(7),\\n \\n1195–1199.\\n 24.  Williamson,  E.  J.,  Walker,  A.  J.,  Bhaskaran,  K.,  et  al.  (2020).  Factors  \\nassociated\\n \\nwith\\n \\nCOVID-19\\n \\ndeath\\n \\nin\\n \\n17\\n \\nmillion\\n \\npatients\\n \\nusing\\n \\nOpenSAFELY.\\n \\nNature,\\n \\n584(7821),\\n \\n430–436.\\n 25.  Apicella,  M.,  Campopiano,  M.  C.,  Mantuano,  M.,  et  al.  (2020).  COVID-19  in  \\npeople\\n \\nwith\\n \\ndiabetes:\\n \\nUnderstanding\\n \\nthe\\n \\nreasons\\n \\nfor\\n \\nworse\\n \\noutcomes.\\n \\nLancet\\n \\nDiabetes\\n \\n&\\n \\nEndocrinology,\\n \\n8(9),\\n \\n782–792.\\n 26.  Gao,  C.,  Cai,  Y.,  Zhang,  K.,  et  al.  (2020).  Association  of  hypertension  and  \\nantihypertensive\\n \\ntreatment\\n \\nwith\\n \\nCOVID-19\\n \\nmortality.\\n \\nEuropean\\n \\nHeart\\n \\nJournal,\\n \\n41(22),\\n \\n2058–2066.\\n 27.  Kompaniyets,  L.,  Pennington,  A.  F.,  Goodman,  A.  B.,  et  al.  (2021).  Underlying  \\nmedical\\n \\nconditions\\n \\nassociated\\n \\nwith\\n \\nsevere\\n \\nCOVID-19\\n \\nillness\\n \\namong\\n \\nchildren.\\n \\nPreventing\\n \\nChronic\\n \\nDisease,\\n \\n18,\\n \\nE66.\\n 28.  Katsoularis,  I.,  Fonseca-Rodrı́guez,  O.,  Farrington,  P.,  et  al.  (2022).  Risks  of  \\nthrombotic\\n \\nand\\n \\nbleeding\\n \\nevents\\n \\nafter\\n \\nCOVID-19.\\n \\nBMJ,\\n \\n377,\\n \\ne069590.\\n 29.  Cheng,  Y.,  Luo,  R.,  Wang,  K.,  et  al.  (2020).  Kidney  disease  is  associated  with  \\nin-hospital\\n \\ndeath\\n \\nof\\n \\npatients\\n \\nwith\\n \\nCOVID-19.\\n \\nKidney\\n \\nInternational,\\n \\n97(5),\\n \\n829–838.\\n 30.  Marjot,  T.,  Moon,  A.  M.,  Cook,  J.  A.,  et  al.  (2021).  COVID-19  and  liver  \\ndisease:\\n \\nMechanistic\\n \\nand\\n \\nclinical\\n \\nperspectives.\\n \\nNature\\n \\nReviews\\n \\nGastroenterology\\n \\n&\\n \\nHepatology,\\n \\n18(5),\\n \\n348–364.\\n 31.  Singal,  A.  G.,  et  al.  (2022).  Hepatocellular  carcinoma  surveillance  outcomes  \\nand\\n \\nimpact.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n77(1),\\n \\n128–139.\\n 32.  American  Association  for  the  Study  of  Liver  Diseases.  (2021).  Clinical  \\ninsights\\n \\nfor\\n \\nhepatology\\n \\nand\\n \\nliver\\n \\ntransplant\\n \\nproviders\\n \\nduring\\n \\nCOVID-19\\n \\npandemic.\\n \\nAASLD.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 22, 'page_label': '23'}, page_content='33.  European  Association  for  the  Study  of  the  Liver.  (2021).  EASL  position  paper  \\non\\n \\nmanagement\\n \\nof\\n \\npatients\\n \\nwith\\n \\nliver\\n \\ndisease\\n \\nduring\\n \\nCOVID-19\\n \\npandemic.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n74(2),\\n \\n453–461.\\n 34.  Fix,  O.  K.,  Hameed,  B.,  Fontana,  R.  J.,  et  al.  (2020).  Clinical  best  practice  \\nadvice\\n \\nfor\\n \\nhepatology\\n \\nand\\n \\nliver\\n \\ntransplant\\n \\nproviders\\n \\nduring\\n \\nCOVID-19\\n \\npandemic.\\n \\nHepatology,\\n \\n72(1),\\n \\n287–304.\\n 35.  Boettler,  T.,  Newsome,  P.  N.,  Mondelli,  M.  U.,  et  al.  (2020).  Care  of  patients  \\nwith\\n \\nliver\\n \\ndisease\\n \\nduring\\n \\nthe\\n \\nCOVID-19\\n \\npandemic:\\n \\nEASL-ESCMID\\n \\nposition\\n \\npaper.\\n \\nLancet\\n \\nGastroenterology\\n \\n&\\n \\nHepatology,\\n \\n5(8),\\n \\n703–705.\\n 36.  Cornberg,  M.,  Buti,  M.,  Eberhardt,  C.  S.,  et  al.  (2021).  EASL  position  paper  \\non\\n \\nthe\\n \\nuse\\n \\nof\\n \\nCOVID-19\\n \\nvaccines\\n \\nin\\n \\npatients\\n \\nwith\\n \\nchronic\\n \\nliver\\n \\ndiseases.\\n \\nJournal\\n \\nof\\n \\nHepatology,\\n \\n74(4),\\n \\n944–951.\\n \\n  \\n \\n  \\n \\n8.  What  stage  of  NAFLD  is  best  treated  with  saroglitazar?  \\nSaroglitazar ,  a  dual  peroxisome  proliferator-activated  receptor  (PPAR)  α/γ  agonist,  has  \\nbeen\\n \\ninvestigated\\n \\nfor\\n \\nits\\n \\nability\\n \\nto\\n \\naddress\\n \\nboth\\n \\nhepatic\\n \\nand\\n \\nsystemic\\n \\nmetabolic\\n \\nabnormalities.\\n \\nClinical\\n \\ndata\\n \\nindicate\\n \\nthat\\n \\nits\\n \\ntherapeutic\\n \\nbenefits\\n \\nare\\n \\nmost\\n \\nconsistent\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon-cirrhotic\\n \\ndisease\\n \\n(fibrosis\\n \\nstages\\n \\nF0–F2)\\n.\\n \\nThe  Ideal  Candidate  for  Saroglitazar  (Maximum  Benefit):  \\n✓  Type  2  diabetes  mellitus  (HbA1c  7.0-9.0%)  \\n \\n✓\\n \\nHypertriglyceridemia\\n \\n(>200\\n \\nmg/dL)\\n \\n \\n✓\\n \\nMetabolic\\n \\nsyndrome\\n \\n(≥3\\n \\ncomponents)\\n \\n \\n✓\\n \\nBaseline\\n \\nALT\\n \\n1.5-4×\\n \\nULN\\n \\n \\n✓\\n \\nEarly-stage\\n \\nfibrosis\\n \\n(F0-F2)\\n \\n \\n✓\\n \\nBMI\\n \\n25-35\\n \\nkg/m²\\n \\n \\n✓\\n \\nAsian\\n \\nethnicity\\n \\n \\n✓\\n \\nWillingness\\n \\nto\\n \\ncombine\\n \\nwith\\n \\nlifestyle\\n \\nmodification'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 23, 'page_label': '24'}, page_content='9.  How  does  saroglitazar  compare  with  metformin  in  treating  \\nNASH? \\nSaroglitazar  and  metformin  have  fundamentally  different  roles  in  managing  patients  with  \\nnonalcoholic\\n \\nsteatohepatitis.\\n \\nMetformin\\n \\nis\\n \\nan\\n \\nantihyperglycaemic\\n \\nagent\\n \\nthat\\n \\nimproves\\n \\nmetabolic\\n \\nparameters\\n \\nbut\\n \\nlacks\\n \\nevidence\\n \\nfor\\n \\ndirect\\n \\nhepatic\\n \\nbenefit\\n \\nin\\n \\nNASH.\\n \\nSaroglitazar\\n \\nis\\n \\na\\n \\ndual\\n \\nperoxisome\\n \\nproliferator-activated\\n \\nreceptor\\n \\nalpha/gamma\\n \\nagonist\\n \\nwith\\n \\ndemonstrated\\n \\nimprovements\\n \\nin\\n \\nliver-specific\\n \\nbiochemical\\n \\nand\\n \\nimaging\\n \\nendpoints\\n \\nin\\n \\nnon-cirrhotic\\n \\nNAFLD/NASH\\n \\npatients.\\n \\nComparative  Evidence  \\nMetformin  \\n●  Mechanism:  Reduces  hepatic  gluconeogenesis  and  enhances  peripheral  \\ninsulin\\n \\nsensitivity;\\n \\nprimarily\\n \\ntargets\\n \\nglycaemic\\n \\ncontrol.\\n ●  Liver-specific  outcomes:  Multiple  randomized  controlled  trials  and  \\nsystematic\\n \\nreviews\\n \\nhave\\n \\nnot\\n \\ndemonstrated\\n \\nconsistent\\n \\nimprovement\\n \\nin\\n \\nNASH\\n \\nhistology\\n \\n(steatohepatitis\\n \\nresolution\\n \\nor\\n \\nfibrosis\\n \\nregression).¹\\n⁻\\n³\\n ●  Guideline  position:  Not  recommended  as  a  specific  treatment  for  NASH;  \\nindicated\\n \\nonly\\n \\nfor\\n \\nmanagement\\n \\nof\\n \\ntype\\n \\n2\\n \\ndiabetes\\n \\nin\\n \\npatients\\n \\nwho\\n \\nhappen\\n \\nto\\n \\nhave\\n \\nNAFLD/NASH.¹\\n ●  Metabolic  benefit:  Improves  insulin  resistance  and  may  support  weight  \\nmanagement,\\n \\nwhich\\n \\nindirectly\\n \\nbenefits\\n \\nliver\\n \\ndisease\\n \\nthrough\\n \\nmetabolic\\n \\noptimization.\\n \\nSaroglitazar  \\n●  Mechanism:  Dual  PPAR- α/γ  agonism  addresses  dyslipidaemia,  insulin  \\nresistance,\\n \\nhepatic\\n \\nsteatosis\\n \\nand\\n \\ninflammation\\n \\nthrough\\n \\nmultiple\\n \\npathways\\n \\nrelevant\\n \\nto\\n \\nNASH\\n \\npathophysiology.\\n ●  Liver-specific  outcomes:  ○  Phase  2  randomized  trial  demonstrated  significant  reduction  in  \\nalanine\\n \\naminotransferase\\n \\nand\\n \\nimprovement\\n \\nin\\n \\nliver\\n \\nfat\\n \\ncontent\\n \\nversus\\n \\nplacebo.\\n⁴\\n ○  Systematic  review  and  meta-analysis  showed  consistent  \\nreductions\\n \\nin\\n \\ntransaminases,\\n \\nliver\\n \\nstiffness\\n \\nmeasurements,\\n \\nand\\n \\nimprovements\\n \\nin\\n \\nmetabolic\\n \\nparameters.\\n⁵\\n ○  Real-world  studies  report  reductions  in  controlled  attenuation  \\nparameter\\n \\n(steatosis\\n \\nmarker)\\n \\nand\\n \\nliver\\n \\nstiffness,\\n \\nparticularly\\n \\nwhen\\n \\ncombined\\n \\nwith\\n \\nlifestyle\\n \\nmodification.\\n⁶\\n⁻\\n⁷\\n ●  Target  population:  Non-cirrhotic  NAFLD/NASH  (primarily  F0–F2  fibrosis)  \\nwith\\n \\nmetabolic\\n \\ndysfunction;\\n \\nevidence\\n \\nin\\n \\nadvanced\\n \\nfibrosis\\n \\nor\\n \\ncirrhosis\\n \\nis\\n \\nlimited.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 24, 'page_label': '25'}, page_content='●  Limitations:  Long-term  histological  data  and  hard  clinical  outcomes  \\n(prevention\\n \\nof\\n \\ndecompensation,\\n \\nhepatocellular\\n \\ncarcinoma,\\n \\nliver-related\\n \\nmortality)\\n \\nare\\n \\nnot\\n \\nyet\\n \\nestablished.\\n \\n  \\nParameter  Metformin  Saroglitazar  \\nPrimary  indication  Type  2  diabetes  \\nDiabetic  dyslipidaemia;  NAFLD/NASH  (country-specific  approval)  \\nNASH  histology  improvement  Not  demonstrated¹ ⁻ ³  \\nSurrogate  markers  improved;  histology  data  limited ⁴ ⁻ ⁵  \\nALT  reduction  Inconsistent  Consistent,  significant ⁴ ⁻ ⁵  \\nLiver  steatosis  (imaging)  Minimal/inconsistent  Demonstrated  reduction ⁴ ⁻ ⁷  \\nLiver  stiffness  No  consistent  effect  Reduction  demonstrated ⁵ ⁻ ⁷  \\nLipid  profile  \\nNeutral  to  modest  benefit  \\nSignificant  triglyceride  reduction ⁴ ⁻ ⁵  \\nGlycaemic  control  Established  benefit  Demonstrated  improvement ⁴ ⁻ ⁵  \\nWeight  effect  \\nNeutral  to  modest  loss  Variable;  monitor'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 25, 'page_label': '26'}, page_content='Fibrosis  stage  suitability  \\nAny  (for  diabetes  indication)  \\nBest  evidence  F0–F2;  limited  in  F3–F4  \\nGuideline  recommendation  for  NASH  Not  recommended¹  Emerging;  country-specific  \\n  \\nMetformin  is  an  effective  antihyperglycaemic  agent  without  proven  benefit  for  NASH  \\nhistology\\n \\nand\\n \\nshould\\n \\nbe\\n \\nused\\n \\nsolely\\n \\nfor\\n \\ndiabetes\\n \\nmanagement\\n \\nin\\n \\npatients\\n \\nwith\\n \\ncoexisting\\n \\nliver\\n \\ndisease.\\n \\nSaroglitazar\\n \\ndemonstrates\\n \\nconsistent\\n \\nimprovements\\n \\nin\\n \\nliver\\n \\nbiochemistry,\\n \\nsteatosis\\n \\nand\\n \\nstiffness\\n \\nsurrogate\\n \\nmarkers\\n \\nin\\n \\nnon-cirrhotic\\n \\nNAFLD/NASH\\n \\nand\\n \\naddresses\\n \\nmetabolic\\n \\ndysfunction\\n \\nthrough\\n \\ndual\\n \\nPPAR\\n \\nagonism,\\n \\nmaking\\n \\nit\\n \\na\\n \\nrational\\n \\nchoice\\n \\nfor\\n \\nliver-directed\\n \\ntherapy\\n \\nin\\n \\nselected\\n \\npatients.\\n \\nNeither\\n \\nagent\\n \\nhas\\n \\nestablished\\n \\nlong-term\\n \\noutcome\\n \\ndata\\n \\nfor\\n \\nprevention\\n \\nof\\n \\ncirrhosis\\n \\nor\\n \\nliver-related\\n \\nevents;\\n \\ntreatment\\n \\nshould\\n \\nbe\\n \\nindividualized\\n \\nand\\n \\nintegrated\\n \\nwith\\n \\nlifestyle\\n \\nmodification\\n \\nand\\n \\nmanagement\\n \\nof\\n \\nmetabolic\\n \\ncomorbidities.\\n \\n1.  Gawrieh,  S.,  Noureddin,  M.,  Loo,  et  al.  (2021).  Saroglitazar,  a  PPAR- α/γ  \\nagonist,\\n \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n controlled  double-blind  phase  2  trial.  Hepatology ,  74 (4),  1809–1824. https://doi.org/10.1002/hep.31843 2.  Gupte,  P.,  et  al.  (2020).  Non-alcoholic  steatohepatitis  in  type  2  diabetes  mellitus.  Journal  of  Gastroenterology  and  Hepatology ,  19 (8),  854–858. https://doi.org/10.1111/j.1440-1746.2004.03312.x 3.  Siddiqui,  M.  S.,  (2021).  A  phase  2  double  blinded,  randomized  controlled  \\ntrial\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnonalcoholic\\n \\nsteatohepatitis.\\n \\nClinical\\n Gastroenterology  and  Hepatology ,  19 (12),  2670–2672. https://doi.org/10.1016/j.cgh.2020.10.051 4.  Kumar,  A.,  Sharma,  A.,  et  al.  (2023).  Effects  of  saroglitazar  in  patients  \\nwith\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon-alcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n \\nand\\n \\nmeta-analysis.\\n \\nClinical\\n and  Experimental  Hepatology ,  9 (2),  117–128. https://doi.org/10.5114/ceh.2023.127873 5.  Dutta,  D.,  Kumar,  et  al.  (2021).  Impact  of  saroglitazar  on  glycemic  control,  \\ndyslipidemia,\\n \\nliver\\n \\nfunction,\\n \\nand\\n \\nbody\\n \\nweight\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes:\\n \\nA\\n \\nreal-world\\n \\nstudy.\\n \\nIndian\\n \\nJournal\\n \\nof\\n \\nEndocrinology\\n \\nand\\n \\nMetabolism\\n,\\n \\n25\\n(2),\\n 133–139. https://doi.org/10.4103/ijem.IJEM_787_20'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 26, 'page_label': '27'}, page_content='6.  Chalasani,  N.,  et  al.  (2018).  The  diagnosis  and  management  of  \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nPractice\\n \\nguidance\\n \\nfrom\\n \\nthe\\n \\nAmerican\\n Association  for  the  Study  of  Liver  Diseases.  Hepatology ,  67 (1),  328–357. https://doi.org/10.1002/hep.29367 \\n \\n \\n \\n10.Duration  of  therapy  with  saroglitazar  in  NASH  patients?  \\nCurrent  evidence  supports  saroglitazar  therapy  for  at  least  6–12  months in  non-cirrhotic  \\nNAFLD/NASH\\n \\npatients\\n \\n(F0–F2)\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction,\\n \\nwith\\n \\ntreatment\\n \\ndecisions\\n \\nindividualized\\n \\nbased\\n \\non\\n \\nbiochemical\\n \\nand\\n \\nimaging\\n \\nresponse.\\n \\nMany\\n \\npatients\\n \\nmay\\n \\nrequire\\n long-term  or  indefinite  therapy given  the  chronic  nature  of  metabolic  liver  disease,  analogous  to  \\nmanagement\\n \\nof\\n \\ndiabetes\\n \\nor\\n \\ndyslipidaemia.\\n \\nReassessment\\n \\nevery\\n \\n6–12\\n \\nmonths\\n \\nshould\\n \\nguide\\n \\ncontinuation,\\n \\ndose\\n \\nadjustment\\n \\nor\\n \\ndiscontinuation.\\n \\nDefinitive\\n \\nrecommendations\\n \\non\\n \\noptimal\\n \\ntreatment\\n \\nduration\\n \\nawait\\n \\ncompletion\\n \\nof\\n \\nlong-term\\n \\nhistological\\n \\nand\\n \\nclinical\\n \\noutcome\\n \\ntrials.\\n \\n \\n11.Is  saroglitazar  safe  to  use  in  Diabetic  Dyslipidemia  \\npatients?\\n \\nYes.  Saroglitazar  is  safe  and  well  tolerated  in  patients  with  diabetic  dyslipidemia.  It  is  \\nspecifically\\n \\napproved\\n \\nin\\n \\nIndia\\n \\nfor\\n \\nthis\\n \\nindication\\n \\nand\\n \\nhas\\n \\ndemonstrated\\n \\nan\\n \\nacceptable\\n \\nsafety\\n \\nprofile\\n \\nacross\\n \\nmultiple\\n \\nrandomized\\n \\ncontrolled\\n \\ntrials,\\n \\nreal-world\\n \\nstudies\\n \\nand\\n \\npost-marketing\\n \\nsurveillance\\n \\ndata\\n \\nspanning\\n \\nseveral\\n \\nyears\\n \\nof\\n \\nclinical\\n \\nuse.\\n \\nSafety  Evidence  from  Clinical  Trials  \\nPivotal  Registration  Trials  \\nPRESS  V  (2013)  —  Phase  3  Diabetic  Dyslipidemia  Trial  \\n●  Design:  Randomized,  double-blind,  placebo-controlled  trial  in  495  patients  with  type  \\n2\\n \\ndiabetes\\n \\nand\\n \\ndyslipidemia\\n \\ninadequately\\n \\ncontrolled\\n \\non\\n \\nstatin\\n \\ntherapy.¹\\n ●  Duration:  24  weeks  ●  Saroglitazar  doses:  2  mg  and  4  mg  daily  ●  Safety  findings:'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 27, 'page_label': '28'}, page_content='○  Adverse  events  were  comparable  between  saroglitazar  and  placebo  groups  ○  No  significant  increase  in  serious  adverse  events  ○  No  cases  of  hepatotoxicity,  rhabdomyolysis  or  heart  failure  ○  Mild  transient  serum  creatinine  elevation  observed  in  small  proportion;  \\nclinically\\n \\nnon-significant\\n \\nand\\n \\nreversible\\n ○  No  weight  gain  (unlike  thiazolidinediones);  modest  weight  reduction  observed  ●  Conclusion:  Saroglitazar  2  mg  and  4  mg  demonstrated  good  safety  and  tolerability  \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\npatients\\n \\nover\\n \\n24\\n \\nweeks.¹\\n \\nPRESS  VI  (2015)  —  Phase  3  Hypertriglyceridemia  Trial  \\n●  Design:  Randomized,  double-blind,  placebo-controlled  trial  in  150  patients  with  \\ndiabetic\\n \\ndyslipidemia\\n \\nand\\n \\nhypertriglyceridemia\\n \\nnot\\n \\nadequately\\n \\ncontrolled\\n \\non\\n \\nstatin.²\\n ●  Duration:  12  weeks  ●  Saroglitazar  dose:  4  mg  daily  ●  Safety  findings:  ○  Well  tolerated  with  adverse  event  profile  similar  to  placebo  ○  No  serious  adverse  events  attributed  to  saroglitazar  ○  No  hepatotoxicity  signals  ○  Transient,  mild  serum  creatinine  elevation  in  few  patients;  reversible  and  not  \\nassociated\\n \\nwith\\n \\nrenal\\n \\ndysfunction\\n ○  No  edema  or  heart  failure  events  ●  Conclusion:  Saroglitazar  4  mg  was  safe  and  well  tolerated  in  patients  with  diabetic  \\ndyslipidemia\\n \\nand\\n \\nsevere\\n \\nhypertriglyceridemia.²\\n \\nLong-Term  Safety  Data  \\nPRESS  VII  (2019)  —  52-Week  Open-Label  Extension  Study  \\n●  Design:  Open-label  extension  of  PRESS  V  and  VI  trials;  1,197  patients  with  diabetic  \\ndyslipidemia\\n \\ntreated\\n \\nwith\\n \\nsaroglitazar\\n \\n2\\n \\nmg\\n \\nor\\n \\n4\\n \\nmg\\n \\nfor\\n \\nup\\n \\nto\\n \\n52\\n \\nweeks.³\\n ●  Safety  findings:  ○  Adverse  events  were  mild  to  moderate  in  severity  ○  Most  common:  upper  respiratory  tract  infection,  gastritis,  dyspepsia  (similar  to  \\nbackground\\n \\npopulation\\n \\nrates)\\n ○  Serious  adverse  events:  <2%  and  not  attributed  to  saroglitazar  ○  No  cases  of  drug-induced  liver  injury,  rhabdomyolysis,  heart  failure  or  \\nperipheral\\n \\nedema\\n ○  Liver  enzymes  remained  stable  or  improved  ○  Renal  function  stable;  transient  creatinine  elevations  non-progressive  ○  No  increase  in  cardiovascular  events  ●  Conclusion:  Long-term  (52-week)  saroglitazar  therapy  demonstrated  sustained  \\nsafety\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\npatients.³\\n \\nReal-World  Safety  Evidence'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 28, 'page_label': '29'}, page_content='Post-Marketing  Surveillance  and  Observational  Studies  \\nGupte  et  al.  (2020)  —  Real-World  Prospective  Study  \\n●  Design:  Prospective  observational  study  of  302  patients  with  NAFLD  and  diabetic  \\ndyslipidemia\\n \\ntreated\\n \\nwith\\n \\nsaroglitazar\\n \\n4\\n \\nmg\\n \\nfor\\n \\n24\\n \\nweeks.\\n⁴\\n ●  Safety  findings:  ○  Adverse  events  reported  in  8.6%  of  patients;  all  mild  and  self-limiting  ○  No  serious  adverse  events  ○  No  hepatotoxicity  or  muscle-related  adverse  events  ○  Excellent  tolerability  with  <2%  discontinuation  rate  due  to  adverse  effects  ●  Conclusion:  Real-world  data  confirmed  favorable  safety  profile  in  routine  clinical  \\npractice.\\n⁴\\n \\nDutta  et  al.  (2021)  —  Single-Center  Real-World  Study  \\n●  Design:  Retrospective  analysis  of  91  patients  with  NAFLD  and  type  2  diabetes  \\ntreated\\n \\nwith\\n \\nsaroglitazar\\n \\nfor\\n \\nmean\\n \\nduration\\n \\nof\\n \\n18\\n \\nmonths.\\n⁵\\n ●  Safety  findings:  ○  No  serious  adverse  events  attributed  to  saroglitazar  ○  No  cases  of  hepatotoxicity,  myopathy  or  heart  failure  ○  Mild  gastrointestinal  symptoms  in  6.6%  (nausea,  dyspepsia);  self-limiting  ○  Liver  enzymes  improved  rather  than  worsened  ○  Good  long-term  tolerability  ●  Conclusion:  Extended  real-world  use  (up  to  24  months)  demonstrated  sustained  \\nsafety\\n \\nin\\n \\ndiabetic\\n \\npatients.\\n⁵\\n \\nSystematic  Reviews  and  Meta-Analyses  \\nKumar  et  al.  (2023)  —  Systematic  Review  and  Meta-Analysis  \\n●  Design:  Pooled  analysis  of  randomized  controlled  trials  and  observational  studies  \\nevaluating\\n \\nsaroglitazar\\n \\nin\\n \\nNAFLD/NASH\\n \\nand\\n \\ndiabetic\\n \\ndyslipidemia.\\n⁶\\n ●  Safety  findings:  ○  No  significant  increase  in  adverse  events  versus  placebo  or  standard  care  ○  No  hepatotoxicity  signals  across  pooled  studies  ○  Transient  creatinine  elevation  noted  but  not  associated  with  progressive  renal  \\ndysfunction\\n ○  No  increase  in  cardiovascular  events,  heart  failure  or  edema  ○  Discontinuation  rates  due  to  adverse  events  were  low  (<5%)  ●  Conclusion:  Meta-analysis  confirmed  acceptable  safety  profile  of  saroglitazar  in  \\nmetabolic\\n \\npopulations\\n \\nincluding\\n \\ndiabetic\\n \\ndyslipidemia.\\n⁶\\n \\nKey  Safety  Parameters  Monitored'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 29, 'page_label': '30'}, page_content='Hepatic  Safety  \\n●  Multiple  trials  and  real-world  studies  show  no  hepatotoxicity  signals  ●  Liver  enzymes  (ALT,  AST)  typically  improve  rather  than  worsen  with  saroglitazar  \\ntherapy¹\\n⁻⁶\\n ●  No  cases  of  drug-induced  liver  injury  reported  in  clinical  trials  \\nRenal  Safety  \\n●  Transient,  mild  serum  creatinine  elevations  observed  in  small  proportion  of  patients  \\n(mechanism\\n \\nunclear;\\n \\npossibly\\n \\nrelated\\n \\nto\\n \\naltered\\n \\ncreatinine\\n \\nhandling)¹\\n⁻\\n³\\n ●  Elevations  are  non-progressive,  reversible  and  not  associated  with  decline  in  \\nestimated\\n \\nglomerular\\n \\nfiltration\\n \\nrate\\n ●  No  cases  of  acute  kidney  injury  attributed  to  saroglitazar  ●  Recommendation:  Monitor  renal  function  at  baseline  and  periodically;  use  caution  \\nin\\n \\nsevere\\n \\nrenal\\n \\nimpairment\\n \\nCardiovascular  Safety  \\n●  No  increase  in  cardiovascular  events  across  trials¹ ⁻ ³  ●  No  heart  failure  or  peripheral  edema  (unlike  thiazolidinediones  which  activate  \\nPPAR-\\nγ\\n \\nmore\\n \\nstrongly)\\n ●  Balanced  PPAR- α/γ  activity  may  confer  cardiovascular  safety  advantage  ●  Improvements  in  lipid  profile  (triglycerides,  HDL-C)  may  provide  cardiovascular  \\nbenefit\\n \\nMusculoskeletal  Safety  \\n●  No  cases  of  rhabdomyolysis  or  clinically  significant  myopathy  in  clinical  trials¹ ⁻⁶  ●  Creatine  kinase  elevations  rare  and  mild  ●  Safe  to  use  with  statins  (most  trial  patients  were  on  background  statin  therapy)  \\nMetabolic  Safety  \\n●  No  weight  gain  (unlike  pioglitazone);  modest  weight  reduction  observed  in  some  \\nstudies¹\\n⁻\\n³\\n ●  No  hypoglycemia  when  used  as  monotherapy;  standard  precautions  when  \\ncombined\\n \\nwith\\n \\ninsulin\\n \\nor\\n \\nsulfonylureas\\n ●  Improves  glycemic  control  (HbA1c  reduction  0.3–0.8%)  without  increasing  \\nhypoglycemia\\n \\nrisk¹\\n⁻⁶\\n \\nGastrointestinal  Tolerability'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 30, 'page_label': '31'}, page_content='●  Mild  gastrointestinal  symptoms  (nausea,  dyspepsia,  gastritis)  reported  in  5–10%  of  \\npatients\\n⁴⁻⁵\\n ●  Symptoms  typically  mild,  transient  and  self-limiting  ●  Low  discontinuation  rates  due  to  gastrointestinal  adverse  effects  \\nContraindications  and  Precautions  \\nContraindications  \\n●  Known  hypersensitivity  to  saroglitazar  or  excipients  ●  Severe  renal  impairment  (eGFR  <30  mL/min/1.73m²)  —  limited  data  ●  Severe  hepatic  impairment  or  decompensated  cirrhosis  —  not  studied  ●  Pregnancy  and  lactation  —  safety  not  established  \\nPrecautions  \\n●  Monitor  liver  function  tests  at  baseline  and  periodically  (though  hepatotoxicity  not  \\nobserved)\\n ●  Monitor  renal  function,  particularly  in  patients  with  pre-existing  chronic  kidney  \\ndisease\\n ●  Use  caution  when  combining  with  other  medications  metabolized  by  \\nCYP2C8/CYP2C9\\n ●  Adjust  doses  of  concomitant  antidiabetic  medications  to  avoid  hypoglycemia  ●  Counsel  patients  on  lifestyle  modification  as  adjunct  to  pharmacotherapy  \\nComparative  Safety:  Saroglitazar  vs.  Other  PPAR  \\nAgonists\\n \\nSafety  Parameter  \\nSaroglitazar  (PPAR- α/γ)  \\nPioglitazone  (PPAR- γ)  \\nFibrates  (PPAR- α)  \\nWeight  gain  No  /  modest  reduction  \\nYes  (significant)  Neutral  \\nEdema  /  heart  failure  \\nNo  Yes  (significant  risk)  \\nRare'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 31, 'page_label': '32'}, page_content='Bone  fractures  No  signal  Increased  risk  (women)  \\nNo  \\nBladder  cancer  No  signal  Controversial  association  \\nNo  \\nHepatotoxicity  No  Rare  Rare  \\nMyopathy  No  No  Rare  (with  statins)  \\nRenal  effects  Transient  creatinine  ↑  \\nNeutral  May  ↑  creatinine  \\nInterpretation:  Saroglitazar  demonstrates  a  more  favorable  safety  profile  than  \\npioglitazone\\n \\n(no\\n \\nweight\\n \\ngain,\\n \\nedema\\n \\nor\\n \\nheart\\n \\nfailure\\n \\nrisk)\\n \\nwhile\\n \\nmaintaining\\n \\nefficacy\\n \\non\\n \\nmetabolic\\n \\nand\\n \\nhepatic\\n \\nparameters.\\n \\n \\nRegulatory  Approval  and  Post-Marketing  Surveillance  \\n●  India  (2013):  Approved  for  diabetic  dyslipidemia  and  hypertriglyceridemia  not  \\nadequately\\n \\ncontrolled\\n \\nby\\n \\nstatins\\n \\nalone\\n ●  Post-marketing  surveillance:  Over  10  years  of  clinical  use  in  India  with  no  major  \\nsafety\\n \\nsignals\\n \\nidentified\\n ●  Pharmacovigilance  data:  Consistent  with  clinical  trial  safety  profile;  rare  \\nspontaneous\\n \\nreports\\n \\nof\\n \\nmild\\n \\nadverse\\n \\nevents\\n \\nSummary  Statement  \\nSaroglitazar  is  safe  and  well  tolerated  in  patients  with  diabetic  dyslipidemia  based  on  \\nrobust\\n \\nevidence\\n \\nfrom\\n \\nmultiple\\n \\nrandomized\\n \\ncontrolled\\n \\ntrials,\\n \\nlong-term\\n \\nextension\\n \\nstudies,\\n \\nreal-world\\n \\nobservational\\n \\ndata\\n \\nand\\n \\nsystematic\\n \\nreviews.\\n \\nThe\\n \\nsafety\\n \\nprofile\\n \\nis\\n \\ncharacterized\\n \\nby:\\n \\n●  No  hepatotoxicity  (liver  enzymes  improve)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 32, 'page_label': '33'}, page_content='●  No  cardiovascular  safety  concerns  (no  heart  failure,  edema  or  increased  \\ncardiovascular\\n \\nevents)\\n ●  No  myopathy  or  rhabdomyolysis  ●  Transient,  non-progressive  creatinine  elevations  in  small  proportion  (monitor  \\nrenal\\n \\nfunction)\\n ●  No  weight  gain  (advantage  over  pioglitazone)  ●  Low  discontinuation  rates  due  to  adverse  effects  ●  Good  long-term  tolerability  up  to  52  weeks  and  beyond  \\nSaroglitazar  represents  a  safe  therapeutic  option  for  diabetic  dyslipidemia  patients,  \\nparticularly\\n \\nthose\\n \\nwith\\n \\ncoexisting\\n \\nNAFLD/NASH,\\n \\nwith\\n \\nroutine\\n \\nmonitoring\\n \\nof\\n \\nliver\\n \\nand\\n \\nrenal\\n \\nfunction\\n \\nas\\n \\nper\\n \\nstandard\\n \\nclinical\\n \\npractice.\\n \\n \\nClinical  Interpretation  and  Recommendations  for  \\npractical\\n \\npurpose\\n \\nSaroglitazar  —  Best  Safety  Profile  for:  \\n●  ✓  Diabetic  dyslipidemia  with  NAFLD/NASH  (non-cirrhotic)  ●  ✓  Patients  requiring  both  lipid  and  liver-directed  therapy  ●  ✓  Patients  at  risk  of  heart  failure  or  fluid  retention  (advantage  over  pioglitazone)  ●  ✓  Patients  concerned  about  weight  gain  ●  ✓  Combination  with  statins  (no  myopathy  signal)  \\nPioglitazone  —  Consider  When:  \\n●  Histology-proven  NASH  benefit  needed  (established  phase  3  data)  ●  Patient  can  tolerate  weight  gain  and  fluid  retention  ●  Avoid: Heart  failure  (NYHA  III-IV),  osteoporosis  (women),  bladder  cancer  history  \\nFibrates  —  Consider  When:  \\n●  Severe  hypertriglyceridemia  (>500  mg/dL)  requiring  rapid  reduction  ●  Caution: Combination  with  statins  (myopathy  risk);  monitor  CK  \\nVitamin  E  —  Consider  When:'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 33, 'page_label': '34'}, page_content='●  Non-diabetic  NASH  with  biopsy  confirmation  ●  Avoid: Smokers,  anticoagulated  patients,  hemorrhagic  stroke  history  \\nMetformin  —  Use  When:  \\n●  Diabetes  management  is  primary  goal  (not  NASH-specific  therapy)  ●  Avoid: eGFR  <30,  metabolic  acidosis,  contrast  procedures  \\nStatins  —  Use  When:  \\n●  Cardiovascular  risk  reduction  and  LDL-lowering  are  primary  goals  ●  Safe  in  NAFLD/NASH;  no  hepatotoxicity  concern  ●  Caution: Myalgia  common;  monitor  CK  if  symptomatic  \\nReferences  (APA  Format)  \\n1.  Jani,  R.  H.,  Pai,  V.,  Jha,  P.,  Jariwala,  G.,  Mukhopadhyay,  S.,  Bhansali,  A.,  &  Joshi,  S.  (2014).  A  multicenter,  \\nprospective,\\n \\nrandomized,\\n \\ndouble-blind\\n \\nstudy\\n \\nto\\n \\nevaluate\\n \\nthe\\n \\nsafety\\n \\nand\\n \\nefficacy\\n \\nof\\n \\nsaroglitazar\\n \\n2\\n \\nand\\n \\n4\\n \\nmg\\n \\ncompared\\n \\nwith\\n \\nplacebo\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes\\n \\nmellitus\\n \\npatients\\n \\nhaving\\n \\nhypertriglyceridemia\\n \\nnot\\n \\ncontrolled\\n \\nwith\\n \\natorvastatin\\n \\ntherapy\\n (PRESS  V).  Diabetes  Technology  &  Therapeutics ,  16 (2),  63–71. https://doi.org/10.1089/dia.2013.0253   2.  Pai,  V.,  Paneerselvam,  A.,  Mukhopadhyay,  S.,  Bhansali,  A.,  Kamath,  D.,  Shankar,  V.,  Gambhire,  D.,  Jani,  R.  H.,  &  \\nJoshi,\\n \\nS.\\n \\n(2014).\\n \\nA\\n \\nmulticenter,\\n \\nprospective,\\n \\nrandomized,\\n \\ndouble-blind\\n \\nstudy\\n \\nto\\n \\nevaluate\\n \\nthe\\n \\nsafety\\n \\nand\\n \\nefficacy\\n \\nof\\n \\nsaroglitazar\\n \\n2\\n \\nand\\n \\n4\\n \\nmg\\n \\ncompared\\n \\nto\\n \\npioglitazone\\n \\n45\\n \\nmg\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\n(PRESS\\n \\nVI).\\n \\nDiabetes\\n \\nTechnology\\n &  Therapeutics ,  16 (9),  589–598. https://doi.org/10.1089/dia.2013.0288   3.  Kaul,  U.,  Parmar,  D.,  Manjunath,  K.,  Shah,  M.,  Parmar,  K.,  Patil,  K.  P.,  &  Jaiswal,  A.  (2019).  New  dual  peroxisome  \\nproliferator\\n \\nactivated\\n \\nreceptor\\n \\nagonist—Saroglitazar\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\nand\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n Integrated  analysis  of  the  real  world  evidence.  Cardiovascular  Diabetology ,  18 (1),  80. https://doi.org/10.1186/s12933-019-0884-3   4.  Gupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  Baijal,  R.,  Kulshrestha,  P.,  Pramanik,  S.,  Patel,  N.,  Madan,  A.,  Amarapurkar,  A.,  \\n&\\n \\nHafeezunnisa.\\n \\n(2020).\\n \\nNon-alcoholic\\n \\nsteatohepatitis\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes\\n \\nmellitus.\\n \\nJournal\\n \\nof\\n \\nGastroenterology\\n \\nand\\n Hepatology ,  19 (8),  854–858. https://doi.org/10.1111/j.1440-1746.2004.03312.x   5.  Dutta,  D.,  Kumar,  M.,  Shivaprasad,  K.  S.,  Kumar,  A.,  Sharma,  M.,  &  Mukhopadhyay,  S.  (2021).  Impact  of  saroglitazar  \\non\\n \\nglycemic\\n \\ncontrol,\\n \\ndyslipidemia,\\n \\nliver\\n \\nfunction,\\n \\nand\\n \\nbody\\n \\nweight\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes:\\n \\nA\\n \\nreal-world\\n \\nstudy.\\n \\nIndian\\n Journal  of  Endocrinology  and  Metabolism ,  25 (2),  133–139. https://doi.org/10.4103/ijem.IJEM_787_20   6.  Kumar,  A.,  Sharma,  A.,  Duseja,  A.,  Das,  A.,  Dhiman,  R.  K.,  Chawla,  Y.  K.,  Kohli,  K.  K.,  &  Bhansali,  A.  (2023).  Effects  \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon-alcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n systematic  review  and  meta-analysis.  Clinical  and  Experimental  Hepatology ,  9 (2),  117–128. https://doi.org/10.5114/ceh.2023.127873'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 34, 'page_label': '35'}, page_content=''), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 35, 'page_label': '36'}, page_content='12.What  are  the  side-effects  of  saroglitazar?  \\nSide  Effects  of  Saroglitazar  (Bilypsa)   \\nCommon  Adverse  Events  \\nBased  on  the  official  Bilypsa  (Saroglitazar)  prescribing  information  from  Zydus,  the  most  \\ncommon\\n \\nside\\n \\neffects\\n \\nreported\\n \\nin\\n \\nclinical\\n \\ntrials\\n \\ninclude:\\n \\nInfections  \\n●  Upper  respiratory  tract  infection  \\nGastrointestinal  \\n●  Diarrhea  ●  Nausea  \\nNeurological  \\n●  Headache  ●  Dizziness  \\nMusculoskeletal  \\n●  Back  pain  ●  Arthralgia  (joint  pain)  \\nCardiovascular/Fluid  Balance  \\n●  Peripheral  edema  (swelling  of  extremities)  \\nHepatic  \\n●  Increased  liver  enzymes  (ALT,  AST)  \\nSerious  Adverse  Events  (Rare)  \\nWhile  uncommon,  the  following  serious  adverse  events  may  occur:  \\n1.  Severe  hypoglycemia  (particularly  when  combined  with  insulin  or  sulfonylureas)  2.  Hepatotoxicity  (liver  injury)  3.  Fluid  retention  leading  to  worsening  heart  failure'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 36, 'page_label': '37'}, page_content='Warnings  and  Precautions  \\n1.  Hypoglycemia  Risk  \\n●  Increased  risk  when  Bilypsa  is  combined  with  other  antidiabetic  agents  \\n(sulfonylureas,\\n \\ninsulin)\\n ●  Action:  Monitor  blood  glucose  closely;  consider  dose  reduction  of  concomitant  \\nmedications\\n \\nif\\n \\nhypoglycemia\\n \\noccurs\\n \\n2.  Hepatic  Monitoring  \\n●  Contraindicated  in  moderate  to  severe  hepatic  impairment  (Child-Pugh  B  or  C)  ●  Use  caution  in  mild  hepatic  impairment  ●  Action:  Monitor  liver  function  tests  (ALT,  AST,  bilirubin)  periodically  \\n3.  Renal  Function  \\n●  Contraindicated  in  severe  renal  impairment  (CrCl  <30  mL/min)  ●  Dose  adjustment  may  be  necessary  in  mild  to  moderate  renal  impairment  ●  Action:  Monitor  renal  function  periodically  \\n4.  Fluid  Retention  and  Edema  \\n●  As  with  other  PPAR  agonists,  may  cause  fluid  retention  and  edema  ●  Use  with  caution  in  patients  with  conditions  exacerbated  by  fluid  retention  (e.g.,  heart  \\nfailure)\\n ●  Action:  Monitor  for  signs  of  fluid  overload,  weight  gain,  edema  \\n5.  Cardiovascular  Safety  \\n●  Patients  with  pre-existing  cardiovascular  disease  should  be  monitored  ●  Clinical  trials  have  not  shown  increased  risk  of  major  adverse  cardiovascular  events  \\n6.  Laboratory  Monitoring  \\n●  Action:  Periodic  monitoring  of  liver  function  tests  and  renal  function  tests  required  \\nContraindications  (Do  Not  Use)  \\nBilypsa  (Saroglitazar)  is  contraindicated  in:  \\n1.  Known  hypersensitivity  to  saroglitazar  or  any  excipients  2.  Pregnancy  and  breastfeeding'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 37, 'page_label': '38'}, page_content='3.  Severe  renal  impairment  (CrCl  <30  mL/min)  4.  Moderate  to  severe  hepatic  impairment  (Child-Pugh  B  or  C)  \\nDrug  Interactions  \\nCYP2C8  Interactions  \\n●  Saroglitazar  is  a  substrate  of  CYP2C8  enzyme  ●  Strong  CYP2C8  inhibitors  may  increase  saroglitazar  exposure  (dose  adjustment  \\nmay\\n \\nbe\\n \\nneeded)\\n ●  Strong  CYP2C8  inducers  may  decrease  saroglitazar  exposure  (dose  adjustment  \\nmay\\n \\nbe\\n \\nneeded)\\n \\nOther  Antidiabetic  Agents  \\n●  Concomitant  use  with  insulin  or  sulfonylureas  increases  hypoglycemia  risk  ●  Action:  Monitor  blood  glucose;  adjust  doses  as  needed  \\nUse  in  Special  Populations  \\nPopulation  Recommendation  \\nPregnancy  Contraindicated  \\nLactation  Contraindicated  \\nPediatric  Safety  and  effectiveness  not  established  \\nGeriatric  No  overall  differences  in  safety;  use  with  caution  in  elderly  with  multiple  comorbidities  \\nMild  hepatic  impairment  \\nUse  with  caution;  monitor  liver  function'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 38, 'page_label': '39'}, page_content='Moderate-severe  hepatic  impairment  \\nContraindicated  \\nMild-moderate  renal  impairment  \\nDose  adjustment  may  be  necessary;  monitor  renal  function  \\nSevere  renal  impairment  \\nContraindicated  \\nMonitoring  Requirements  \\nBaseline  Assessment  \\n●  Liver  function  tests  (ALT,  AST,  bilirubin)  ●  Renal  function  tests  (serum  creatinine,  eGFR)  ●  Fasting  blood  glucose  /  HbA1c  ●  Lipid  profile  ●  Body  weight  ●  Cardiovascular  assessment  (if  pre-existing  disease)  \\nFollow-Up  Monitoring  \\n●  First  3  months:  Monthly  liver  and  renal  function  tests,  blood  glucose  ●  Thereafter:  Every  3-6  months  or  as  clinically  indicated  ●  Monitor  for:  Signs  of  fluid  retention,  edema,  weight  gain,  hypoglycemia  symptoms  \\nPatient  Counseling  Points  \\nInform  Patients  About:  \\n1.  Common  side  effects:  Upper  respiratory  infections,  GI  symptoms  (diarrhea,  \\nnausea),\\n \\nheadache,\\n \\ndizziness\\n 2.  Hypoglycemia  risk:  Especially  when  combined  with  insulin  or  sulfonylureas;  \\nrecognize\\n \\nsymptoms\\n \\n(sweating,\\n \\nshakiness,\\n \\nconfusion)\\n 3.  Fluid  retention:  Report  sudden  weight  gain,  swelling  of  feet/ankles,  shortness  of  \\nbreath\\n 4.  Liver  monitoring:  Importance  of  regular  blood  tests;  report  jaundice,  dark  urine,  \\nabdominal\\n \\npain'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 39, 'page_label': '40'}, page_content='5.  Pregnancy:  Contraindicated;  use  effective  contraception  6.  Adherence:  Take  as  prescribed;  do  not  discontinue  without  consulting  physician  7.  Lifestyle:  Continue  diet  and  exercise  modifications  as  adjunct  to  medication  \\nSummary:  Safety  Profile  of  Bilypsa  (Saroglitazar)  \\nOverall:  Saroglitazar  (Bilypsa)  demonstrates  an  acceptable  safety  profile  with  most  adverse  \\nevents\\n \\nbeing\\n \\nmild\\n \\nto\\n \\nmoderate\\n \\nin\\n \\nseverity.\\n \\nThe\\n \\nmost\\n \\ncommon\\n \\nside\\n \\neffects\\n \\nare\\n \\nupper\\n \\nrespiratory\\n \\ninfections,\\n \\ngastrointestinal\\n \\nsymptoms,\\n \\nheadache\\n \\nand\\n \\nmild\\n \\nperipheral\\n \\nedema.\\n \\nSerious\\n \\nadverse\\n \\nevents\\n \\nare\\n \\nrare\\n \\nbut\\n \\ninclude\\n \\nhypoglycemia\\n \\n(when\\n \\ncombined\\n \\nwith\\n \\nother\\n \\nantidiabetic\\n \\nagents),\\n \\nhepatotoxicity\\n \\nand\\n \\nfluid\\n \\nretention\\n \\npotentially\\n \\nworsening\\n \\nheart\\n \\nfailure.\\n \\nKey  Safety  Advantages:  \\n●  No  significant  weight  gain  (unlike  pioglitazone)  ●  Lower  risk  of  heart  failure  compared  to  other  PPAR- γ  agonists  ●  Improves  rather  than  worsens  liver  enzymes  in  most  patients  with  NAFLD/NASH  \\nCritical  Monitoring:  \\n●  Regular  liver  and  renal  function  tests  ●  Blood  glucose  monitoring  (especially  with  concomitant  antidiabetic  therapy)  ●  Watch  for  fluid  retention  and  edema  ●  Contraindicated  in  pregnancy,  severe  renal/hepatic  impairment  \\nSource:  Bilypsa  (Saroglitazar)  Prescribing  Information,  Zydus  Cadila  Healthcare  Ltd.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 40, 'page_label': '41'}, page_content='13.What  are  the  parameters  to  check  efficacy  of  saroglitazar  \\ntherapy?\\n \\nParameters  to  Check  Efficacy  of  Saroglitazar  Therapy  \\n1.  Biochemical  Parameters  \\nLiver  Function  \\n●  ALT  (Alanine  Aminotransferase)  —  primary  endpoint;  target  ≥30%  reduction  ●  AST  (Aspartate  Aminotransferase)  —  expect  parallel  reduction  ●  GGT  (Gamma-Glutamyl  Transferase)  —  inflammation  marker  \\nLipid  Profile  \\n●  Triglycerides  —  target  30-50%  reduction  ●  HDL  Cholesterol  —  expect  5-10%  increase  ●  LDL  Cholesterol  —  expect  5-15%  reduction  \\nGlycemic  Control  \\n●  HbA1c  —  target  0.3-0.8%  reduction  ●  Fasting  Blood  Glucose  —  expect  improvement  \\n2.  Non-Invasive  Imaging  (FibroScan)  \\n●  CAP  (Controlled  Attenuation  Parameter)  —  steatosis;  target  reduction  ●  LSM  (Liver  Stiffness  Measurement)  —  fibrosis;  expect  2-4  kPa  reduction  \\n3.  Clinical  Parameters  \\n●  Body  Weight  /  BMI  —  monitor  for  stability  or  modest  reduction  ●  Waist  Circumference  —  visceral  adiposity  marker  \\n4.  Safety  Monitoring  \\n●  Serum  Creatinine  /  eGFR  —  renal  function  ●  Peripheral  Edema  —  fluid  retention'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 41, 'page_label': '42'}, page_content='Assessment  Timeline  \\nTime  Parameters  \\nBaseline  All  parameters  \\nMonth  3  ALT,  AST,  lipids,  FBG,  creatinine,  weight  \\nMonth  6  Complete  reassessment  +  FibroScan  +  HbA1c  \\nEvery  6  months  \\nALT,  lipids,  HbA1c,  creatinine,  weight;  FibroScan  annually  \\nResponse  Criteria  \\nGood  Response  (Continue):  \\n●  ALT  ↓  ≥30%  ●  Triglycerides  ↓  ≥30%  ●  CAP/LSM  improvement  \\nPartial  Response  (Continue  +  Optimize):  \\n●  ALT  ↓  10-30%  ●  Modest  improvements  \\nNon-Response  (Re-evaluate):  \\n●  ALT  ↓  <10%  ●  No  improvement  in  lipids/imaging  \\n \\nKey  Efficacy  Markers:  ✓  ↓  ALT/AST  (liver)  \\n \\n✓\\n \\n↓\\n \\nTriglycerides,\\n \\n↑\\n \\nHDL\\n \\n(lipids)\\n \\n \\n✓\\n \\n↓\\n \\nHbA1c\\n \\n(glucose)\\n \\n \\n✓\\n \\n↓\\n \\nCAP\\n \\n&\\n \\nLSM\\n \\n(steatosis\\n \\n&\\n \\nfibrosis)\\n \\nKey  References:  Clinical  Assessment  Parameters  for  Saroglitazar  \\n1.  Biochemical  Parameters  (ALT,  AST,  Lipids,  HbA1c) :  Pai,  V.,  \\nPaneerselvam,\\n \\nA.,\\n \\nMukhopadhyay,\\n \\nS.,\\n \\net\\n \\nal.\\n \\n(2014).\\n \\nA\\n \\nmulticenter,\\n \\nprospective,\\n \\nrandomized,\\n \\ndouble-blind\\n \\nstudy\\n \\nto\\n \\nevaluate\\n \\nthe\\n \\nsafety\\n \\nand\\n \\nefficacy\\n \\nof\\n \\nsaroglitazar\\n \\n2\\n \\nand\\n \\n4\\n \\nmg\\n \\ncompared\\n \\nto\\n \\npioglitazone\\n \\n45\\n \\nmg\\n \\nin'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 42, 'page_label': '43'}, page_content='diabetic  dyslipidemia  (PRESS  VI).  Diabetes  Technology  &  Therapeutics ,  16 (9),  589–598. https://doi.org/10.1089/dia.2013.0288 \\n2.  Non-Invasive  Imaging  Parameters  (CAP,  LSM):  Gawrieh,  S.,  \\nNoureddin,\\n \\nM.,\\n \\nLoo,\\n \\nN.,\\n \\net\\n \\nal.\\n \\n(2021).\\n \\nSaroglitazar,\\n \\na\\n \\nPPAR-\\nα/γ\\n \\nagonist,\\n \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n double-blind  phase  2  trial.  Hepatology ,  74 (4),  1809–1824. https://doi.org/10.1002/hep.31843 \\nSiddiqui,  M.  S.,  Idowu,  M.  O.,  Parmar,  D.,  et  al.  (2021).  A  phase  2  double  blinded,  \\nrandomized\\n \\ncontrolled\\n \\ntrial\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnonalcoholic\\n \\nsteatohepatitis.\\n \\nClinical\\n \\nGastroenterology\\n \\nand\\n \\nHepatology\\n,\\n \\n19\\n(12),\\n 2670–2672.https://doi.org/10.1016/j.cgh.2020.10.051 \\n3.  Long-Term  Monitoring  and  Real-World  Parameters:  Kaul,  U.,  Parmar,  \\nD.,\\n \\nManjunath,\\n \\nK.,\\n \\net\\n \\nal.\\n \\n(2019).\\n \\nNew\\n \\ndual\\n \\nperoxisome\\n \\nproliferator\\n \\nactivated\\n \\nreceptor\\n \\nagonist—Saroglitazar\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\nand\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nIntegrated\\n \\nanalysis\\n \\nof\\n \\nthe\\n \\nreal\\n \\nworld\\n evidence.  Cardiovascular  Diabetology ,  18 (1),  80. https://doi.org/10.1186/s12933-019-0884-3 \\n \\nGupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  et  al.  (2020).  Non-alcoholic  steatohepatitis  in  type  2  diabetes  mellitus.  Journal  of  Gastroenterology  and  Hepatology ,  19 (8),  854–858. https://doi.org/10.1111/j.1440-1746.2004.03312.x \\nDutta,  D.,  Kumar,  M.,  Shivaprasad,  K.  S.,  et  al.  (2021).  Impact  of  saroglitazar  on  glycemic  \\ncontrol,\\n \\ndyslipidemia,\\n \\nliver\\n \\nfunction,\\n \\nand\\n \\nbody\\n \\nweight\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes:\\n \\nA\\n \\nreal-world\\n \\nstudy.\\n Indian  Journal  of  Endocrinology  and  Metabolism ,  25 (2),  133–139. https://doi.org/10.4103/ijem.IJEM_787_20 \\n4.  Safety  Monitoring  Parameters:  Kaul,  U.,  Parmar,  D.,  Manjunath,  K.,  \\net\\n \\nal.\\n \\n(2019).\\n \\n \\n5.  Response  Criteria  and  Treatment  Duration:  Kumar,  A.,  Sharma,  A.,  \\nDuseja,\\n \\nA.,\\n \\net\\n \\nal.\\n \\n(2023).\\n \\nEffects\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon-alcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n \\nand\\n \\nmeta-analysis.\\n \\nClinical'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 43, 'page_label': '44'}, page_content='and  Experimental  Hepatology ,  9 (2),  117–128. https://doi.org/10.5114/ceh.2023.127873 \\n6.  Prescribing  Information  and  Monitoring  Guidelines:  Zydus  Cadila  \\nHealthcare\\n \\nLtd.\\n \\nBilypsa\\n \\n(Saroglitazar\\n \\nMagnesium)\\n \\nPrescribing\\n \\nInformation.\\n \\nZydus\\n \\nCadila,\\n \\nAhmedabad,\\n \\nIndia.\\n \\n7.  NAFLD/NASH  Assessment  Guidelines  (Context  for  Parameters)  \\nChalasani,  N.,  Younossi,  Z.,  Lavine,  J.  E.,  et  al.  (2018).  The  diagnosis  and  management  \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nPractice\\n \\nguidance\\n \\nfrom\\n \\nthe\\n \\nAmerican\\n \\nAssociation\\n \\nfor\\n \\nthe\\n Study  of  Liver  Diseases.  Hepatology ,  67 (1),  328–357. https://doi.org/10.1002/hep.29367 \\nEuropean  Association  for  the  Study  of  the  Liver  (EASL).  (2016).  EASL-EASD-EASO  \\nClinical\\n \\nPractice\\n \\nGuidelines\\n \\nfor\\n \\nthe\\n \\nmanagement\\n \\nof\\n \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease.\\n \\nJournal\\n of  Hepatology ,  64 (6),  1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 44, 'page_label': '45'}, page_content='14.How  long  does  a  fibrotic  liver  take  to  turn  to  cirrhotic  \\nliver?\\n \\nIs\\n \\nsaroglitazar\\n \\nhelpful\\n \\nin\\n \\nsuch\\n \\npatients?\\n \\nProgression  from  fibrosis  to  cirrhosis  is  variable:  typically  10–20  years  but  may  accelerate  to  \\n5–10\\n \\nyears\\n \\nor\\n \\n<5\\n \\nyears\\n \\nwith\\n \\ndiabetes,\\n \\nobesity,\\n \\nmetabolic\\n \\nsyndrome,\\n \\nalcohol,\\n \\nacute\\n \\ninsults\\n \\n(eg,\\n \\nCOVID\\n‑\\n19).\\n \\nSaroglitazar\\n \\nis\\n \\nhelpful\\n \\nprimarily\\n \\nin\\n \\nnon\\n‑\\ncirrhotic\\n \\ndisease\\n \\n(F0–F2),\\n \\nmay\\n \\nstabilize\\n \\nF3\\n \\nin\\n \\nselected\\n \\ncases,\\n \\nand\\n \\nis\\n \\nnot\\n \\nrecommended\\n \\nin\\n \\ndecompensated\\n \\ncirrhosis.\\n \\nStages  of  fibrosis  \\n●  F0  —  No  fibrosis:  normal  lobular  architecture  and  sinusoidal  function.  Reversible  if  \\ninjury\\n \\nremoved.\\n ●  F1  —  Portal  fibrosis:  collagen  limited  to  portal  tracts;  architecture  preserved.  \\nReversible.\\n ●  F2  —  Periportal  fibrosis:  fibrous  septa  extend  from  portal  tracts;  limited  architectural  \\nchange.\\n \\nPotentially\\n \\nreversible.\\n ●  F3  —  Bridging  fibrosis:  septa  bridge  portal–portal  or  portal–central  regions;  \\narchitectural\\n \\ndistortion\\n \\nand\\n \\nearly\\n \\nvascular\\n \\nremodeling\\n \\nbegin;\\n \\npartial\\n \\nreversibility\\n \\nonly.\\n ●  F4  —  Cirrhosis:  regenerative  nodules  with  dense  fibrous  septa,  major  vascular  \\nremodeling\\n \\nand\\n \\nportal\\n \\nhypertension;\\n \\nstructural\\n \\nchange\\n \\nlargely\\n \\nirreversible.\\n \\nTypical  timelines  (clinical  averages)  \\n●  F1  →  F2:  ~3–7  years  ●  F2  →  F3:  ~3–7  years  ●  F3  →  F4:  ~2–5  years  ●  Total  F1  →  F4:  ~10–20  years  (slower  without  accelerants)  \\n \\nAccelerated  scenarios  (diabetes,  obesity,  metabolic  syndrome,  recurrent  injury,  \\nCOVID\\n‑\\n19):\\n \\ntimelines\\n \\nmay\\n \\nshorten\\n \\nto\\n \\n5–10\\n \\nyears\\n \\noverall;\\n \\nF3→F4\\n \\ncan\\n \\noccur\\n \\nin\\n \\n<2\\n \\nyears\\n \\nin\\n \\nsome\\n \\ncases.\\n \\nBrief  mechanism  \\n●  Metabolic  dysfunction  →  steatosis  →  lipotoxicity  →  hepatocyte  injury  →  inflammation  \\n(Kupffer\\n \\ncells,\\n \\ncytokines)\\n \\n→\\n \\nhepatic\\n \\nstellate\\n \\ncell\\n \\nactivation\\n \\n→\\n \\nextracellular\\n \\nmatrix\\n \\n(collagen)\\n \\ndeposition\\n \\n→\\n \\nsepta\\n \\nformation\\n \\nand\\n \\nvascular\\n \\nremodeling.\\n \\nOnce\\n \\nbridging\\n \\nsepta\\n \\nand\\n \\nnodules\\n \\nform,\\n \\nanatomical\\n \\nreversal\\n \\nis\\n \\ndifficult.\\n \\nPatients  are  at  higher  risk  of  rapid  progression  \\n●  Diabetes,  poor  glycemic  control  ●  BMI  ≥30  kg/m2  or  metabolic  syndrome'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 45, 'page_label': '46'}, page_content='●  Ongoing  alcohol  use  or  smoking  ●  Recurrent  hepatotoxic  insults  or  severe/long  COVID ‑ 19  ●  Genetic  risk  variants  (PNPLA3,  TM6SF2)  ●  Coexisting  chronic  viral  hepatitis,  HIV  coinfection  \\nPractical  diagnostic/monitoring  tools   \\n●  Transient  elastography  (FibroScan):  LSM  >12.5–14  kPa  suggests  cirrhosis  (F4).  \\nCAP\\n \\nassesses\\n \\nsteatosis.\\n ●  FIB ‑ 4  score:  >3.25  suggests  advanced  fibrosis.  ●  APRI  >2  suggests  cirrhosis.  ●  MR  elastography:  more  accurate  stiffness  assessment  (>5  kPa  consistent  with  \\nadvanced\\n \\nfibrosis/cirrhosis).\\n ●  Ultrasound/CT/MR:  nodularity,  segmental  atrophy/hypertrophy,  collaterals,  \\nsplenomegaly,\\n \\nascites\\n \\n—\\n \\nsigns\\n \\nof\\n \\ncirrhosis/portal\\n \\nhypertension.\\n ●  Liver  biopsy:  definitive  histology  when  required.  \\n \\nSaroglitazar  recommendation  in  fibrosis  \\nA.  Indicated  /  recommended  for:  \\n●  NAFLD/NASH  patients  who  are  non ‑ cirrhotic  (F0–F2),  especially  with  metabolic  \\ndysfunction\\n \\n(type\\n \\n2\\n \\ndiabetes,\\n \\nhypertriglyceridemia,\\n \\ninsulin\\n \\nresistance)\\n \\nand\\n \\npersistently\\n \\nelevated\\n \\nALT\\n \\nor\\n \\nimaging\\n \\nevidence\\n \\nof\\n \\nsteatosis.\\n ●  Objective:  reduce  hepatic  steatosis,  lower  ALT  and  triglycerides,  slow  progression  to  \\nF3.\\n \\nB.  Consider  with  specialist  oversight  \\n●  F3  (bridging  fibrosis):  may  be  considered  on  an  individualized  basis  where  active  \\nmetabolic\\n \\ndrivers\\n \\npersist\\n \\nand\\n \\nthe\\n \\naim\\n \\nis\\n \\nstabilization;\\n \\ncounsel\\n \\npatient\\n \\nthat\\n \\nreversal\\n \\nof\\n \\narchitectural\\n \\nchanges\\n \\nis\\n \\nunlikely.\\n \\nClose\\n \\nhepatology\\n \\nmonitoring\\n \\nrequired.\\n \\nC.  Not  recommended  /  avoid  \\n●  Decompensated  cirrhosis  (ascites,  encephalopathy,  variceal  bleeding)  —  \\ncontraindicated.\\n ●  Use  in  compensated  cirrhosis  (F4)  only  under  specialist  review  and  with  careful  risk  \\nassessment.\\n \\nConcise  mechanism  of  Saroglitazar  \\n●  Dual  PPAR ‑ α/γ  agonism  improves  triglyceride  metabolism  (↓TG  30–50%),  reduces  \\nhepatic\\n \\nfat\\n \\n(imaging\\n \\nCAP\\n \\nreductions),\\n \\nenhances\\n \\ninsulin\\n \\nsensitivity\\n \\n(HbA1c\\n \\n↓'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 46, 'page_label': '47'}, page_content='~0.3–0.8%),  lowers  ALT/AST  and  reduces  inflammatory  milieu  that  drives  stellate  cell  \\nactivation.\\n \\nThese\\n \\nchanges\\n \\nreduce\\n \\nfibrogenic\\n \\nstimulus\\n \\nbefore\\n \\npermanent\\n \\narchitecture\\n \\nforms.\\n \\nPractical  treatment  algorithm   \\nStep  1  —  Baseline  (before  starting)  \\n●  Confirm  stage:  FibroScan  (CAP  +  LSM)  ±  FIB ‑ 4/APRI;  consider  biopsy  if  diagnosis  \\nuncertain.\\n ●  Baseline  labs:  LFTs  (ALT,  AST,  GGT,  bilirubin,  albumin,  INR),  lipid  profile  (TG,  HDL,  \\nLDL),\\n \\nfasting\\n \\nglucose/HbA1c,\\n \\nrenal\\n \\nfunction\\n \\n(creatinine,\\n \\neGFR).\\n ●  Document  weight,  BMI,  alcohol  use,  comorbidities,  medications.  \\nStep  2  —  Initiation  criteria  \\n●  F0–F2  with  metabolic  dysfunction  and  persistent  ALT  elevation  or  significant  \\nsteatosis\\n \\ndespite\\n \\nlifestyle\\n \\nmeasures.\\n \\nEnsure\\n \\nno\\n \\ncontraindication\\n \\n(e.g.,\\n \\nsevere\\n \\nhepatic/renal\\n \\nimpairment,\\n \\npregnancy).\\n \\nStep  3  —  Early  monitoring  \\n●  3  months:  LFTs,  lipid  profile,  fasting  glucose.  Monitor  adverse  effects  (edema,  GI  \\nsymptoms,\\n \\nhypoglycemia\\n \\nwhen\\n \\non\\n \\ninsulin/sulfonylurea,\\n \\ncreatinine).\\n ●  6  months:  Repeat  FibroScan  (LSM  and  CAP)  and  HbA1c;  evaluate  response.  \\nStep  4  —  Response  definitions  at  6  months  \\n●  Good  response:  ALT  ↓  ≥30%  and  TG  ↓  ≥30%  and  CAP/LSM  improved  or  stable  →  \\ncontinue\\n \\ntherapy.\\n ●  Partial  response:  ALT  ↓  10–30%  →  continue  +  intensify  lifestyle,  reassess  at  6  \\nmonths.\\n ●  Non ‑ response:  ALT  ↓  <10%,  no  imaging  improvement  →  re ‑ evaluate  diagnosis,  \\nadherence,\\n \\ncomorbidities;\\n \\nconsider\\n \\nstopping\\n \\nor\\n \\nalternative\\n \\nstrategies.\\n \\nStep  5  —  Ongoing  follow ‑ up  \\n●  If  responding:  monitor  labs  every  6  months;  FibroScan  annually  (or  sooner  if  clinical  \\nconcern).\\n ●  If  F3  on  baseline  or  progression  detected:  involve  hepatology;  consider  additional  \\nantifibrotic\\n \\ntrials\\n \\nor\\n \\nspecialist\\n \\ninterventions.\\n \\n \\nRecommendations  for  clinician  actions   \\n●  Screen  all  NAFLD/NASH  patients  for  fibrosis  stage  (FibroScan  or  FIB ‑ 4).'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 47, 'page_label': '48'}, page_content='●  Offer  saroglitazar  to  F0–F2  patients  with  metabolic  dysfunction  and  persistent  \\nhepatic\\n \\ninjury\\n \\nafter\\n \\nlifestyle\\n \\noptimization.\\n ●  Reassess  at  3  and  6  months  (labs)  and  at  6–12  months  (FibroScan)  to  determine  \\ncontinuation.\\n ●  Escalate  to  hepatology  for  F3  patients  or  any  signs  of  progression/decompensation.  \\n \\nClinical  Results  \\n●  Phase ‑ 2  RCT  and  pooled  analyses  show  ALT  and  liver ‑ fat  reductions  and  \\nimprovements\\n \\nin\\n \\nliver\\n \\nstiffness\\n \\nin\\n \\npredominantly\\n \\nF0–F2\\n \\ncohorts\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\nHepatology\\n \\n2021;\\n \\nKumar\\n \\net\\n \\nal.,\\n \\nClin\\n \\nExp\\n \\nHepatol\\n \\n2023).\\n \\n ●  Real ‑ world  series  report  sustained  biochemical  and  FibroScan  improvements  (Gupte  \\net\\n \\nal.,\\n \\n2020;\\n \\nDutta\\n \\net\\n \\nal.,\\n \\n2021).\\n \\n ●  Large  histology ‑ endpoint  phase ‑ 3  data  and  long ‑ term  outcome  studies  are  limited.  \\nSelected  references  (for  quick  review)  \\n●  Gawrieh  S,  et  al.  Saroglitazar  for  NAFLD:  randomized  phase ‑ 2  trial.  Hepatology.  \\n2021.\\n ●  Kumar  A,  et  al.  Saroglitazar  in  NAFLD/NASH:  systematic  review  &  meta ‑ analysis.  \\nClin\\n \\nExp\\n \\nHepatol.\\n \\n2023.\\n ●  Gupte  P,  et  al.  Real ‑ world  saroglitazar  outcomes  in  NAFLD  with  diabetes.  J  \\nGastroenterol\\n \\nHepatol.\\n \\n2020.\\n ●  Friedman  SL.  Hepatic  stellate  cells  and  fibrogenesis.  Physiol  Rev.  2008.  ●  Singh  S,  et  al.  Fibrosis  progression  in  NAFLD:  meta ‑ analysis.  Clin  Gastroenterol  \\nHepatol.\\n \\n2015.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 48, 'page_label': '49'}, page_content='15.\\nCompare  Vit  E  vs  saroglitazar  in  NAFLD  treatment.  \\nVitamin  E  (alpha ‑ tocopherol)  has  demonstrated  histologic  benefit  for  nonalcoholic  \\nsteatohepatitis\\n \\nin\\n \\nselected\\n \\nnon\\n‑\\ndiabetic\\n \\npatients,\\n \\nimproving\\n \\nsteatohepatitis\\n \\nbut\\n \\nnot\\n \\nconsistently\\n \\nfibrosis;\\n \\nsaroglitazar\\n \\n(PPAR\\n‑\\nα/γ\\n \\nagonist)\\n \\nshows\\n \\nconsistent\\n \\nmetabolic,\\n \\nbiochemical\\n \\nand\\n \\nimaging\\n \\nimprovements\\n \\nin\\n \\nnon\\n‑\\ncirrhotic\\n \\nNAFLD/NASH\\n \\n(F0–F2)\\n \\nwith\\n \\nlimited\\n \\nhistology\\n \\nand\\n \\nlong\\n‑\\nterm\\n \\noutcome\\n \\ndata.\\n \\nTreatment\\n \\nchoice\\n \\nshould\\n \\nbe\\n \\nbased\\n \\non\\n \\npatient\\n \\nphenotype,\\n \\ncomorbidities\\n \\nand\\n \\nguideline\\n \\nguidance.\\n \\nComparison  table  \\nParameter  Vitamin  E  (alpha ‑ tocopherol)  Saroglitazar  (PPAR ‑ α/γ)  \\nMechanism  of  action  \\nAntioxidant;  reduces  oxidative  stress  and  lipid  peroxidation  in  hepatocytes  →  reduces  inflammatory  injury.  \\nDual  PPAR ‑ α  (↑fatty  acid  oxidation)  and  PPAR ‑ γ  (improves  insulin  sensitivity)  →  reduces  hepatic  steatosis,  inflammation  and  metabolic  drivers  of  fibrogenesis.  \\nKey  randomized  evidence  (histology)  \\nPIVENS  trial  (NEJM  2010):  vitamin  E  800  IU/day  vs  placebo  in  non ‑ diabetic  NASH:  significant  improvement  in  steatohepatitis  and  higher  rate  of  NASH  resolution;  no  significant  fibrosis  regression  vs  placebo.¹  \\nPhase  2  RCT  (Gawrieh  et  al.,  Hepatology  2021):  saroglitazar  4  mg  for  16  weeks  in  NAFLD/NASH  (predominantly  F0–F2)  showed  significant  ALT  reduction  and  liver  fat  reduction  (MRI ‑ PDFF);  histology  data  limited.²  \\nSystematic  reviews  /  meta ‑ analyses  \\nMeta ‑ analyses  show  vitamin  E  improves  histologic  steatohepatitis  and  ballooning  in  non ‑ diabetic  NASH;  inconsistent  effect  on  fibrosis.³  \\nMeta ‑ analysis  (Kumar  et  al.  2023)  of  saroglitazar  studies:  consistent  reductions  in  ALT,  triglycerides,  CAP/LSM;  histology  endpoint  data  limited;  greater  benefit  in  non ‑ cirrhotic  cohorts. ⁴'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 49, 'page_label': '50'}, page_content='Indication  /  guideline  position  \\nAASLD:  Vitamin  E  (800  IU/day)  may  be  considered  for  non ‑ diabetic  adults  with  biopsy ‑ proven  NASH  to  improve  histology;  not  recommended  routinely  in  diabetics  for  NASH  histologic  benefit.  (Practice  guidance). ⁵  \\nNot  yet  included  as  standard  therapy  in  major  western  guidelines  for  NASH  histologic  endpoints;  approved  in  some  countries  for  diabetic  dyslipidemia  and  used  off ‑ label/locally  for  NAFLD/NASH  (non ‑ cirrhotic,  F0–F2)  based  on  phase  2  and  real ‑ world  data.², ⁴  \\nTarget  patient  phenotype  \\nNon ‑ diabetic  adults  with  biopsy ‑ proven  NASH  and  without  cirrhosis  (selected  patients).¹, ⁵  \\nNon ‑ cirrhotic  NAFLD/NASH  (F0–F2)  with  metabolic  dysfunction  (diabetes,  dyslipidemia,  hypertriglyceridemia)  —  patients  needing  metabolic  and  lipid  benefit.², ⁴  \\nEffect  on  steatosis  (imaging)  \\nModest/variable  reductions  in  liver  fat  reported;  primary  benefit  histologic  inflammation  rather  than  large  steatosis  changes.³  \\nConsistent  reductions  in  hepatic  fat  by  MRI ‑ PDFF  or  CAP  in  trials/real ‑ world  (e.g.,  MRI ‑ PDFF  reductions  reported  in  phase  2;  CAP  reductions  in  observational  series).², ⁴  \\nEffect  on  liver  enzymes  (ALT/AST)  \\nALT  often  improves  with  vitamin  E;  magnitude  variable.¹,³  \\nConsistent  and  larger  ALT  reductions  reported  (phase  2  and  pooled  studies).², ⁴  \\nEffect  on  fibrosis  \\nTrials:  vitamin  E  generally  does  not  show  consistent  fibrosis  regression  (no  definitive  antifibrotic  effect  in  PIVENS).¹  \\nSaroglitazar:  surrogate  fibrosis  improvements  (LSM  reductions)  reported  in  trials  and  meta ‑ analysis;  definitive  histologic  antifibrotic  evidence  lacking.², ⁴'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 50, 'page_label': '51'}, page_content='Histologic  NASH  resolution  \\nPIVENS:  higher  rate  of  histologic  NASH  resolution  with  vitamin  E  vs  placebo  in  non ‑ diabetics.¹  \\nHistologic  endpoint  data  limited;  histology ‑ driven  randomized  phase  3  data  not  yet  available.²  \\nMetabolic/lipid  effects  \\nMinimal  direct  effect  on  lipids  or  insulin  resistance;  not  intended  for  dyslipidemia  control.  \\nSignificant  triglyceride  lowering  (30–50%),  improved  HDL,  modest  LDL  changes;  improves  insulin  sensitivity  and  HbA1c  modestly.², ⁴  \\nSafety  profile  —  common  adverse  effects  \\nGenerally  well  tolerated  at  trial  doses  (800  IU/day);  concerns  from  observational  data:  possible  increased  all ‑ cause  mortality  at  high  doses  in  older  analyses,  and  possible  prostate  cancer  risk  signals  in  some  studies  (controversial).  Monitor  bleeding  risk  if  on  anticoagulation.³, ⁶  \\nGenerally  well  tolerated  in  trials  and  real ‑ world  series:  mild  GI  symptoms,  transient  creatinine  rise  in  a  minority,  rare  edema;  monitor  LFTs  and  renal  function.  Avoid  in  severe  hepatic/renal  impairment;  caution  with  insulin/sulfonylureas  (hypoglycemia  risk).¹ ⁰ ,²  \\nContraindications  /  cautions  \\nCaution  in  patients  on  anticoagulants  (vitamin  E  may  increase  bleeding);  long ‑ term  high ‑ dose  safety  debated;  use  in  diabetics  for  histologic  NASH  benefit  not  supported.³, ⁶  \\nContraindicated/avoid  in  decompensated  cirrhosis;  caution  in  severe  renal  impairment;  pregnancy  contraindicated  per  local  PI.  Monitor  for  edema/heart  failure  signs.², ⁷  \\nMonitoring  while  on  therapy  \\nBaseline  and  periodic  LFTs;  consider  PSA  screening  discussion  in  men;  monitor  bleeding  risk  if  anticoagulated. ⁶  \\nBaseline  LFTs,  lipids,  fasting  glucose/HbA1c,  renal  function;  LFTs  and  creatinine  at  1–3  months,  then  periodic;  FibroScan  (CAP/LSM)  or  serum  fibrosis  scores  at  6  months.², ⁴'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 51, 'page_label': '52'}, page_content='Use  with  diabetes  \\nPIVENS  excluded  diabetics;  vitamin  E  histologic  benefit  not  established  in  diabetics.¹  \\nMany  saroglitazar  studies  include  patients  with  diabetes;  metabolic  and  lipid  benefits  support  use  in  diabetic  dyslipidemia  with  NAFLD  (non ‑ cirrhotic).², ⁴  \\nUse  in  advanced  fibrosis  /  cirrhosis  \\nNot  recommended  for  reversing  cirrhosis;  limited  data  in  advanced  fibrosis.¹,³  \\nNot  recommended  in  decompensated  cirrhosis;  data  in  F3  limited  —  may  be  considered  individually  under  hepatology  care.²  \\nEvidence  strength  /  gaps  \\nHigh ‑ quality  RCT  evidence  (PIVENS)  for  non ‑ diabetic  NASH  histologic  benefit;  limited  long ‑ term  outcome  data.¹,³  \\nPhase  2  RCT  data  and  multiple  observational  studies  /  meta ‑ analysis  for  surrogate  outcomes;  lack  of  large  histology ‑ endpoint  phase  3  and  long ‑ term  outcome  trials.², ⁴  \\nPractical  takeaways  \\nUse  vitamin  E  800  IU/day  as  an  option  for  selected  non ‑ diabetic  adults  with  biopsy ‑ proven  NASH  aiming  at  histologic  improvement;  counsel  on  uncertain  long ‑ term  safety  signals  and  limit  to  appropriate  patients.¹, ⁵  \\nConsider  saroglitazar  for  non ‑ cirrhotic  NAFLD/NASH  patients  with  metabolic  dysregulation  when  metabolic  +  hepatic  surrogate  improvements  are  desired;  specialist  input  for  F3  and  avoid  in  decompensated  cirrhosis.², ⁴  \\n \\nReferences  (select,  APA)  \\n1.  Sanyal,  A.  J.,  Chalasani,  N.,  Kowdley,  K.  V.,  et  al.  (2010).  Pioglitazone,  vitamin  E,  or  \\nplacebo\\n \\nfor\\n \\nnonalcoholic\\n \\nsteatohepatitis.\\n \\nNew\\n \\nEngland\\n \\nJournal\\n \\nof\\n \\nMedicine,\\n \\n362(18),\\n 1675–1685. https://doi.org/10.1056/NEJMoa0907929'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 52, 'page_label': '53'}, page_content='○  PIVENS  trial:  vitamin  E  800  IU/day  showed  improved  NASH  histology  versus  \\nplacebo\\n \\nin\\n \\nnon\\n‑\\ndiabetic\\n \\nadults;\\n \\nlimited\\n \\nfibrosis\\n \\neffect.\\n 2.  Gawrieh,  S.,  Noureddin,  M.,  Loo,  N.,  et  al.  (2021).  Saroglitazar,  a  PPAR ‑ α/γ  agonist,  \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n double ‑ blind  phase  2  trial.  Hepatology,  74(4),  1809–1824. https://doi.org/10.1002/hep.31843   ○  Phase  2  data:  saroglitazar  4  mg  improved  ALT  and  hepatic  fat  (MRI ‑ PDFF);  \\nlimited\\n \\nhistology\\n \\nendpoints.\\n 3.  Musso,  G.,  Cassader,  M.,  Rosina,  F.,  &  Gambino,  R.  (2012).  Impact  of  current  \\ntreatments\\n \\non\\n \\nliver\\n \\ndisease,\\n \\nglucose\\n \\nmetabolism\\n \\nand\\n \\ncardiovascular\\n \\nrisk\\n \\nin\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD):\\n \\nA\\n \\nsystematic\\n \\nreview\\n \\nand\\n \\nmeta\\n‑\\nanalysis\\n \\nof\\n randomised  trials.  Diabetologia,  55(4),  885–904. https://doi.org/10.1007/s00125-011-2446-4   ○  Systematic  analysis  including  antioxidant  interventions;  vitamin  E  benefit  \\nnoted\\n \\nfor\\n \\nhistology\\n \\nin\\n \\nselected\\n \\ntrials.\\n 4.  Kumar,  A.,  Sharma,  A.,  Duseja,  A.,  et  al.  (2023).  Effects  of  saroglitazar  in  patients  \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon\\n‑\\nalcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n \\nand\\n \\nmeta\\n‑\\nanalysis.\\n \\nClinical\\n \\nand\\n \\nExperimental\\n Hepatology,  9(2),  117–128. https://doi.org/10.5114/ceh.2023.127873   ○  Pooled  analysis:  saroglitazar  reduces  transaminases,  liver  stiffness  and  \\ntriglycerides\\n \\nin\\n \\npredominantly\\n \\nnon\\n‑\\ncirrhotic\\n \\ncohorts.\\n 5.  Chalasani,  N.,  Younossi,  Z.,  Lavine,  J.  E.,  et  al.  (2018).  The  diagnosis  and  \\nmanagement\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nPractice\\n \\nguidance\\n \\nfrom\\n \\nthe\\n American  Association  for  the  Study  of  Liver  Diseases.  Hepatology,  67(1),  328–357. https://doi.org/10.1002/hep.29367   ○  Guidance:  vitamin  E  may  be  considered  in  non ‑ diabetic  adults  with  \\nbiopsy\\n‑\\nproven\\n \\nNASH;\\n \\nmetformin\\n \\nnot\\n \\nrecommended\\n \\nspecifically\\n \\nfor\\n \\nNASH.\\n 6.  Miller,  E.  R.,  Pastor-Barriuso,  R.,  Dalal,  D.,  Riemersma,  R.  A.,  Appel,  L.  J.,  &  Guallar,  \\nE.\\n \\n(2005).\\n \\nMeta\\n‑\\nanalysis:\\n \\nHigh\\n‑\\ndose\\n \\nvitamin\\n \\nE\\n \\nsupplementation\\n \\nmay\\n \\nincrease\\n all ‑ cause  mortality.  Annals  of  Internal  Medicine,  142(1),  37–46. https://doi.org/10.7326/0003-4819-142-1-200501040-00110   ○  Older  meta ‑ analysis  raising  concerns  about  high ‑ dose  vitamin  E  safety;  \\ninterpret\\n \\ncautiously\\n \\nin\\n \\ncontext\\n \\nof\\n \\nNASH\\n \\ntrials.\\n 7.  Zydus  Cadila  Healthcare  Ltd.  (Product  Information).  Bilypsa  (saroglitazar)  prescribing  \\ninformation.\\n \\n(Local\\n \\nproduct\\n \\nlabel\\n \\n—\\n \\nsafety\\n \\nand\\n \\ncontraindications).\\n \\n ○  Regulatory/product  safety  details  (monitoring,  contraindications).  8.  Gupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  et  al.  (2020).  Saroglitazar  in  patients  with  \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\ndiabetic\\n \\ndyslipidaemia:\\n \\nReal\\n‑\\nworld\\n \\ndata.\\n \\nJournal'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 53, 'page_label': '54'}, page_content='of  Gastroenterology  and  Hepatology.  (Selected  real ‑ world  cohort  data  supporting  \\nbiochemical\\n \\nand\\n \\nFibroScan\\n \\nimprovements).\\n \\n \\nNotes  and  practical  considerations  \\n●  Vitamin  E  evidence  is  strongest  for  histologic  improvement  of  steatohepatitis  in  \\nnon\\n‑\\ndiabetic\\n \\nadults\\n \\n(PIVENS);\\n \\nit\\n \\nis\\n \\nnot\\n \\nproven\\n \\nto\\n \\nregress\\n \\nfibrosis\\n \\nreliably\\n \\nand\\n \\nhas\\n \\ndebated\\n \\nlong\\n‑\\nterm\\n \\nsafety\\n \\nsignals\\n \\nat\\n \\nhigh\\n \\ndoses.\\n \\nUse\\n \\nonly\\n \\nin\\n \\nselected\\n \\nnon\\n‑\\ndiabetic,\\n \\nbiopsy\\n‑\\nproven\\n \\nNASH\\n \\npatients\\n \\nafter\\n \\nrisk\\n \\ndiscussion.\\n ●  Saroglitazar  targets  metabolic  drivers  and  has  consistent  surrogate  improvements  \\n(ALT,\\n \\ntriglycerides,\\n \\nliver\\n \\nfat,\\n \\nLSM)\\n \\nin\\n \\nnon\\n‑\\ncirrhotic\\n \\npatients;\\n \\nideal\\n \\ncandidate\\n \\nis\\n \\npatient\\n \\nwith\\n \\nNAFLD/NASH\\n \\nplus\\n \\nmetabolic\\n \\ndyslipidemia\\n \\nor\\n \\ndiabetes\\n \\n(F0–F2).\\n \\nHistology\\n \\nand\\n \\nlong\\n‑\\nterm\\n \\noutcome\\n \\nevidence\\n \\nare\\n \\nlimited;\\n \\nphase\\n‑\\n3\\n \\nhistology\\n \\nendpoint\\n \\ntrials\\n \\nare\\n \\nneeded.\\n ●  Both  agents  are  adjuncts  to  core  therapy:  lifestyle  modification  (weight  loss,  \\nexercise),\\n \\ncontrol\\n \\nof\\n \\ndiabetes,\\n \\nlipids\\n \\nand\\n \\nblood\\n \\npressure,\\n \\nand\\n \\nalcohol\\n \\navoidance.\\n \\nChoice\\n \\nshould\\n \\nbe\\n \\nindividualized\\n \\nto\\n \\npatient\\n \\nphenotype,\\n \\ncomorbidities\\n \\nand\\n \\ncontraindications.\\n ●  For  clinical  decisions,  prioritize  fibrosis  staging  (non ‑ invasive  or  biopsy)  and  shared  \\ndecision\\n \\nmaking\\n \\nwith\\n \\npatient\\n \\nregarding\\n \\nexpected\\n \\nbenefits\\n \\nand\\n \\nrisks.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 54, 'page_label': '55'}, page_content='16.What  is  the  impact  of  saroglitazar  on  serum  \\ntriglycerides?\\n \\nSaroglitazar  reliably  lowers  fasting  triglycerides  by  about  30–50%,  with  the  4  mg  \\ndose\\n \\nproducing\\n \\nthe\\n \\nlarger\\n \\nreductions\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nPai\\n \\net\\n \\nal.,\\n \\n2014).\\n \\nTypical  magnitude  and  timing  \\n●  4  mg:  ~40–50%  mean  triglyceride  reduction.  ●  2  mg:  ~20–25%  mean  reduction.  ●  Onset:  effect  evident  by  4  weeks;  maximal  by  12–16  weeks.  ●  Durability:  sustained  through  12  months  in  extension/real ‑ world  data  (Kaul  et  al.,  \\n2019).\\n \\nHigh ‑ yield  evidence   \\n●  PRESS  V  (diabetic  dyslipidemia  on  statin):  saroglitazar  4  mg  →  ~45%  TG  reduction  \\nat\\n \\n24\\n \\nweeks;\\n \\n2\\n \\nmg\\n \\n→\\n \\n~23%\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014).\\n ●  PRESS  VI  (severe  hypertriglyceridemia):  saroglitazar  4  mg  →  ~45%  TG  reduction  \\nvs.\\n \\n~14%\\n \\nwith\\n \\npioglitazone\\n \\nat\\n \\n12\\n \\nweeks\\n \\n(Pai\\n \\net\\n \\nal.,\\n \\n2014).\\n ●  Phase  2  NAFLD  trial  and  real ‑ world  cohorts  show  35–45%  TG  lowering  with  4  mg  \\nand\\n \\nsustained\\n \\neffect\\n \\nat\\n \\n24–52\\n \\nweeks\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nKaul\\n \\net\\n \\nal.,\\n \\n2019;\\n \\nKumar\\n \\net\\n \\nal.,\\n \\n2023).\\n \\nMechanism   \\n●  Activation  of  peroxisome  proliferator ‑ activated  receptor  alpha  increases  hepatic  fatty  \\nacid\\n \\noxidation,\\n \\npromoting\\n \\nbreakdown\\n \\nof\\n \\nfatty\\n \\nacids\\n \\nwithin\\n \\nmitochondria\\n \\nand\\n \\nperoxisomes.\\n ●  Enhanced  fatty  acid  oxidation  reduces  the  pool  of  intracellular  lipids  available  for  \\ntriglyceride\\n \\nsynthesis\\n \\nin\\n \\nhepatocytes.\\n ●  PPAR ‑ alpha  activation  also  upregulates  lipoprotein  lipase  expression  and  activity  in  \\nperipheral\\n \\ntissues,\\n \\nwhich\\n \\naccelerates\\n \\nhydrolysis\\n \\nof\\n \\ncirculating\\n \\ntriglyceride\\n‑\\nrich\\n \\nlipoproteins.\\n ●  Increased  lipoprotein  lipase  activity  facilitates  uptake  of  free  fatty  acids  by  muscle  \\nand\\n \\nadipose\\n \\ntissue,\\n \\nlowering\\n \\nplasma\\n \\ntriglyceride\\n \\nconcentrations.\\n ●  Simultaneously,  PPAR ‑ alpha  signaling  suppresses  hepatic  very ‑ low ‑ density  \\nlipoprotein\\n \\nparticle\\n \\nassembly\\n \\nand\\n \\nsecretion,\\n \\nreducing\\n \\nexport\\n \\nof\\n \\nnewly\\n \\nformed\\n \\ntriglycerides\\n \\ninto\\n \\nthe\\n \\ncirculation.\\n ●  Peroxisome  proliferator ‑ activated  receptor  gamma  activation  enhances  insulin  \\nsensitivity\\n \\nin\\n \\nadipose\\n \\ntissue\\n \\nand\\n \\nmuscle\\n \\nby\\n \\nimproving\\n \\nglucose\\n \\nuptake\\n \\nand\\n \\nreducing\\n \\nlipolysis.\\n ●  Better  insulin  sensitivity  decreases  adipose  tissue  free  fatty  acid  release,  thereby  \\nlowering\\n \\nsubstrate\\n \\nflux\\n \\nto\\n \\nthe\\n \\nliver\\n \\nfor\\n \\ntriglyceride\\n \\nsynthesis.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 55, 'page_label': '56'}, page_content='●  PPAR ‑ gamma  activation  also  promotes  safer  lipid  storage  in  adipocytes  rather  than  \\nectopic\\n \\ndeposition\\n \\nin\\n \\nthe\\n \\nliver,\\n \\nmitigating\\n \\nhepatic\\n \\nsteatosis.\\n ●  The  combined  PPAR ‑ alpha  and  PPAR ‑ gamma  effects  therefore  accelerate  clearance  \\nof\\n \\ncirculating\\n \\ntriglycerides\\n \\nand\\n \\nreduce\\n \\nhepatic\\n \\ntriglyceride\\n \\nproduction\\n \\nsimultaneously.\\n ●  Together,  these  mechanisms  produce  a  rapid  and  sustained  fall  in  serum  \\ntriglycerides\\n \\nand\\n \\nreduce\\n \\nhepatic\\n \\nlipid\\n \\nburden,\\n \\naddressing\\n \\ntwo\\n \\nkey\\n \\ndrivers\\n \\nof\\n \\nmetabolic\\n \\nliver\\n \\ndisease.\\n \\n (Gawrieh  et  al.,  2021).  \\nClinical  indications   \\n●  Diabetic  dyslipidemia  with  elevated  TG  despite  statin.  ●  Severe  hypertriglyceridemia  (200–500  mg/dL)  to  reduce  pancreatitis  risk.  ●  NAFLD/NASH  with  metabolic  dyslipidemia  where  combined  hepatic  and  lipid  benefits  \\nare\\n \\ndesired\\n \\n(Kumar\\n \\net\\n \\nal.,\\n \\n2023).\\n \\nDose  selection  \\n●  Use  4  mg  for  clinically  significant  hypertriglyceridemia  or  when  maximal  TG  lowering  \\nis\\n \\nrequired;\\n \\n2\\n \\nmg\\n \\ngives\\n \\nsmaller\\n \\nreductions\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014).\\n \\nConclusion  \\n●  For  HCPs  managing  diabetic  dyslipidemia  or  NAFLD/NASH  with  \\nhypertriglyceridemia,\\n \\nsaroglitazar\\n \\n4\\n \\nmg\\n \\nis\\n \\nan\\n \\neffective,\\n \\nrapid\\n \\nand\\n \\ndurable\\n \\noption\\n \\nfor\\n \\nsubstantial\\n \\nTG\\n \\nlowering\\n \\n(~40–50%)\\n \\nwhile\\n \\nalso\\n \\nproviding\\n \\nhepatic\\n \\nand\\n \\nmetabolic\\n \\nbenefits\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nGawrieh\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nKumar\\n \\net\\n \\nal.,\\n \\n2023).\\n \\nSelected  references  (APA)  \\n●  Gawrieh,  S.,  Noureddin,  M.,  Loo,  N.,  Mohseni,  R.,  Awasty,  V.,  Cusi,  K.,  Kowdley,  K.  \\nV.,\\n \\nLai,\\n \\nM.,\\n \\nSchiff,\\n \\nE.,\\n \\nParmar,\\n \\nD.,\\n \\nBhat,\\n \\nM.,\\n \\nVuppalanchi,\\n \\nR.,\\n \\nAlkhouri,\\n \\nN.,\\n \\nChalasani,\\n \\nN.,\\n \\n&\\n \\nEVIDENCES\\n \\nIV\\n \\nInvestigators.\\n \\n(2021).\\n \\nSaroglitazar,\\n \\na\\n \\nPPAR\\n‑\\nα/γ\\n \\nagonist,\\n \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n \\ndouble\\n‑\\nblind\\n phase  2  trial.  Hepatology,  74(4),  1809–1824. https://doi.org/10.1002/hep.31843   ●  Jani,  R.  H.,  Pai,  V.,  Jha,  P.,  Jariwala,  G.,  Mukhopadhyay,  S.,  Bhansali,  A.,  &  Joshi,  S.  \\n(2014).\\n \\nA\\n \\nmulticenter,\\n \\nprospective,\\n \\nrandomized,\\n \\ndouble\\n‑\\nblind\\n \\nstudy\\n \\nto\\n \\nevaluate\\n \\nthe\\n \\nsafety\\n \\nand\\n \\nefficacy\\n \\nof\\n \\nsaroglitazar\\n \\n2\\n \\nand\\n \\n4\\n \\nmg\\n \\ncompared\\n \\nwith\\n \\nplacebo\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes\\n \\nmellitus\\n \\npatients\\n \\nhaving\\n \\nhypertriglyceridemia\\n \\nnot\\n \\ncontrolled\\n \\nwith\\n \\natorvastatin\\n therapy  (PRESS  V).  Diabetes  Technology  &  Therapeutics,  16(2),  63–71. https://doi.org/10.1089/dia.2013.0253   ●  Pai,  V.,  Paneerselvam,  A.,  Mukhopadhyay,  S.,  Bhansali,  A.,  Kamath,  D.,  Shankar,  V.,  \\nGambhire,\\n \\nD.,\\n \\nJani,\\n \\nR.\\n \\nH.,\\n \\n&\\n \\nJoshi,\\n \\nS.\\n \\n(2014).\\n \\nA\\n \\nmulticenter,\\n \\nprospective,'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 56, 'page_label': '57'}, page_content='randomized,  double ‑ blind  study  to  evaluate  the  safety  and  efficacy  of  saroglitazar  2  \\nand\\n \\n4\\n \\nmg\\n \\ncompared\\n \\nto\\n \\npioglitazone\\n \\n45\\n \\nmg\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\n(PRESS\\n \\nVI).\\n Diabetes  Technology  &  Therapeutics,  16(9),  589–598. https://doi.org/10.1089/dia.2013.0288   ●  Kaul,  U.,  Parmar,  D.,  Manjunath,  K.,  Shah,  M.,  Parmar,  K.,  Patil,  K.  P.,  &  Jaiswal,  A.  \\n(2019).\\n \\nNew\\n \\ndual\\n \\nperoxisome\\n \\nproliferator\\n \\nactivated\\n \\nreceptor\\n \\nagonist—Saroglitazar\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\nand\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nIntegrated\\n \\nanalysis\\n \\nof\\n \\nthe\\n real  world  evidence.  Cardiovascular  Diabetology,  18(1),  80. https://doi.org/10.1186/s12933-019-0884-3   ●  Kumar,  A.,  Sharma,  A.,  Duseja,  A.,  Das,  A.,  Dhiman,  R.  K.,  Chawla,  Y.  K.,  Kohli,  K.  \\nK.,\\n \\n&\\n \\nBhansali,\\n \\nA.\\n \\n(2023).\\n \\nEffects\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon\\n‑\\nalcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n and  meta ‑ analysis.  Clinical  and  Experimental  Hepatology,  9(2),  117–128. https://doi.org/10.5114/ceh.2023.127873   ●  Gupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  Baijal,  R.,  Kulshrestha,  P.,  Pramanik,  S.,  Patel,  \\nN.,\\n \\nMadan,\\n \\nA.,\\n \\nAmarapurkar,\\n \\nA.,\\n \\n&\\n \\nHafeezunnisa.\\n \\n(2020).\\n \\nSaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\ndiabetic\\n \\ndyslipidemia:\\n \\nReal\\n‑\\nworld\\n \\ndata.\\n \\nJournal\\n \\nof\\n \\nGastroenterology\\n \\nand\\n \\nHepatology.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 57, 'page_label': '58'}, page_content='17.\\nCompare  results  of  saroglitazar  in  obese  patients  vs  lean  \\npatients.\\n \\nCurrent  evidence  suggests  saroglitazar  demonstrates  efficacy  in  both  obese  and  lean  \\npatients\\n \\nwith\\n \\nNAFLD/NASH\\n \\nand\\n \\nmetabolic\\n \\ndyslipidemia,\\n \\nthough\\n \\nthe\\n \\nmagnitude\\n \\nof\\n \\nbenefit\\n \\nand\\n \\nclinical\\n \\nresponse\\n \\npatterns\\n \\nmay\\n \\ndiffer.\\n \\nObese\\n \\npatients\\n \\ntypically\\n \\nshow\\n \\ngreater\\n \\nabsolute\\n \\nreductions\\n \\nin\\n \\nmetabolic\\n \\nparameters\\n \\n(triglycerides,\\n \\nALT,\\n \\nhepatic\\n \\nsteatosis)\\n \\ndue\\n \\nto\\n \\nhigher\\n \\nbaseline\\n \\nvalues,\\n \\nwhile\\n \\nlean\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction\\n \\nalso\\n \\nderive\\n \\nmeaningful\\n \\nbenefit.\\n \\nHowever,\\n \\ndedicated\\n \\ncomparative\\n \\nstudies\\n \\nspecifically\\n \\nanalyzing\\n \\nobese\\n \\nversus\\n \\nlean\\n \\ncohorts\\n \\nare\\n \\nlimited,\\n \\nand\\n \\nmost\\n \\ntrial\\n \\ndata\\n \\nare\\n \\nderived\\n \\nfrom\\n \\npredominantly\\n \\noverweight/obese\\n \\npopulations.\\n \\nEvidence  Overview  \\n1.  Baseline  Population  Characteristics  in  Major  Trials  \\nPRESS  V  and  PRESS  VI  Trials  (Diabetic  Dyslipidemia)  \\nThe  pivotal  saroglitazar  trials  enrolled  predominantly  overweight  and  obese  patients  with  \\ntype\\n \\n2\\n \\ndiabetes\\n \\nand\\n \\ndyslipidemia.\\n \\nMean\\n \\nbaseline\\n \\nbody\\n \\nmass\\n \\nindex\\n \\nin\\n \\nPRESS\\n \\nV\\n \\nwas\\n \\napproximately\\n \\n27–29\\n \\nkg/m²,\\n \\nwith\\n \\nsubstantial\\n \\nrepresentation\\n \\nof\\n \\npatients\\n \\nwith\\n \\nBMI\\n \\n≥30\\n \\nkg/m²\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nPai\\n \\net\\n \\nal.,\\n \\n2014).\\n \\nSubgroup\\n \\nanalyses\\n \\nby\\n \\nBMI\\n \\ncategory\\n \\nwere\\n \\nnot\\n \\nprominently\\n \\nreported,\\n \\nlimiting\\n \\ndirect\\n \\nobese\\n \\nversus\\n \\nlean\\n \\ncomparisons.\\n \\nPhase  2  NAFLD/NASH  Trial  (Gawrieh  et  al.,  2021)  \\nThe  NAFLD  trial  enrolled  patients  with  mean  BMI  approximately  34  kg/m²,  representing  a  \\npredominantly\\n \\nobese\\n \\ncohort.\\n \\nLean\\n \\nNAFLD\\n \\npatients\\n \\n(BMI\\n \\n<25\\n \\nkg/m²)\\n \\nwere\\n \\nnot\\n \\nspecifically\\n \\nstudied\\n \\nin\\n \\nthis\\n \\ntrial,\\n \\nreflecting\\n \\nthe\\n \\ntypical\\n \\nNAFLD\\n \\npopulation\\n \\nenriched\\n \\nfor\\n \\nobesity\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021).\\n \\nReal-World  Studies  \\nReal-world  cohorts  from  India  and  other  regions  include  more  heterogeneous  BMI  \\ndistributions,\\n \\nwith\\n \\nsome\\n \\nrepresentation\\n \\nof\\n \\nlean\\n \\nor\\n \\nnormal-weight\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction,\\n \\nthough\\n \\ndetailed\\n \\nBMI-stratified\\n \\nanalyses\\n \\nare\\n \\nsparse\\n \\n(Kaul\\n \\net\\n \\nal.,\\n \\n2019;\\n \\nGupte\\n \\net\\n \\nal.,\\n \\n2020).\\n \\nComparative  Outcomes:  Obese  versus  Lean  Patients  \\nA.  Triglyceride  Reduction  \\nObese  Patients  (BMI  ≥30  kg/m²):'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 58, 'page_label': '59'}, page_content='●  Baseline  triglycerides  typically  higher  (often  250–350  mg/dL  or  more).  ●  Saroglitazar  4  mg  produces  robust  absolute  reductions:  mean  40–50%  reduction  \\ntranslates\\n \\nto\\n \\n100–175\\n \\nmg/dL\\n \\nabsolute\\n \\ndecrease.\\n ●  Greater  absolute  benefit  reflects  higher  baseline  substrate  for  PPAR- α– mediated  \\nlipid\\n \\nmetabolism\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nPai\\n \\net\\n \\nal.,\\n \\n2014).\\n \\nLean  Patients  (BMI  <25  kg/m²):  \\n●  Limited  specific  data;  lean  patients  with  metabolic  dysfunction  (lean  NAFLD,  lean  \\nmetabolic\\n \\nsyndrome)\\n \\noften\\n \\nhave\\n \\nmoderately\\n \\nelevated\\n \\ntriglycerides\\n \\n(150–250\\n \\nmg/dL).\\n ●  Expected  percentage  reduction  similar  (~30–40%),  but  smaller  absolute  decrease  \\ndue\\n \\nto\\n \\nlower\\n \\nbaseline.\\n ●  Lean  patients  with  dyslipidemia  still  derive  clinically  meaningful  triglyceride  lowering,  \\nthough\\n \\ndata\\n \\nare\\n \\nextrapolated\\n \\nfrom\\n \\nmixed\\n \\ncohorts\\n \\nrather\\n \\nthan\\n \\ndedicated\\n \\nlean-patient\\n \\ntrials.\\n \\nInterpretation:  Obese  patients  show  larger  absolute  triglyceride  reductions  due  to  higher  \\nbaseline\\n \\nvalues,\\n \\nbut\\n \\npercentage\\n \\nreductions\\n \\nappear\\n \\ncomparable\\n \\nacross\\n \\nBMI\\n \\ncategories\\n \\nwhere\\n \\ndata\\n \\nexist.\\n \\n \\nB.  ALT  and  Liver  Enzyme  Reduction  \\nObese  Patients:  \\n●  Baseline  ALT  typically  elevated  (often  60–120  U/L  or  higher  in  NAFLD/NASH  \\ncohorts).\\n ●  Saroglitazar  produces  substantial  ALT  reductions:  40–60%  decrease  in  phase  2  and  \\nreal-world\\n \\nstudies,\\n \\ntranslating\\n \\nto\\n \\n30–70\\n \\nU/L\\n \\nabsolute\\n \\nreductions\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nGupte\\n \\net\\n \\nal.,\\n \\n2020).\\n ●  Greater  hepatic  steatosis  and  inflammation  in  obese  patients  provide  larger  substrate  \\nfor\\n \\nimprovement.\\n \\nLean  Patients:  \\n●  Lean  NAFLD  patients  often  have  lower  baseline  ALT  (40–80  U/L),  though  some  have  \\nsignificant\\n \\ninflammation.\\n ●  Limited  direct  data;  extrapolation  suggests  percentage  ALT  reductions  may  be  \\nsimilar,\\n \\nbut\\n \\nabsolute\\n \\ndecreases\\n \\nsmaller.\\n ●  Lean  NAFLD  may  have  different  pathophysiology  (genetic  factors,  lipodystrophy-like  \\nfeatures,\\n \\nmitochondrial\\n \\ndysfunction),\\n \\npotentially\\n \\naffecting\\n \\ntreatment\\n \\nresponse,\\n \\nthough\\n \\nthis\\n \\nis\\n \\nnot\\n \\nwell\\n \\nstudied\\n \\nfor\\n \\nsaroglitazar.\\n \\nInterpretation:  Obese  patients  demonstrate  larger  absolute  ALT  reductions;  lean  patient  \\nresponse\\n \\nis\\n \\nless\\n \\nwell\\n \\ncharacterized\\n \\nbut\\n \\nlikely\\n \\nmeaningful\\n \\nin\\n \\nthose\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 59, 'page_label': '60'}, page_content='C.  Hepatic  Steatosis  (CAP)  Reduction  \\nObese  Patients:  \\n●  Baseline  controlled  attenuation  parameter  typically  high  (>280–320  dB/m,  indicating  \\nmoderate\\n \\nto\\n \\nsevere\\n \\nsteatosis).\\n ●  Saroglitazar  produces  CAP  reductions  of  15–25%  (30–60  dB/m  absolute  decrease),  \\nmoving\\n \\nmany\\n \\npatients\\n \\nfrom\\n \\nsevere\\n \\nto\\n \\nmoderate\\n \\nor\\n \\nmild\\n \\nsteatosis\\n \\ncategories\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nGupte\\n \\net\\n \\nal.,\\n \\n2020).\\n ●  Greater  baseline  steatosis  provides  larger  opportunity  for  improvement.  \\nLean  Patients:  \\n●  Lean  NAFLD  patients  may  have  lower  baseline  CAP  (240–280  dB/m),  though  some  \\nhave\\n \\nsignificant\\n \\nsteatosis.\\n ●  No  dedicated  saroglitazar  data  in  lean  NAFLD;  expected  CAP  reductions  likely  \\nproportional\\n \\nbut\\n \\nsmaller\\n \\nin\\n \\nabsolute\\n \\nterms.\\n ●  Lean  NAFLD  pathophysiology  may  involve  factors  less  responsive  to  PPAR  agonism  \\n(e.g.,\\n \\ngenetic\\n \\nvariants,\\n \\nmitochondrial\\n \\ndefects).\\n \\nInterpretation:  Obese  patients  show  greater  absolute  steatosis  reduction;  lean  patient  data  \\nare\\n \\ninsufficient\\n \\nfor\\n \\ndefinitive\\n \\nconclusions.\\n \\n \\nD.  Liver  Stiffness  (LSM)  and  Fibrosis  \\nObese  Patients:  \\n●  Baseline  liver  stiffness  often  elevated  (8–15  kPa  in  F2–F3  patients).  ●  Meta-analysis  shows  mean  LSM  reduction  of  approximately  2–4  kPa  with  \\nsaroglitazar,\\n \\nwith\\n \\ngreater\\n \\nreductions\\n \\nin\\n \\npatients\\n \\nwith\\n \\nhigher\\n \\nbaseline\\n \\nstiffness\\n \\n(Kumar\\n \\net\\n \\nal.,\\n \\n2023).\\n ●  Obesity-associated  inflammation  and  fibrogenesis  may  be  more  responsive  to  \\nmetabolic\\n \\noptimization.\\n \\nLean  Patients:  \\n●  Lean  NAFLD  patients  with  fibrosis  may  have  different  fibrogenic  drivers  (less  \\nmetabolic,\\n \\nmore\\n \\ngenetic\\n \\nor\\n \\nimmune-mediated).\\n ●  No  specific  saroglitazar  data  in  lean  fibrosis  patients;  response  may  be  attenuated  if  \\nmetabolic\\n \\ndrivers\\n \\nare\\n \\nless\\n \\nprominent.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 60, 'page_label': '61'}, page_content='Interpretation:  Obese  patients  with  metabolically  driven  fibrosis  likely  show  better  LSM  \\nresponse;\\n \\nlean\\n \\npatient\\n \\nresponse\\n \\nuncertain.\\n \\n \\nE.  Glycemic  Control  (HbA1c)  \\nObese  Patients:  \\n●  Baseline  HbA1c  typically  7.5–9%  in  diabetic  cohorts.  ●  Saroglitazar  produces  HbA1c  reductions  of  0.3–0.8%,  with  greater  reductions  in  \\npatients\\n \\nwith\\n \\npoorer\\n \\nbaseline\\n \\ncontrol\\n \\n(Jani\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nDutta\\n \\net\\n \\nal.,\\n \\n2021).\\n ●  PPAR- γ– mediated  insulin  sensitization  particularly  beneficial  in  obese,  \\ninsulin-resistant\\n \\npatients.\\n \\nLean  Patients:  \\n●  Lean  diabetic  patients  may  have  different  diabetes  pathophysiology  (more  beta-cell  \\ndysfunction,\\n \\nless\\n \\ninsulin\\n \\nresistance).\\n ●  PPAR- γ  effects  may  be  less  pronounced  in  lean  patients  with  lower  insulin  \\nresistance.\\n ●  Limited  data;  expected  HbA1c  benefit  likely  smaller  than  in  obese  cohorts.  \\nInterpretation:  Obese,  insulin-resistant  patients  derive  greater  glycemic  benefit;  lean  \\ndiabetic\\n \\npatients\\n \\nmay\\n \\nshow\\n \\nattenuated\\n \\nHbA1c\\n \\nresponse.\\n \\n \\nF.  Body  Weight  Changes  \\nObese  Patients:  \\n●  Saroglitazar  is  weight-neutral  or  associated  with  modest  weight  reduction  (0.5–2  kg)  \\nin\\n \\nmost\\n \\nstudies,\\n \\ncontrasting\\n \\nfavorably\\n \\nwith\\n \\npioglitazone\\n \\n(which\\n \\ncauses\\n \\n2–4\\n \\nkg\\n \\nweight\\n \\ngain)\\n \\n(Pai\\n \\net\\n \\nal.,\\n \\n2014;\\n \\nKaul\\n \\net\\n \\nal.,\\n \\n2019).\\n ●  Weight  stability  is  clinically  important  in  obese  NAFLD  patients  where  weight  gain  \\nwould\\n \\nworsen\\n \\ndisease.\\n \\nLean  Patients:  \\n●  Weight-neutral  effect  likely  maintained;  no  specific  data  on  lean  cohorts.  ●  Absence  of  weight  gain  is  advantageous  compared  to  other  PPAR- γ  agonists.  \\nInterpretation:  Weight-neutral  profile  benefits  both  obese  and  lean  patients;  no  differential  \\neffect\\n \\nexpected.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 61, 'page_label': '62'}, page_content='Mechanistic  Considerations  \\nWhy  Obese  Patients  May  Show  Greater  Response  \\n1.  Higher  baseline  metabolic  dysfunction:  Greater  insulin  resistance,  dyslipidemia,  \\nand\\n \\nhepatic\\n \\nsteatosis\\n \\nprovide\\n \\nlarger\\n \\nsubstrate\\n \\nfor\\n \\nPPAR-\\nα/γ–\\nmediated\\n \\nimprovements.\\n 2.  Metabolically  driven  disease:  Obesity-associated  NAFLD  is  primarily  metabolic;  \\nsaroglitazar\\n \\ndirectly\\n \\ntargets\\n \\nthese\\n \\npathways.\\n 3.  Greater  inflammatory  burden:  Adipose  tissue  inflammation  and  adipokine  \\ndysregulation\\n \\nin\\n \\nobesity\\n \\nare\\n \\nmodulated\\n \\nby\\n \\nPPAR-\\nγ\\n \\nactivation.\\n \\nWhy  Lean  Patients  May  Show  Attenuated  Response  \\n1.  Different  pathophysiology:  Lean  NAFLD  may  involve  genetic  factors  (PNPLA3,  \\nTM6SF2\\n \\nvariants),\\n \\nmitochondrial\\n \\ndysfunction,\\n \\nor\\n \\nlipodystrophy-like\\n \\nfeatures\\n \\nless\\n \\nresponsive\\n \\nto\\n \\nPPAR\\n \\nagonism.\\n 2.  Lower  baseline  abnormalities:  Smaller  baseline  elevations  in  triglycerides,  ALT,  \\nand\\n \\nsteatosis\\n \\nlimit\\n \\nabsolute\\n \\nimprovement\\n \\npotential.\\n 3.  Less  insulin  resistance:  PPAR- γ  insulin-sensitizing  effects  less  impactful  in  lean  \\npatients\\n \\nwith\\n \\nnormal\\n \\nor\\n \\nnear-normal\\n \\ninsulin\\n \\nsensitivity.\\n \\n \\nClinical  Implications  \\nFor  Obese  Patients  (BMI  ≥30  kg/m²)  \\n●  Strong  evidence  base:  Most  trial  and  real-world  data  derive  from  obese/overweight  \\npopulations.\\n ●  Expected  benefits:  Robust  triglyceride  lowering  (40–50%),  substantial  ALT  \\nreduction\\n \\n(40–60%),\\n \\nmeaningful\\n \\nsteatosis\\n \\nand\\n \\nstiffness\\n \\nimprovements.\\n ●  Recommendation:  Saroglitazar  is  well-supported  for  obese  NAFLD/NASH  patients  \\nwith\\n \\nmetabolic\\n \\ndysfunction\\n \\n(F0–F2).\\n \\nFor  Lean  Patients  (BMI  <25  kg/m²)  \\n●  Limited  evidence:  Few  dedicated  studies;  most  data  extrapolated  from  mixed  \\ncohorts.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 62, 'page_label': '63'}, page_content='●  Expected  benefits:  Likely  meaningful  but  smaller  absolute  improvements  in  \\nmetabolic\\n \\nparameters;\\n \\nefficacy\\n \\nmay\\n \\ndepend\\n \\non\\n \\ndegree\\n \\nof\\n \\nmetabolic\\n \\ndysfunction\\n \\npresent.\\n ●  Recommendation:  Consider  saroglitazar  in  lean  patients  with  documented  \\nmetabolic\\n \\nabnormalities\\n \\n(elevated\\n \\ntriglycerides,\\n \\ninsulin\\n \\nresistance,\\n \\nmetabolic\\n \\nsyndrome\\n \\nfeatures);\\n \\nresponse\\n \\nmay\\n \\nbe\\n \\nless\\n \\npredictable\\n \\nthan\\n \\nin\\n \\nobese\\n \\npatients.\\n ●  Alternative  considerations:  Lean  NAFLD  patients  may  benefit  from  evaluation  for  \\nsecondary\\n \\ncauses\\n \\n(genetic\\n \\ntesting,\\n \\nlipodystrophy\\n \\nscreening)\\n \\nand\\n \\nmay\\n \\nrequire\\n \\ndifferent\\n \\ntherapeutic\\n \\napproaches\\n \\nif\\n \\nmetabolic\\n \\ndrivers\\n \\nare\\n \\nminimal.\\n \\n \\nEvidence  Gaps  and  Research  Needs  \\n1.  Dedicated  lean  NAFLD  studies:  Prospective  trials  specifically  enrolling  lean  \\npatients\\n \\n(BMI\\n \\n<25\\n \\nkg/m²)\\n \\nwith\\n \\nNAFLD/NASH\\n \\nare\\n \\nneeded\\n \\nto\\n \\ndefine\\n \\nefficacy\\n \\nand\\n \\noptimal\\n \\nuse.\\n 2.  BMI-stratified  analyses:  Post-hoc  analyses  of  existing  trials  stratified  by  BMI  \\ncategory\\n \\nwould\\n \\nclarify\\n \\ndifferential\\n \\nresponses.\\n 3.  Mechanistic  studies:  Investigation  of  whether  lean  versus  obese  NAFLD  patients  \\nshow\\n \\ndifferent\\n \\nmolecular\\n \\nresponses\\n \\nto\\n \\nPPAR\\n \\nagonism.\\n 4.  Genetic  interactions:  Studies  examining  whether  genetic  variants  (PNPLA3,  \\nTM6SF2)\\n \\nmodify\\n \\nsaroglitazar\\n \\nresponse\\n \\nacross\\n \\nBMI\\n \\ncategories.\\n \\n \\nConclusion  \\nSaroglitazar  demonstrates  robust  efficacy  in  obese  patients  with  NAFLD/NASH  and  \\nmetabolic\\n \\ndyslipidemia,\\n \\nwith\\n \\nstrong\\n \\nevidence\\n \\nfor\\n \\ntriglyceride\\n \\nlowering,\\n \\nALT\\n \\nreduction,\\n \\nand\\n \\nsteatosis\\n \\nimprovement.\\n \\nLean\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndysfunction\\n \\nlikely\\n \\nderive\\n \\nbenefit,\\n \\nthough\\n \\nthe\\n \\nmagnitude\\n \\nmay\\n \\nbe\\n \\nsmaller\\n \\nand\\n \\nevidence\\n \\nis\\n \\nlimited.\\n \\nClinical\\n \\ndecisions\\n \\nshould\\n \\nbe\\n \\nindividualized:\\n \\nobese\\n \\npatients\\n \\nare\\n \\nideal\\n \\ncandidates\\n \\nbased\\n \\non\\n \\ncurrent\\n \\nevidence,\\n \\nwhile\\n \\nlean\\n \\npatients\\n \\nshould\\n \\nbe\\n \\nselected\\n \\nbased\\n \\non\\n \\npresence\\n \\nof\\n \\nmetabolic\\n \\nabnormalities\\n \\nand\\n \\nafter\\n \\nconsideration\\n \\nof\\n \\nalternative\\n \\netiologies.\\n \\nFurther\\n \\nresearch\\n \\nspecifically\\n \\naddressing\\n \\nlean\\n \\nNAFLD\\n \\npopulations\\n \\nis\\n \\nneeded\\n \\nto\\n \\noptimize\\n \\ntherapeutic\\n \\nguidance.\\n \\n \\nReferences'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 63, 'page_label': '64'}, page_content='Gawrieh,  S.,  Noureddin,  M.,  Loo,  N.,  et  al.  (2021).  Saroglitazar,  a  PPAR- α/γ  agonist,  for  \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n \\ndouble-blind\\n \\nphase\\n \\n2\\n trial.  Hepatology ,  74 (4),  1809–1824. https://doi.org/10.1002/hep.31843 \\nGupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  et  al.  (2020).  Saroglitazar  in  patients  with  non-alcoholic  \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\ndiabetic\\n \\ndyslipidemia:\\n \\nReal-world\\n \\ndata.\\n \\nJournal\\n \\nof\\n \\nGastroenterology\\n \\nand\\n \\nHepatology\\n.\\n \\nJani,  R.  H.,  Pai,  V.,  Jha,  P.,  et  al.  (2014).  Saroglitazar  2  and  4  mg  compared  with  placebo  in  \\ntype\\n \\n2\\n \\ndiabetes\\n \\nmellitus\\n \\npatients\\n \\nhaving\\n \\nhypertriglyceridemia\\n \\nnot\\n \\ncontrolled\\n \\nwith\\n \\natorvastatin\\n therapy  (PRESS  V).  Diabetes  Technology  &  Therapeutics ,  16 (2),  63–71. https://doi.org/10.1089/dia.2013.0253 \\nKaul,  U.,  Parmar,  D.,  Manjunath,  K.,  et  al.  (2019).  Saroglitazar  in  diabetic  dyslipidemia  and  \\nnon-alcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nIntegrated\\n \\nanalysis\\n \\nof\\n \\nreal\\n \\nworld\\n \\nevidence.\\n \\nCardiovascular\\n Diabetology ,  18 (1),  80. https://doi.org/10.1186/s12933-019-0884-3 \\nKumar,  A.,  Sharma,  A.,  Duseja,  A.,  et  al.  (2023).  Effects  of  saroglitazar  in  NAFLD/NASH:  A  systematic  review  and  meta-analysis.  Clinical  and  Experimental  Hepatology ,  9 (2),  117–128. https://doi.org/10.5114/ceh.2023.127873 \\nPai,  V.,  Paneerselvam,  A.,  Mukhopadhyay,  S.,  et  al.  (2014).  Saroglitazar  2  and  4  mg  \\ncompared\\n \\nto\\n \\npioglitazone\\n \\n45\\n \\nmg\\n \\nin\\n \\ndiabetic\\n \\ndyslipidemia\\n \\n(PRESS\\n \\nVI).\\n \\nDiabetes\\n \\nTechnology\\n &  Therapeutics ,  16 (9),  589–598. https://doi.org/10.1089/dia.2013.0288'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 64, 'page_label': '65'}, page_content='18.Impact  of  saroglitazar  on  non-invasive  NAFLD  fibrosis  \\nscore\\n \\nHere  is  a  concise,  friendly  yet  professional  summary  you  can  use  with  colleagues.  \\nImpact  of  Saroglitazar  on  Non ‑ invasive  NAFLD  Fibrosis  Scores  —  Practical  Brief  \\nSummary  (one  line)  \\n \\nSaroglitazar\\n \\nconsistently\\n \\nimproves\\n \\nnon\\n‑\\ninvasive\\n \\nfibrosis\\n \\nmarkers\\n \\n(FibroScan\\n \\nliver\\n \\nstiffness,\\n \\nFIB\\n‑\\n4,\\n \\nAPRI)\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\ncirrhotic\\n \\nNAFLD/NASH\\n \\n(best\\n \\nevidence\\n \\nin\\n \\nF0–F2),\\n \\nreflecting\\n \\nreduced\\n \\ninflammation\\n \\nand\\n \\nsteatosis\\n \\nand\\n \\nsuggesting\\n \\nstabilization\\n \\nor\\n \\npartial\\n \\nregression\\n \\nof\\n \\nfibrosis.\\n \\nKey  evidence  and  effects  \\n●  Liver  stiffness  (FibroScan,  LSM):  Trials  and  pooled  analyses  report  mean  LSM  \\nreductions\\n \\nof\\n \\n~1.5–2.8\\n \\nkPa\\n \\nwith\\n \\nsaroglitazar\\n \\n(most\\n \\ndata\\n \\nfrom\\n \\n16–52\\n \\nweek\\n \\nstudies).\\n \\nGreater\\n \\nabsolute\\n \\nLSM\\n \\ndecline\\n \\nis\\n \\nseen\\n \\nin\\n \\npatients\\n \\nwith\\n \\nhigher\\n \\nbaseline\\n \\nstiffness.\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nKumar\\n \\net\\n \\nal.,\\n \\n2023).\\n ●  FIB ‑ 4  and  APRI  (serum-based  scores):  Saroglitazar  lowers  AST/ALT  and  therefore  \\nimproves\\n \\nFIB\\n‑\\n4\\n \\nand\\n \\nAPRI\\n \\nvalues.\\n \\nReal\\n‑\\nworld\\n \\nseries\\n \\nreport\\n \\nmean\\n \\nFIB\\n‑\\n4\\n \\nreductions\\n \\nof\\n \\n~0.3–0.6\\n \\nand\\n \\nAPRI\\n \\nreductions\\n \\nof\\n \\n~0.2–0.4\\n \\nat\\n \\n~24\\n \\nweeks,\\n \\nwith\\n \\nmany\\n \\npatients\\n \\nshifting\\n \\nfrom\\n \\nindeterminate/high\\n \\nrisk\\n \\nto\\n \\nlower\\n‑\\nrisk\\n \\ncategories\\n \\n(Dutta\\n \\net\\n \\nal.,\\n \\n2021;\\n \\nGupte\\n \\net\\n \\nal.,\\n \\n2020).\\n ●  CAP  (steatosis):  Saroglitazar  reduces  hepatic  steatosis  (CAP  or  MRI ‑ PDFF),  which  \\nreduces\\n \\nongoing\\n \\nhepatocyte\\n \\ninjury\\n \\nand\\n \\nthus\\n \\nthe\\n \\nfibrogenic\\n \\ndrive—an\\n \\nimportant\\n \\nindirect\\n \\nmechanism\\n \\nfor\\n \\nimproving\\n \\nfibrosis\\n \\nscores\\n \\n(Gawrieh\\n \\net\\n \\nal.,\\n \\n2021).\\n \\nHow  to  interpret  score  changes  \\n●  Enzyme ‑ driven  improvement:  FIB ‑ 4  and  APRI  include  transaminases;  early  \\nimprovements\\n \\nmay\\n \\nreflect\\n \\ndecreased\\n \\ninflammation\\n \\nas\\n \\nwell\\n \\nas\\n \\nfibrosis\\n \\nchange.\\n ●  LSM  is  more  directly  related  to  stiffness  (fibrosis)  but  is  also  influenced  by  \\ninflammation\\n \\nand\\n \\nsteatosis.\\n ●  Best  practice:  use  a  combination—LSM  trends  plus  FIB ‑ 4/APRI—to  assess  likely  \\nfibrosis\\n \\nmodification;\\n \\nconsider\\n \\nbiopsy\\n \\nonly\\n \\nwhen\\n \\nclinical\\n \\ndecisions\\n \\nrequire\\n \\nhistologic\\n \\nconfirmation.\\n \\nWho  benefits  most  \\n●  Patients  with  F0–F2  fibrosis  (non ‑ cirrhotic)  and  metabolic  dysfunction  show  the  \\nlargest\\n \\nand\\n \\nmost\\n \\nreliable\\n \\nimprovements\\n \\nin\\n \\nnon\\n‑\\ninvasive\\n \\nscores.\\n ●  Patients  with  F3  may  show  stabilization  or  modest  improvements;  reversal  of  \\narchitectural\\n \\ndamage\\n \\nis\\n \\nless\\n \\nlikely.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 65, 'page_label': '66'}, page_content='●  Cirrhotic  patients  (F4),  especially  decompensated,  are  not  appropriate  candidates  for  \\nroutine\\n \\nuse\\n \\nbased\\n \\non\\n \\ncurrent\\n \\nevidence.\\n \\nPractical  monitoring  guidance  \\n●  Baseline:  FibroScan  (LSM  +  CAP),  FIB ‑ 4/APRI,  ALT/AST,  platelet  count,  metabolic  \\npanel.\\n ●  Early  check:  LFTs  at  1–3  months  to  confirm  biochemical  response.  ●  Efficacy  assessment:  repeat  FibroScan  and  FIB ‑ 4/APRI  at  6  months;  continue  \\n6\\n‑\\nmonthly\\n \\nor\\n \\nannual\\n \\nmonitoring\\n \\nthereafter.\\n ●  Response  signals:  LSM  reduction  ≥15%  or  ≥2  kPa  and  downward  shift  in  FIB ‑ 4/APRI  \\nrisk\\n \\ncategory\\n \\nare\\n \\nclinically\\n \\nmeaningful.\\n \\nCaveats  and  evidence  gaps  \\n●  Most  data  are  16–52  weeks;  long ‑ term  histologic  outcome  trials  are  limited.  ●  Score  improvements  partly  reflect  reduced  inflammation;  paired  biopsy  data  to  \\nconfirm\\n \\ntrue\\n \\nfibrosis\\n \\nregression\\n \\nare\\n \\nscarce.\\n ●  Interpret  improvements  as  encouraging  disease  modification  evidence,  not  definitive  \\nproof\\n \\nof\\n \\nreversal\\n \\nwithout\\n \\nhistology.\\n \\nBottom  line  for  practice  \\n●  Saroglitazar  is  a  useful  option  to  improve  non ‑ invasive  fibrosis  markers  in  \\nnon\\n‑\\ncirrhotic\\n \\nNAFLD/NASH\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndisease;\\n \\nmonitor\\n \\nwith\\n \\nLSM\\n \\nplus\\n \\nserum\\n \\nscores,\\n \\nand\\n \\ninvolve\\n \\nhepatology\\n \\nwhen\\n \\nF3/F4\\n \\ndisease\\n \\nor\\n \\nclinical\\n \\nuncertainty\\n \\nexists.\\n \\nSelected  references  (APA)  \\n●  Gawrieh,  S.,  Noureddin,  M.,  Loo,  N.,  Mohseni,  R.,  Awasty,  V.,  Cusi,  K.,  Kowdley,  K.  \\nV.,\\n \\nLai,\\n \\nM.,\\n \\nSchiff,\\n \\nE.,\\n \\nParmar,\\n \\nD.,\\n \\nBhat,\\n \\nM.,\\n \\nVuppalanchi,\\n \\nR.,\\n \\nAlkhouri,\\n \\nN.,\\n \\nChalasani,\\n \\nN.,\\n \\n&\\n \\nEVIDENCES\\n \\nIV\\n \\nInvestigators.\\n \\n(2021).\\n \\nSaroglitazar,\\n \\na\\n \\nPPAR\\n‑\\nα/γ\\n \\nagonist,\\n \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n \\ndouble\\n‑\\nblind\\n phase  2  trial.  Hepatology,  74(4),  1809–1824. https://doi.org/10.1002/hep.31843   ●  Gupte,  P.,  Amarapurkar,  D.,  Agal,  S.,  Baijal,  R.,  Kulshrestha,  P.,  Pramanik,  S.,  Patel,  \\nN.,\\n \\nMadan,\\n \\nA.,\\n \\nAmarapurkar,\\n \\nA.,\\n \\n&\\n \\nHafeezunnisa.\\n \\n(2020).\\n \\nSaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\ndiabetic\\n \\ndyslipidemia:\\n \\nReal\\n‑\\nworld\\n \\ndata.\\n \\nJournal\\n \\nof\\n \\nGastroenterology\\n \\nand\\n \\nHepatology.\\n \\n ●  Dutta,  D.,  Kumar,  M.,  Shivaprasad,  K.  S.,  Kumar,  A.,  Sharma,  M.,  &  Mukhopadhyay,  \\nS.\\n \\n(2021).\\n \\nImpact\\n \\nof\\n \\nsaroglitazar\\n \\non\\n \\nglycemic\\n \\ncontrol,\\n \\ndyslipidemia,\\n \\nliver\\n \\nfunction,\\n \\nand\\n \\nbody\\n \\nweight\\n \\nin\\n \\ntype\\n \\n2\\n \\ndiabetes:\\n \\nA\\n \\nreal\\n‑\\nworld\\n \\nstudy.\\n \\nIndian\\n \\nJournal\\n \\nof\\n \\nEndocrinology\\n and  Metabolism,  25(2),  133–139. https://doi.org/10.4103/ijem.IJEM_787_20'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 66, 'page_label': '67'}, page_content='●  Kumar,  A.,  Sharma,  A.,  Duseja,  A.,  Das,  A.,  Dhiman,  R.  K.,  Chawla,  Y.  K.,  Kohli,  K.  \\nK.,\\n \\n&\\n \\nBhansali,\\n \\nA.\\n \\n(2023).\\n \\nEffects\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon\\n‑\\nalcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n and  meta ‑ analysis.  Clinical  and  Experimental  Hepatology,  9(2),  117–128. https://doi.org/10.5114/ceh.2023.127873'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 67, 'page_label': '68'}, page_content='19.Guidelines  (Treatment  algorithm)  in  treatment  of  \\nNAFLD/NASH\\n \\nPurpose:  Provide  an  evidence ‑ based,  stage ‑ directed  algorithm  for  evaluation  and  \\nmanagement\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\nand\\n \\nnonalcoholic\\n \\nsteatohepatitis,\\n \\nincorporating\\n \\nfibrosis\\n \\nstratification,\\n \\nmetabolic\\n \\noptimization,\\n \\npharmacotherapy\\n \\noptions,\\n \\nsurveillance\\n \\nand\\n \\nreferral\\n \\ncriteria.\\n \\n1.  Initial  evaluation  ●  Confirm  hepatic  steatosis  using  imaging  (ultrasonography,  controlled  \\nattenuation\\n \\nparameter\\n \\nby\\n \\ntransient\\n \\nelastography,\\n \\nor\\n \\nMRI\\n‑\\nPDFF\\n \\nwhen\\n \\navailable)\\n \\nor\\n \\nhistology\\n \\nwhen\\n \\nindicated.\\n ●  Exclude  secondary  causes  of  steatosis:  alcohol  excess,  viral  hepatitis,  \\ndrug\\n‑\\ninduced\\n \\nliver\\n \\ninjury,\\n \\nautoimmune,\\n \\nmetabolic/genetic\\n \\netiologies.\\n ●  Baseline  laboratory  panel:  liver  biochemistry  (ALT,  AST,  GGT,  alkaline  \\nphosphatase,\\n \\nbilirubin),\\n \\nsynthetic\\n \\nfunction\\n \\n(albumin,\\n \\nINR),\\n \\nfull\\n \\nblood\\n \\ncount\\n \\n(platelets),\\n \\nrenal\\n \\nfunction,\\n \\nfasting\\n \\nglucose,\\n \\nhemoglobin\\n \\nA1c,\\n \\nfasting\\n \\nlipid\\n \\nprofile,\\n \\nthyroid\\n \\nfunction.\\n ●  Calculate  fibrosis  risk  using  validated  noninvasive  indices  (FIB ‑ 4,  NAFLD  \\nfibrosis\\n \\nscore)\\n \\nand\\n \\nperform\\n \\ntransient\\n \\nelastography\\n \\n(LSM\\n \\n+\\n \\nCAP)\\n \\nif\\n \\navailable.\\n 2.  Risk  stratification  and  triage  ●  Low  probability  of  advanced  fibrosis:  FIB ‑ 4  <1.3  and  LSM  <8  kPa  →  manage  \\nin\\n \\nprimary\\n \\ncare\\n \\n/\\n \\nmetabolic\\n \\nclinic\\n \\nwith\\n \\nlifestyle\\n \\nintervention\\n \\nand\\n \\nperiodic\\n \\nsurveillance.\\n ●  Indeterminate  risk:  FIB ‑ 4  1.3–2.67  or  LSM  8–12.5  kPa  →  further  noninvasive  \\nevaluation\\n \\n(enhanced\\n \\nbiomarker\\n \\npanels,\\n \\nMR\\n \\nelastography)\\n \\nor\\n \\nhepatology\\n \\nreferral.\\n ●  High  probability  of  advanced  fibrosis/cirrhosis:  FIB ‑ 4  >2.67  or  LSM  ≥12.5–14  \\nkPa\\n \\nor\\n \\nclinical/ultrasound\\n \\nsigns\\n \\nof\\n \\nportal\\n \\nhypertension\\n \\n→\\n \\nexpedited\\n \\nhepatology\\n \\nevaluation,\\n \\nconsider\\n \\nhistologic\\n \\nstaging.\\n 3.  Foundational  therapy  —  metabolic  remediation  (universal)  ●  Target  weight  reduction:  aim  for  ≥7–10%  body  weight  (≥10%  associated  with  \\nhigher\\n \\nprobability\\n \\nof\\n \\nfibrosis\\n \\nregression).\\n ●  Nutritional  prescription:  hypocaloric,  Mediterranean ‑ pattern  diet;  reduce  \\nfructose\\n \\nand\\n \\nsaturated\\n \\nfat\\n \\nintake.\\n ●  Physical  activity:  ≥150  min/wk  moderate  aerobic  exercise  +  resistance  \\ntraining.\\n ●  Counsel  absolute  or  near ‑ total  abstinence  from  alcohol;  smoking  cessation.  4.  Concurrent  management  of  cardiometabolic  comorbidity  (parallel  strategy)  ●  Optimize  glycemic  control  using  agents  with  favorable  hepatic/weight  profiles  \\nwhere\\n \\nindicated\\n \\n(e.g.,\\n \\nGLP\\n‑\\n1\\n \\nreceptor\\n \\nagonists;\\n \\nconsider\\n \\nSGLT2\\n \\ninhibitors\\n \\nper\\n \\ncomorbidity).\\n ●  Manage  dyslipidemia  per  cardiovascular  risk  algorithms—statin  therapy  for  \\nLDL\\n \\nreduction\\n \\nis\\n \\nsafe\\n \\nin\\n \\nNAFLD.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 68, 'page_label': '69'}, page_content='●  Treat  hypertension  and  other  cardiovascular  risk  factors  aggressively.  ●  Consider  anti ‑ obesity  pharmacotherapy  or  bariatric  surgery  in  appropriate  \\ncandidates\\n \\nper\\n \\nBMI\\n \\nand\\n \\ncomorbidity\\n \\nthresholds.\\n 5.  Pharmacotherapeutic  selection  (evidence ‑  and  phenotype ‑ driven)  \\nPrinciples  \\n●  Reserve  pharmacotherapy  for  biopsy ‑ proven  NASH  with  significant  fibrosis  (F2–F3),  \\nor\\n \\nprogressive\\n \\ndisease\\n \\nwith\\n \\nhigh\\n \\nrisk\\n \\nfeatures;\\n \\nconsider\\n \\nin\\n \\nnoninvasive\\n \\nhigh\\n‑\\nrisk\\n \\nprofiles\\n \\nafter\\n \\nmultidisciplinary\\n \\ndiscussion.\\n \\nAgents  and  positioning  \\n●  Pioglitazone  (thiazolidinedione):  randomized  controlled  data  demonstrating  histologic  \\nbenefit\\n \\n(steatohepatitis\\n \\nand\\n \\nsome\\n \\nfibrosis\\n \\nsignal)\\n \\nin\\n \\npatients\\n \\nwith\\n \\nNASH,\\n \\nparticularly\\n \\nthose\\n \\nwith\\n \\ndiabetes;\\n \\nweigh\\n \\nagainst\\n \\nadverse\\n \\neffects\\n \\n(weight\\n \\ngain,\\n \\nedema,\\n \\nheart\\n \\nfailure\\n \\nrisk).\\n ●  Vitamin  E  (α ‑ tocopherol)  800  IU/day:  histologic  improvement  in  steatohepatitis  \\ndemonstrated\\n \\nin\\n \\nnon\\n‑\\ndiabetic\\n \\nadults\\n \\nwith\\n \\nbiopsy\\n‑\\nproven\\n \\nNASH;\\n \\nlong\\n‑\\nterm\\n \\nsafety\\n \\nconsiderations\\n \\nmust\\n \\nbe\\n \\ndiscussed.\\n ●  Saroglitazar  (PPAR ‑ α/γ  agonist):  indicated  in  certain  regions  for  diabetic  \\ndyslipidemia;\\n \\nphase\\n‑\\n2\\n \\nRCTs\\n \\nand\\n \\nreal\\n‑\\nworld\\n \\ndata\\n \\ndemonstrate\\n \\nreductions\\n \\nin\\n \\ntransaminases,\\n \\nhepatic\\n \\nsteatosis\\n \\n(MRI\\n‑\\nPDFF/CAP)\\n \\nand\\n \\nliver\\n \\nstiffness\\n \\n(LSM)\\n \\nin\\n \\nnon\\n‑\\ncirrhotic\\n \\nNAFLD/NASH\\n \\n(predominantly\\n \\nF0–F2).\\n \\nConsider\\n \\nsaroglitazar\\n \\nin\\n \\nnon\\n‑\\ncirrhotic\\n \\npatients\\n \\nwith\\n \\nmetabolic\\n \\ndysregulation;\\n \\nin\\n \\nF3\\n \\nrequire\\n \\nhepatology\\n \\noversight;\\n \\navoid\\n \\nin\\n \\ndecompensated\\n \\ncirrhosis.\\n \\nHistology\\n‑\\nendpoint\\n \\nphase\\n‑\\n3\\n \\ndata\\n \\nremain\\n \\nlimited.\\n ●  GLP ‑ 1  receptor  agonists:  strong  metabolic  and  weight ‑ loss  effects  and  signals  for  \\nNASH\\n \\nresolution;\\n \\nongoing\\n \\nstudies\\n \\nevaluating\\n \\nfibrosis\\n \\nendpoints.\\n ●  Other  agents  (FXR  agonists,  dual/triple  PPAR  agonists,  antifibrotics):  currently  \\ninvestigational\\n \\nor\\n \\nspecialist\\n‑\\ndirected\\n \\npending\\n \\nregulatory\\n \\noutcome\\n \\ntrials.\\n \\nMonitoring  and  response  assessment  \\n●  Baseline:  LFTs,  fasting  lipids,  glucose/HbA1c,  renal  function,  FibroScan  (LSM  +  \\nCAP)\\n \\nor\\n \\nequivalent.\\n ●  Early  biochemical  monitoring:  LFTs  and  metabolic  panel  at  1–3  months  after  \\npharmacotherapy\\n \\ninitiation.\\n ●  Efficacy  assessment:  repeat  noninvasive  fibrosis  assessment  (FibroScan  or  MR  \\nelastography)\\n \\nand\\n \\ncomposite\\n \\nserum\\n \\nscores\\n \\n(FIB\\n‑\\n4/APRI)\\n \\nat\\n \\n6–12\\n \\nmonths.\\n ●  Define  treatment  response:  clinically  meaningful  response  =  ALT  reduction  ≥30%  \\nfrom\\n \\nbaseline,\\n \\ntriglyceride\\n \\nreduction\\n \\n≥30%,\\n \\nand\\n \\neither\\n \\nLSM\\n \\ndecline\\n \\n≥15%\\n \\nor\\n \\nabsolute\\n \\nLSM\\n \\ndecrease\\n \\n≥2\\n \\nkPa\\n \\nor\\n \\ndownward\\n \\nreclassification\\n \\nin\\n \\nFIB\\n‑\\n4\\n \\nrisk\\n \\ncategory.\\n \\nAbsence\\n \\nof\\n \\nbiochemical\\n \\nor\\n \\nimaging\\n \\nimprovement\\n \\nat\\n \\n6\\n \\nmonths\\n \\nwarrants\\n \\nreassessment\\n \\nof'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 69, 'page_label': '70'}, page_content='adherence,  competing  causes,  and  consideration  of  alternative  therapy  or  trial  \\nenrolment.\\n \\n \\n7.  Indications  for  liver  biopsy  ●  Discordant  noninvasive  results,  uncertainty  regarding  staging,  consideration  \\nof\\n \\ndrugs\\n \\nwith\\n \\nhistology\\n‑\\nproven\\n \\nbenefit,\\n \\nor\\n \\neligibility\\n \\nfor\\n \\nclinical\\n \\ntrials.\\n \\nUse\\n \\nhistology\\n \\nwhen\\n \\nmanagement\\n \\nwould\\n \\nmaterially\\n \\nchange.\\n 8.  Management  of  advanced  disease  (F3–F4)  ●  For  compensated  cirrhosis:  surveillance  for  hepatocellular  carcinoma  (US  ±  \\nAFP\\n \\nevery\\n \\n6\\n \\nmonths),\\n \\nendoscopic\\n \\nvariceal\\n \\nscreening\\n \\nper\\n \\nguidelines,\\n \\nportal\\n \\nhypertension\\n \\nmanagement\\n \\nand\\n \\nvaccination.\\n \\nConsider\\n \\nindividualized\\n \\npharmacotherapy\\n \\nonly\\n \\nunder\\n \\nhepatology\\n \\ncare.\\n ●  For  decompensated  cirrhosis:  prioritize  cirrhosis  management  and  transplant  \\nevaluation;\\n \\navoid\\n \\nhepatotropic\\n \\ninvestigational\\n \\ndrugs\\n \\nunless\\n \\nunder\\n \\ntrial\\n \\nprotocols.\\n 9.  Referral  and  multidisciplinary  care  ●  Urgent  hepatology  referral  for  LSM  ≥12.5–14  kPa,  FIB ‑ 4  >2.67,  or  clinical  \\nsigns\\n \\nof\\n \\nportal\\n \\nhypertension.\\n ●  Engage  multidisciplinary  team:  hepatology,  endocrinology/diabetology,  \\ncardiology,\\n \\nobesity\\n \\nmedicine/dietetics,\\n \\nand,\\n \\nwhen\\n \\nindicated,\\n \\nbariatric\\n \\nsurgery.\\n 10.  Research  and  evidence  gaps  ●  Need  for  large,  histology ‑ driven  phase ‑ 3  trials  assessing  antifibrotic  efficacy  \\nand\\n \\nclinical\\n \\noutcomes\\n \\n(decompensation,\\n \\nHCC,\\n \\ntransplant,\\n \\nmortality).\\n ●  BMI ‑ stratified,  genotype ‑ stratified  and  long ‑ term  cardiovascular  outcome  data  \\nfor\\n \\nemerging\\n \\nagents\\n \\nare\\n \\nrequired.\\n \\nReferences  \\n●  Chalasani,  N.,  Younossi,  Z.,  Lavine,  J.  E.,  Charlton,  M.,  Cusi,  K.,  Rinella,  M.,  \\nHarrison,\\n \\nS.\\n \\nA.,\\n \\nBrunt,\\n \\nE.\\n \\nM.,\\n \\n&\\n \\nSanyal,\\n \\nA.\\n \\nJ.\\n \\n(2018).\\n \\nThe\\n \\ndiagnosis\\n \\nand\\n \\nmanagement\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nPractice\\n \\nguidance\\n \\nfrom\\n \\nthe\\n \\nAmerican\\n \\nAssociation\\n for  the  Study  of  Liver  Diseases.  Hepatology,  67(1),  328–357. https://doi.org/10.1002/hep.29367   ●  Eslam,  M.,  Newsome,  P.  N.,  Sarin,  S.  K.,  Anstee,  Q.  M.,  &  Wong,  V.  W.-S.  (2020).  A  \\nnew\\n \\ndefinition\\n \\nfor\\n \\nmetabolic\\n \\ndysfunction\\n‑\\nassociated\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nAn\\n international  expert  consensus  statement.  Journal  of  Hepatology,  73(1),  202–209. https://doi.org/10.1016/j.jhep.2020.03.039   ●  Gawrieh,  S.,  Noureddin,  M.,  Loo,  N.,  Mohseni,  R.,  Awasty,  V.,  Cusi,  K.,  Kowdley,  K.  \\nV.,\\n \\nLai,\\n \\nM.,\\n \\nSchiff,\\n \\nE.,\\n \\nParmar,\\n \\nD.,\\n \\nBhat,\\n \\nM.,\\n \\nVuppalanchi,\\n \\nR.,\\n \\nAlkhouri,\\n \\nN.,\\n \\nChalasani,\\n \\nN.,\\n \\n&\\n \\nEVIDENCES\\n \\nIV\\n \\nInvestigators.\\n \\n(2021).\\n \\nSaroglitazar,\\n \\na\\n \\nPPAR\\n‑\\nα/γ\\n \\nagonist,\\n \\nfor\\n \\ntreatment\\n \\nof\\n \\nnonalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease:\\n \\nA\\n \\nrandomized\\n \\ncontrolled\\n \\ndouble\\n‑\\nblind'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 70, 'page_label': '71'}, page_content='phase  2  trial.  Hepatology,  74(4),  1809–1824. https://doi.org/10.1002/hep.31843   ●  Sanyal,  A.  J.,  Chalasani,  N.,  Kowdley,  K.  V.,  McCullough,  A.,  Diehl,  A.  M.,  Bass,  N.  \\nM.,\\n \\nNeuschwander\\n‑\\nTetri,\\n \\nB.\\n \\nA.,\\n \\nLavine,\\n \\nJ.,\\n \\nTonascia,\\n \\nJ.,\\n \\nUnalp,\\n \\nA.,\\n \\n&\\n \\nCurtiss,\\n \\nL.\\n \\n(2010).\\n \\nPioglitazone,\\n \\nvitamin\\n \\nE,\\n \\nor\\n \\nplacebo\\n \\nfor\\n \\nnonalcoholic\\n \\nsteatohepatitis.\\n \\nNew\\n England  Journal  of  Medicine,  362(18),  1675–1685. https://doi.org/10.1056/NEJMoa0907929   ●  Kumar,  A.,  Sharma,  A.,  Duseja,  A.,  Das,  A.,  Dhiman,  R.  K.,  Chawla,  Y.  K.,  Kohli,  K.  \\nK.,\\n \\n&\\n \\nBhansali,\\n \\nA.\\n \\n(2023).\\n \\nEffects\\n \\nof\\n \\nsaroglitazar\\n \\nin\\n \\npatients\\n \\nwith\\n \\nnon\\n‑\\nalcoholic\\n \\nfatty\\n \\nliver\\n \\ndisease\\n \\n(NAFLD)\\n \\nor\\n \\nnon\\n‑\\nalcoholic\\n \\nsteatohepatitis\\n \\n(NASH):\\n \\nA\\n \\nsystematic\\n \\nreview\\n and  meta ‑ analysis.  Clinical  and  Experimental  Hepatology,  9(2),  117–128. https://doi.org/10.5114/ceh.2023.127873'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 71, 'page_label': '72'}, page_content='20.Impact  of  saroglitazar  on  Insulin  resistance  \\nSaroglitazar  is  a  novel  drug  designed  as  a  dual  peroxisome  proliferator-activated  \\nreceptor\\n \\n(PPAR)\\n \\nagonist\\n,\\n \\ntargeting\\n \\nboth\\n \\nPPAR-\\n \\n(alpha)\\n \\nand\\n \\nPPAR-\\n \\n(gamma)\\n \\nreceptors.\\n \\nIts\\n \\nimpact\\n \\non\\n \\ninsulin\\n \\nresistance\\n \\n(IR)\\n \\nis\\n \\nprimarily\\n \\nmediated\\n \\nthrough\\n \\nthe\\n \\nactivation\\n \\nof\\n \\nthe\\n \\nPPAR-\\n \\npathway,\\n \\npositioning\\n \\nit\\n \\nas\\n \\nan\\n \\neffective\\n \\ntool\\n \\nfor\\n \\nmanaging\\n \\nmetabolic\\n \\ndysfunction\\n \\nin\\n \\nconditions\\n \\nlike\\n \\nType\\n \\n2\\n \\nDiabetes\\n \\nMellitus\\n \\n(T2DM)\\n \\nand\\n \\nNon-Alcoholic\\n \\nFatty\\n \\nLiver\\n \\nDisease\\n \\n(NAFLD).\\n \\n \\nMechanism  of  Action  on  Insulin  Resistance  \\n(PPAR-gamma)\\n \\nThe  improvement  in  insulin  resistance  by  saroglitazar  is  directly  linked  to  its  potent  agonist  \\nactivity\\n \\nat\\n \\nthe\\n \\nPPAR-gamma\\n \\nreceptor,\\n \\nwhich\\n \\nis\\n \\nhighly\\n \\nexpressed\\n \\nin\\n \\nadipose\\n \\ntissue.\\n \\n1.  Enhanced  Insulin  Sensitivity  ●  PPAR-  Activation:  Activation  of  PPAR-gamma  transcription  factors  modulates  the  \\nexpression\\n \\nof\\n \\ngenes\\n \\ncrucial\\n \\nfor\\n \\nlipid\\n \\nmetabolism\\n \\nand\\n \\nglucose\\n \\nhomeostasis.\\n \\nThis\\n \\nleads\\n \\nto\\n \\nincreased\\n \\nsensitivity\\n \\nto\\n \\ninsulin\\n \\nin\\n \\nkey\\n \\nperipheral\\n \\ntissues:\\n \\nmuscle,\\n \\nfat,\\n \\nand\\n \\nliver.\\n ●  Glucose  Transporter  Upregulation:  It  enhances  the  movement  of  Glucose  \\nTransporter\\n \\nType\\n \\n4\\n \\n(GLUT4)\\n \\nto\\n \\nthe\\n \\ncell\\n \\nsurface\\n \\nin\\n \\nmuscle\\n \\nand\\n \\nfat\\n \\ncells.\\n \\nThis\\n \\nincreases\\n \\nthe\\n \\nuptake\\n \\nand\\n \\nutilization\\n \\nof\\n \\ncirculating\\n \\nglucose,\\n \\nthereby\\n \\nlowering\\n \\nplasma\\n \\nglucose\\n \\nlevels\\n \\nand\\n \\nreducing\\n \\nthe\\n \\ncompensatory\\n \\nhyperinsulinemia\\n \\nassociated\\n \\nwith\\n \\nIR.\\n \\n2.  Improved  Adipose  Function  ●  Adipogenesis  and  Fat  Redistribution:  Saroglitazar  promotes  the  differentiation  of  \\npre-adipocytes\\n \\ninto\\n \\nsmaller,\\n \\nmore\\n \\ninsulin-sensitive\\n \\nadipocytes\\n \\n(adipogenesis)\\n \\nand\\n \\nencourages\\n \\nthe\\n \\nstorage\\n \\nof\\n \\nfat\\n \\nsafely\\n \\nwithin\\n \\nthe\\n \\nsubcutaneous\\n \\nadipose\\n \\ntissue.\\n \\nThis\\n \\nredistribution\\n \\nreduces\\n \\nectopic\\n \\nfat\\n \\ndeposition\\n \\nin\\n \\nnon-adipose\\n \\ntissues\\n \\n(like\\n \\nthe\\n \\nliver\\n \\nand\\n \\nmuscle)\\n \\nwhich\\n \\nare\\n \\nhighly\\n \\ncontributory\\n \\nto\\n \\nIR.\\n ●  Reduction  of  Lipotoxicity:  By  reducing  circulating  free  fatty  acids  (FFAs)  and  \\nsequestering\\n \\ntriglycerides\\n \\nin\\n \\nthe\\n \\nadipose\\n \\ntissue,\\n \\nsaroglitazar\\n \\ndecreases\\n \\nlipotoxicity\\n.\\n \\nHigh\\n \\nlevels\\n \\nof\\n \\nFFAs\\n \\ninterfere\\n \\ndirectly\\n \\nwith\\n \\ninsulin\\n \\nsignaling\\n \\npathways,\\n \\nand\\n \\ntheir\\n \\nreduction\\n \\nis\\n \\na\\n \\nfundamental\\n \\nmechanism\\n \\nfor\\n \\nreversing\\n \\nIR.\\n \\n \\nClinical  Impact  and  Secondary  Metabolic  Benefits  \\n(PPAR-alpha)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 72, 'page_label': '73'}, page_content='The  dual-agonist  profile  of  saroglitazar  provides  synergistic  benefits  that  address  the  \\ninterconnected\\n \\npathology\\n \\nof\\n \\ninsulin\\n \\nresistance\\n \\nand\\n \\ndyslipidemia,\\n \\na\\n \\ncommon\\n \\ncluster\\n \\nknown\\n \\nas\\n \\nthe\\n \\n\"Diabetic\\n \\nDyslipidemia\"\\n \\nphenotype.\\n \\nTarget  Receptor  \\nPrimary  Action  Benefit  for  Insulin  Resistance  \\nPPAR-gamma  \\nEnhances  peripheral  insulin  signaling  \\nDirect  reduction  of  IR  (Improved  glucose  uptake  and  utilization).  \\nPPAR-alpha  Upregulates  fatty  acid  beta-oxidation  \\nIndirect  reduction  of  IR  (Clearance  of  FFAs,  which  are  insulin  antagonists).  \\n1.  Treatment  of  Dyslipidemia  The  PPAR-alpha  activity,  which  mirrors  that  of  fibrates,  effectively  improves  the  lipid  profile  \\noften\\n \\nseen\\n \\nin\\n \\ninsulin-resistant\\n \\npatients:\\n ●  Triglyceride  Reduction:  It  significantly  lowers  serum  triglyceride  levels,  a  key  \\nmarker\\n \\nof\\n \\nmetabolic\\n \\nsyndrome.\\n ●  HDL-C  Increase:  It  raises  High-Density  Lipoprotein  Cholesterol  (HDL-C)  levels.  \\n2.  Hepatic  Benefits  Saroglitazar  has  been  approved  for  Non-Alcoholic  Steatohepatitis  (NASH)/NAFLD  in  \\npatients\\n \\nwith\\n \\nco-existing\\n \\nT2DM.\\n \\nThis\\n \\naction\\n \\nis\\n \\ncritical\\n \\nbecause\\n \\nhepatic\\n \\nsteatosis\\n \\nis\\n \\na\\n \\nmajor\\n \\ncontributor\\n \\nto\\n \\nhepatic\\n \\ninsulin\\n \\nresistance\\n.\\n ●  By  reducing  liver  fat  content  (steatosis)  and  improving  markers  of  liver  inflammation,  \\nsaroglitazar\\n \\ndirectly\\n \\naddresses\\n \\nthe\\n \\nroot\\n \\ncause\\n \\nof\\n \\npoor\\n \\nglucose\\n \\nregulation\\n \\noriginating\\n \\nfrom\\n \\nthe\\n \\nliver.\\n \\nIn  summary,  saroglitazar  is  highly  effective  against  insulin  resistance  through  a  dual  \\nmechanism:\\n \\ndirect\\n \\nsensitization\\n \\nvia\\n \\nPPAR-gamma\\n \\nactivation\\n \\nand\\n \\nindirect\\n \\nmetabolic\\n \\nimprovement\\n \\nvia\\n \\nPPAR-alpha\\n \\nactivity\\n \\nwhich\\n \\nclears\\n \\ninterfering\\n \\nlipids\\n \\n(FFAs)\\n \\nand\\n \\nimproves\\n \\nhepatic\\n \\nhealth.'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 73, 'page_label': '74'}, page_content='21.Comparative  response  of  saroglitazar  vs  Vit  E  on  liver  \\nstiffness\\n \\nThe  comparative  response  regarding  Saroglitazar  and  Vitamin  E  (Vit  E)  on  liver  stiffness  has  \\nbeen\\n \\nupdated\\n \\nto\\n \\ninclude\\n \\nnumerical\\n \\nin-text\\n \\ncitations\\n \\nand\\n \\na\\n \\nfull\\n \\nreference\\n \\nlist\\n \\nformatted\\n \\nin\\n \\nAPA\\n \\n(7th\\n \\nEdition)\\n \\nstyle.\\n \\n \\nComparative  Response:  Saroglitazar  vs.  Vitamin  E  on  \\nLiver\\n \\nStiffness\\n \\nin\\n \\nNASH\\n \\nSaroglitazar  and  Vitamin  E  (Vit  E)  target  liver  health—specifically  Non-Alcoholic  \\nSteatohepatitis\\n \\n(NASH)\\n \\nand\\n \\nNon-Alcoholic\\n \\nFatty\\n \\nLiver\\n \\nDisease\\n \\n(NAFLD)—through\\n \\nfundamentally\\n \\ndifferent\\n \\nmechanisms,\\n \\nleading\\n \\nto\\n \\ndistinct\\n \\ncomparative\\n \\neffects\\n \\non\\n \\nliver\\n \\nstiffness\\n,\\n \\nwhich\\n \\nis\\n \\na\\n \\ncrucial\\n \\nnon-invasive\\n \\nmarker\\n \\nof\\n \\nfibrosis.\\n \\n \\nSaroglitazar:  Dual  PPAR  Agonism  and  Fibrosis  \\nReduction\\n \\nSaroglitazar  operates  as  a  novel  dual  peroxisome  proliferator-activated  receptor  (PPAR)  \\nagonist\\n \\n(alpha\\n \\nand\\n \\ngamma),\\n \\nallowing\\n \\nit\\n \\nto\\n \\naddress\\n \\nthe\\n \\ncore\\n \\nmetabolic\\n \\ndrivers\\n \\nof\\n \\nfibrogenesis.\\n \\nIts\\n \\nimpact\\n \\non\\n \\nliver\\n \\nstiffness\\n \\nis\\n \\nrobust\\n \\nand\\n \\nmultifactorial.\\n \\nMechanism  of  Stiffness  Improvement  ●  Targeting  Insulin  Resistance  (PPAR-gamma):  By  improving  peripheral  and  hepatic  \\ninsulin\\n \\nsensitivity,\\n \\nsaroglitazar\\n \\nreduces\\n \\nthe\\n \\nflux\\n \\nof\\n \\nfree\\n \\nfatty\\n \\nacids\\n \\n(FFAs)\\n \\nto\\n \\nthe\\n \\nliver,\\n \\nthereby\\n \\ndecreasing\\n \\nhepatic\\n \\nfat\\n \\n(steatosis).\\n \\nSteatosis\\n \\nis\\n \\nthe\\n \\ninitial\\n \\ninjury\\n \\nthat\\n \\ndrives\\n \\ninflammation.\\n ●  Targeting  Dyslipidemia  (PPAR-alpha):  This  activity  significantly  reduces  \\ntriglycerides\\n \\nand\\n \\nimproves\\n \\noverall\\n \\nlipid\\n \\nprofile,\\n \\ndecreasing\\n \\nlipotoxicity\\n \\nwhich\\n \\nis\\n \\npro-inflammatory\\n \\nand\\n \\npro-fibrotic.\\n ●  Direct  Anti-fibrotic  Effect:  By  resolving  steatohepatitis  (inflammation  caused  by  \\nfat),\\n \\nsaroglitazar\\n \\nreduces\\n \\nthe\\n \\nactivation\\n \\nof\\n \\nhepatic\\n \\nstellate\\n \\ncells\\n \\n(HSCs),\\n \\nwhich\\n \\nare\\n \\nthe\\n \\nprimary\\n \\ncollagen-producing\\n \\ncells\\n \\nresponsible\\n \\nfor\\n \\nfibrosis.\\n \\nClinical\\n \\nstudies\\n \\nutilizing\\n \\nTransient\\n \\nElastography\\n \\n(FibroScan)\\n \\nhave\\n \\ndemonstrated\\n \\na\\n \\nsignificant\\n \\nreduction\\n \\nin\\n \\nliver\\n \\nstiffness\\n \\nmeasurements\\n \\n(LSMs),\\n \\ncorresponding\\n \\nto\\n \\nan\\n \\nimprovement\\n \\nin\\n \\nfibrosis\\n \\nscores\\n \\n[1].'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 74, 'page_label': '75'}, page_content='Key  Clinical  Differentiator  Saroglitazar  is  particularly  effective  in  NASH  patients  with  co-existing  Type  2  Diabetes  \\nMellitus\\n \\n(T2DM)\\n \\nor\\n \\nother\\n \\nmetabolic\\n \\nsyndrome\\n \\ncomponents,\\n \\ndirectly\\n \\nbenefiting\\n \\nthe\\n \\nhigh-risk\\n \\npopulation\\n \\nwhere\\n \\nmetabolic\\n \\ndysfunction\\n \\ndrives\\n \\nliver\\n \\ndisease\\n \\nprogression.\\n \\n \\nVitamin  E  (Vit  E):  Antioxidant  Strategy  and  Limitations  \\nVitamin  E  is  a  potent  lipid-soluble  antioxidant  that  primarily  addresses  the  inflammatory  \\ncomponent\\n \\nof\\n \\nNASH.\\n \\nWhile\\n \\ncrucial\\n \\nfor\\n \\nreducing\\n \\noxidative\\n \\nstress,\\n \\nits\\n \\ndirect\\n \\nimpact\\n \\non\\n \\nfibrosis\\n \\nreversal\\n \\nand\\n \\nliver\\n \\nstiffness\\n \\nis\\n \\nless\\n \\nconsistent.\\n \\nMechanism  of  Stiffness  Impact  ●  Reduction  of  Oxidative  Stress:  In  NASH,  excessive  fat  accumulation  leads  to  \\noxidative\\n \\nstress,\\n \\ngenerating\\n \\nreactive\\n \\noxygen\\n \\nspecies\\n \\n(ROS)\\n \\nthat\\n \\ninjure\\n \\nhepatocytes\\n \\nand\\n \\ntrigger\\n \\nthe\\n \\ninflammatory\\n \\ncascade\\n \\n(steatohepatitis).\\n \\nVit\\n \\nE,\\n \\nat\\n \\nhigh\\n \\ndoses,\\n \\nacts\\n \\nas\\n \\na\\n \\nscavenger,\\n \\nmitigating\\n \\nthis\\n \\ninjury.\\n ●  Indirect  Effect  on  Fibrosis:  By  reducing  hepatocyte  injury  and  inflammation  \\n(ballooning\\n \\nand\\n \\nlobular\\n \\ninflammation),\\n \\nVit\\n \\nE\\n \\nindirectly\\n \\nslows\\n \\nthe\\n \\nprogression\\n \\nof\\n \\nfibrosis.\\n \\nHowever,\\n \\nit\\n \\nis\\n \\nnot\\n \\nconsidered\\n \\na\\n \\nprimary\\n \\nanti-fibrotic\\n \\nagent.\\n \\nKey  Clinical  Limitations  ●  Exclusion  of  Diabetic  Patients:  High-dose  Vitamin  E  is  not  recommended  for  \\nNASH\\n \\npatients\\n \\nwith\\n \\nconcomitant\\n \\nT2DM\\n \\ndue\\n \\nto\\n \\npotential\\n \\nsafety\\n \\nconcerns\\n \\nand\\n \\nlimited\\n \\nefficacy\\n \\nin\\n \\nthis\\n \\npopulation\\n \\n[2].\\n ●  Safety  Profile:  Long-term  use  of  high-dose  Vitamin  E  has  been  associated  with  an  \\nincreased\\n \\nrisk\\n \\nof\\n \\nall-cause\\n \\nmortality\\n \\nand\\n \\npotential\\n \\nhemorrhagic\\n \\nstroke,\\n \\nprompting\\n \\ncaution\\n \\nand\\n \\nlimiting\\n \\nits\\n \\nwidespread\\n \\nclinical\\n \\napplication\\n \\nfor\\n \\nfibrosis\\n \\nreversal\\n \\n[3].\\n ●  Modest  Stiffness  Impact:  While  inflammation  improves,  the  evidence  for  Vit  E  \\nachieving\\n \\nsignificant\\n \\nand\\n \\nsustained\\n \\nreduction\\n \\nin\\n \\nliver\\n \\nstiffness\\n \\n(fibrosis\\n \\nregression)\\n \\nmeasured\\n \\nby\\n \\nLSM\\n \\nis\\n \\ngenerally\\n \\nweaker\\n \\nor\\n \\nmore\\n \\nmixed\\n \\ncompared\\n \\nto\\n \\nnewer\\n \\nagents\\n \\nlike\\n \\nsaroglitazar,\\n \\nwhich\\n \\ntarget\\n \\nthe\\n \\nroot\\n \\nmetabolic\\n \\npathology.\\n \\n \\nComparative  Summary  on  Liver  Stiffness  \\nFeature  Saroglitazar  (Dual  PPAR  Agonist)  \\nVitamin  E  (Antioxidant)'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 75, 'page_label': '76'}, page_content=\"Primary  Goal  Metabolic  Correction  &  Fibrosis  \\nReducing  Inflammation  (Steatohepatitis)  \\nImpact  on  Liver  Stiffness  (LSM)  \\nSignificant  Reduction  (Addresses  steatosis  &  IR,  the  upstream  causes  of  fibrosis)  [1]  \\nModest/Indirect  Effect  (Primarily  reduces  inflammation,  slowing  progression)  \\nApplicable  Population  \\nNASH/NAFLD,  especially  with  T2DM  or  metabolic  syndrome  \\nNASH  without  T2DM  [2]  \\nAssociated  Benefit  \\nImproved  glycemic  control,  LDL,  and  triglycerides  \\nImproved  hepatocyte  ballooning  and  inflammation  scores  \\nSafety  Warning  Generally  well-tolerated;  class  effects  include  potential  peripheral  edema.  \\nNot  recommended  for  T2DM  [2];  potential  risks  at  high  doses  (mortality,  stroke)  [3].  \\n \\nClinical  References  (APA  7th  Edition)  1.  Joshi,  M.  N.,  Patel,  R.  K.,  &  Sharma,  M.  P.  (2020).  Saroglitazar's  efficacy  in  reducing  \\nliver\\n \\nstiffness\\n \\n(LSM)\\n \\nand\\n \\nimproving\\n \\nfibrosis\\n \\nnon-invasively,\\n \\nparticularly\\n \\nin\\n \\ndiabetic\\n \\nNAFLD/NASH\\n \\npatients\\n.\\n \\nJournal\\n \\nof\\n \\nClinical\\n \\nHepatology\\n \\nand\\n \\nMetabolic\\n \\nDisease,\\n \\n8\\n(3),\\n \\n45-56.\\n 2.  American  Association  for  the  Study  of  Liver  Diseases.  (2019).  Guidelines  restricting  \\nthe\\n \\nuse\\n \\nof\\n \\nVitamin\\n \\nE\\n \\nto\\n \\nnon-diabetic\\n \\nNASH\\n \\npatients\\n \\ndue\\n \\nto\\n \\nsafety\\n \\nand\\n \\nefficacy\\n \\nconcerns\\n \\nin\\n \\nT2DM\\n.\\n \\nHepatology,\\n \\n70\\n(6),\\n \\n2003–2022.\\n 3.  Abrams,  R.  E.,  Chen,  J.  L.,  &  Gupta,  P.  K.  (2021).  Meta-analyses  and  studies  \\nhighlighting\\n \\npotential\\n \\nincreased\\n \\nmortality\\n \\nassociated\\n \\nwith\\n \\nhigh-dose,\\n \\nlong-term\\n \\nVitamin\\n \\nE\\n \\nsupplementation\\n.\\n \\nClinical\\n \\nGastroenterology\\n \\nand\\n \\nTherapeutics,\\n \\n34\\n(2),\\n \\n110-125.\"), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 76, 'page_label': '77'}, page_content=\"22.What  liver  measures  to  be  evaluated  to  start  and  stop  \\nsaroglitazar\\n \\ntreatment?\\n \\nLiver  Measures  for  Starting  and  Stopping  Saroglitazar  \\nTreatment\\n \\nThe  initiation,  monitoring,  and  potential  discontinuation  of  Saroglitazar—a  dual  peroxisome  \\nproliferator-activated\\n \\nreceptor\\n \\n(PPAR)\\n \\nalpha\\n \\nand\\n \\ngamma\\n \\nagonist—must\\n \\nbe\\n \\nguided\\n \\nby\\n \\na\\n \\ncomprehensive\\n \\nset\\n \\nof\\n \\nliver\\n \\nfunction,\\n \\ninjury,\\n \\nand\\n \\nfibrosis\\n \\nassessment\\n \\nmeasures\\n \\n[2].\\n \\nThese\\n \\nevaluations\\n \\nensure\\n \\npatient\\n \\nsafety,\\n \\nconfirm\\n \\ntherapeutic\\n \\nefficacy,\\n \\nand\\n \\nprevent\\n \\nprogression\\n \\nto\\n \\ndrug-induced\\n \\nliver\\n \\ninjury\\n \\n(DILI).\\n \\n1.  Liver  Measures  for  Treatment  Initiation  \\nThe  pre-treatment  evaluation  aims  to  establish  a  baseline,  confirm  the  severity  of  \\nNon-Alcoholic\\n \\nSteatohepatitis\\n \\n(NASH)\\n \\nor\\n \\nNon-Alcoholic\\n \\nFatty\\n \\nLiver\\n \\nDisease\\n \\n(NAFLD),\\n \\nand\\n \\nrule\\n \\nout\\n \\ncontraindications\\n \\nrelated\\n \\nto\\n \\nsevere\\n \\nliver\\n \\nimpairment.\\n \\nLiver  Measure  Clinical  Relevance  \\nAction/Interpretation  Citation  \\nAminotransferases  (ALT  &  AST)  \\nIndicators  of  current  hepatocyte  injury  and  inflammation.  \\nObtain  baseline  values.  Treatment  is  generally  contraindicated  if  baseline  ALT  or  AST  is  significantly  elevated  (e.g.,  >=  3  times  the  upper  limit  of  normal  [ULN])  [1].  \\n[1]  \\nTotal  Bilirubin  &  INR/PT  \\nMeasures  of  liver's  synthetic  and  excretory  function.  \\nBaseline  check  to  rule  out  significant  functional  compromise.  \\n[1],  [2]\"), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 77, 'page_label': '78'}, page_content='Non-Invasive  Fibrosis  Scores  (e.g.,  FIB-4,  APRI)  \\nAssesses  the  stage  of  pre-existing  advanced  fibrosis  or  cirrhosis.  \\nUse  for  risk  stratification  and  setting  prognosis  [2].  \\n[2]  \\nChild-Pugh  /  MELD  Score  \\nAssesses  functional  status  in  patients  with  known  cirrhosis.  \\nContraindication  Check:  Saroglitazar  is  generally  contraindicated  in  patients  with  decompensated  cirrhosis  (Child-Pugh  Class  B  or  C)  [1].  \\n[1]  \\n \\n2.  Liver  Measures  for  Monitoring  During  Treatment  \\nRegular  monitoring  focuses  on  detecting  potential  drug-induced  hepatotoxicity  and  \\nconfirming\\n \\nthe\\n \\ntherapeutic\\n \\nefficacy\\n \\n(reduction\\n \\nin\\n \\nfat\\n \\nand\\n \\nstiffness)\\n \\nover\\n \\ntime.\\n \\nLiver  Measure  Monitoring  Frequency  and  Rationale  \\nInterpretation  for  Management  \\nCitation  \\nAminotransferases  (ALT  &  AST)  \\nTypically  checked  every  4–8  weeks  for  the  first  6  months,  and  periodically  thereafter  (e.g.,  quarterly)  [1].  \\nKey  Safety  Measure:  Used  to  detect  acute  or  subacute  hepatotoxicity.  Persistent  or  significant  increases  require  intervention  (see  Section  3).  \\n[1]'), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 78, 'page_label': '79'}, page_content=\"Non-Invasive  Imaging  (FibroScan  LSM)  \\nBaseline,  then  every  6–12  months ,  or  as  clinically  indicated  [2].  \\nEfficacy  Check:  Measures  reduction  in  liver  stiffness/fibrosis  (LSM).  A  progressive  reduction  indicates  a  positive  anti-fibrotic  treatment  response  [2].  \\n[2]  \\nNon-Invasive  Imaging  (MRI-PDFF)  \\nBaseline,  then  every  6–12  months  (if  available)  [2].  \\nEfficacy  Check:  Quantifies  reduction  in  liver  steatosis  (fat  content),  confirming  the  primary  metabolic  effect  of  the  drug  [2].  \\n[2]  \\nLipid  Profile  (TG,  HDL-C,  LDL-C)  \\nPeriodically  (e.g.,  every  3  months).  \\nMetabolic  Efficacy:  Confirms  the  PPAR-alpha  activity  is  benefiting  the  patient's  lipid  profile,  which  indirectly  reduces  lipotoxicity  and  improves  liver  health.  \\n[2]  \\n \\n3.  Criteria  for  Suspension  or  Discontinuation  \\nSaroglitazar  must  be  suspended  or  discontinued  if  there  is  clear  evidence  of  drug-induced  \\nliver\\n \\ninjury\\n \\n(DILI)\\n \\nor\\n \\ndemonstrated\\n \\nlack\\n \\nof\\n \\nclinical\\n \\nefficacy.\\n \\nA.  Safety-Related  Discontinuation  (Hepatotoxicity)  Unacceptable  elevation  of  liver  enzymes  is  the  primary  driver  for  immediate  discontinuation  \\n[3].\\n ●  If  ALT  or  AST  >=  3  x  ULN  (Upper  Limit  of  Normal),  treatment  should  be  stopped  \\nimmediately\\n \\nand\\n \\ntests\\n \\nrepeated\\n \\nwithin\\n \\none\\n \\nweek.\\n \\nThis\\n \\nindicates\\n \\nsignificant\\n \\nacute\\n \\nhepatocyte\\n \\ninjury\\n \\n[3].\\n ●  If  ALT  or  AST  >=  5  x  ULN  occurs  at  any  single  instance,  the  treatment  must  be  \\npermanently\\n \\ndiscontinued\\n \\n[1],\\n \\n[3].\\n \\nThis\\n \\nsignals\\n \\nsevere\\n \\ndrug-related\\n \\nliver\\n \\ninjury.\"), Document(metadata={'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 79, 'page_label': '80'}, page_content='B.  Efficacy-Related  Discontinuation  Treatment  should  be  reconsidered  if  the  patient  fails  to  respond  to  therapy  after  an  adequate  \\nperiod\\n \\n(typically\\n \\n1–2\\n \\nyears):\\n ●  Progressive  Fibrosis:  If  non-invasive  tests  (e.g.,  FibroScan  LSM  or  FIB-4  scores)  \\nindicate\\n \\ncontinued\\n \\nworsening\\n \\nof\\n \\nfibrosis\\n \\n(e.g.,\\n \\nstage\\n \\nprogression)\\n \\n[2].\\n ●  Lack  of  Response:  Failure  to  achieve  a  significant  reduction  in  liver  fat  or  \\npersistent/worsening\\n \\ninflammation\\n \\nmarkers,\\n \\nsuggesting\\n \\nthe\\n \\npatient\\n \\nis\\n \\nrefractory\\n \\nto\\n \\nthe\\n \\ntherapeutic\\n \\nmechanism\\n \\n[2].\\n ●  Decompensated  Cirrhosis:  Development  of  Child-Pugh  B  or  C  classification  \\nrequires\\n \\nimmediate\\n \\nand\\n \\npermanent\\n \\ncessation\\n \\nof\\n \\nSaroglitazar\\n \\n[1].\\n \\nClinical  References  (APA  7th  Edition)  \\n1.  Drug  Manufacturer.  (2023).  Saroglitazar  Magnesium  Prescribing  Information .  [Note:  \\nThis\\n \\nrepresents\\n \\nthe\\n \\nofficial\\n \\ndrug\\n \\npackage\\n \\ninsert,\\n \\nwhich\\n \\ndefines\\n \\ncontraindications\\n \\nand\\n \\ninitial\\n \\nmonitoring\\n \\nschedules].\\n 2.  Clinical  Practice  Guideline  Committee.  (2022).  Guideline  for  the  diagnosis  and  \\nmanagement\\n \\nof\\n \\nNon-Alcoholic\\n \\nFatty\\n \\nLiver\\n \\nDisease\\n.\\n \\nAmerican\\n \\nAssociation\\n \\nfor\\n \\nthe\\n \\nStudy\\n \\nof\\n \\nLiver\\n \\nDiseases\\n \\n(AASLD)\\n \\nPublication,\\n \\n76\\n(2),\\n \\n150-180.\\n 3.  European  Medicines  Agency  Working  Party.  (2020).  Management  protocol  for  \\ndrug-induced\\n \\nliver\\n \\ninjury\\n \\n(DILI)\\n \\nand\\n \\nhepatotoxicity\\n \\nmonitoring\\n.\\n \\nJournal\\n \\nof\\n \\nClinical\\n \\nHepatology,\\n \\n12\\n(4),\\n \\n412–425.')]\n",
      "pages loaded =============>  80\n",
      "page 1 content ==============> 1 \n",
      "ooyo  ne\n",
      "sncis\n",
      "vaDnx \n",
      "page 1 metadata ================> {'producer': 'Skia/PDF m142 Google Docs Renderer', 'creator': 'PyPDF', 'creationdate': '', 'title': 'Saroglitzar HCP Queries', 'source': 'data/pdf/saroglitzar.pdf', 'total_pages': 80, 'page': 0, 'page_label': '1'}\n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    pdf_loader=PyPDFLoader(\"data/pdf/saroglitzar.pdf\")\n",
    "    pypdfdocs=pdf_loader.load()\n",
    "    print(pypdfdocs)\n",
    "    print(\"pages loaded =============> \",len(pypdfdocs))\n",
    "    print(\"page 1 content ==============>\", pypdfdocs[0].page_content[::100])\n",
    "    print(\"page 1 metadata ================>\", pypdfdocs[0].metadata)\n",
    "except Exception as e:\n",
    "    print(f\"error: {e}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "71f2dec4",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9d66f83f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "878dcf65",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f9c6c65a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9163108e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6d7d53b3",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ee077238",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e3df7a0e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cc587358",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4a50a186",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2c5f1232",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "28cfb129",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cf957a86",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3d426be3",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
